,PageNo,Text
0,page_0,
1,page_1,"N o v arti s C o nfi d e nti al P a g e 2 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 T a bl e of c o nt e nt s Ta ble of c o nt e nts ................................................................................................................. 2 List of ta bles ........................................................................................................................ 5 List of fi g ur es ...................................................................................................................... 5 List of a b bre viati o ns ............................................................................................................ 6 Gl ossar y of ter ms ................................................................................................................. 8 A me n d me nt 2 ...................................................................................................................... 9 A me n d me nt 1 .................................................................................................................... 1 0 Pr ot oc ol s u m mar y .............................................................................................................. 1 2 1 I ntr o d u cti o n ....................................................................................................................... 1 5 1. 1 Bac k gr o u n d ............................................................................................................ 1 5 1. 2 P ur p ose .................................................................................................................. 1 6 2 St u d y o bj ecti ves a n d e n d p oi nts ......................................................................................... 1 6 2. 1 St u d y O bjecti ves a n d E n d p oi nts ............................................................................ 1 7 3 I n v esti gati o nal pla n ........................................................................................................... 1 8 3. 1 St u d y d esi g n ........................................................................................................... 1 8 3. 2 Rati o nale f or st u d y desi g n ..................................................................................... 2 0 3. 3 Rati o nale f or d ose/r e gi me n, r o ute of a d mi nistrati o n a n d d urati o n of treat me nt .... 2 1 3. 4 Rati o nale f or c h oice of c o m parat or ....................................................................... 2 3 3. 5 P ur p ose a n d ti mi n g of i nt eri m a nal yses/ desi g n a d a ptati o ns .................................. 2 3 3. 6 Ris ks a n d be nefits .................................................................................................. 2 3 4 P o p ulati o n .......................................................................................................................... 2 5 4. 1 I n cl usi o n criteria .................................................................................................... 2 5 4. 2 E x cl usi o n criteria ................................................................................................... 2 6 5 Treat me nt ........................................................................................................................... 2 9 5. 1 St u d y treat me nt ...................................................................................................... 2 9 5. 1. 1 I n v esti gati o nal a n d c o ntr ol dr u gs .......................................................... 2 9 5. 1. 2 A d diti o nal treat me nt .............................................................................. 3 0 5. 2 Treat me nt ar ms ...................................................................................................... 3 0 5. 3 Treat me nt assi g n me nt a n d ra n d o mizati o n ............................................................. 3 0 5. 4 Treat me nt bli n di n g ................................................................................................. 3 1 5. 5 Treati n g t he patie nt ................................................................................................ 3 1 5. 5. 1 Patie nt n u m beri n g ................................................................................. 3 1 5. 5. 2 Dis pe nsi n g t he st u d y dr u g ..................................................................... 3 2 5. 5. 3 Ha n dli n g of st u d y a n d a d diti o nal treat me nt .......................................... 3 2"
2,page_2,"N o v arti s C o nfi d e nti al P a g e 3 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 5. 5. 4 I nstr u cti o ns f or pr escri bi n g a n d t a ki n g st u d y tr eat me nt ........................ 3 3 5. 5. 5 Per mitte d d ose a dj ust me nts a n d i nterr u pti o ns of st u d y treat me nt ........ 3 4 5. 5. 6 Resc ue me dicati o n ................................................................................ 3 5 5. 5. 7 C o nc o mita nt me dicati o n ....................................................................... 3 6 5. 5. 8 Pr o hi bite d me dicati o ns .......................................................................... 3 6 5. 5. 9 E mer ge nc y brea ki n g of assi g ne d tr eat me nt c o de .................................. 3 9 5. 6 St u d y C o m pleti o n a n d Disc o nti n uati o n ................................................................. 3 9 5. 6. 1 St u d y c o m pleti o n, p ost- st u d y treat me nt a n d e n d of trial ...................... 3 9 5. 6. 2 Disc o nti n uati o n of St u d y Treat me nt ..................................................... 4 0 5. 6. 3 Wit h dra wal of i nf or me d c o nse nt ........................................................... 4 1 5. 6. 4 L ost t o f oll o w- u p ................................................................................... 4 1 5. 6. 5 Earl y st u d y ter mi nati o n b y t he s p o ns or ................................................. 4 1 6 Visit sc he d ule a n d assess me nts ......................................................................................... 4 1 6. 1 I nf or mati o n t o be c ollecte d o n scree ni n g fail ur es .................................................. 4 4 6. 2 Patie nt de m o gr a p hics/ ot her baseli ne c har acteristics ............................................. 4 5 6. 3 Treat me nt e x p os ure a n d c o m plia nce ..................................................................... 4 5 6. 4 Efficac y .................................................................................................................. 4 5 6. 4. 1 Healt h Stat us ( Patie nt Re p orte d O utc o mes) .......................................... 4 6 6. 4. 2 S pir o metr y ............................................................................................. 4 7 4 8 6. 4. 4 W orse ni n g of ast h ma ............................................................................. 4 8 6. 4. 5 Ast h ma E x acer bati o n ............................................................................ 4 9 5 0 6. 4. 7 A p pr o priate n ess of efficac y assess me nts .............................................. 5 1 6. 5 Safet y ..................................................................................................................... 5 1 6. 5. 1 P h ysical e x a mi nati o n ............................................................................ 5 1 6. 5. 2 Vital si g ns .............................................................................................. 5 2 6. 5. 3 Hei g ht a n d wei g ht ................................................................................. 5 2 6. 5. 4 La b orat or y e val uati o ns .......................................................................... 5 2 6. 5. 5 Electr ocar di o gra m ( E C G) ..................................................................... 5 2 6. 5. 6 Pre g n a nc y a n d assess me nts of fertilit y ................................................. 5 3 6. 5. 7 A p pr o priate n ess of saf et y meas ure me nts .............................................. 5 3 5 3 5 3 5 4 5 4"
3,page_3,"N o v arti s C o nfi d e nti al P a g e 4 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 7 Safet y m o nit ori n g .............................................................................................................. 5 4 7. 1 A d verse e ve nts ....................................................................................................... 5 4 7. 2 Seri o us a d verse e ve nts ........................................................................................... 5 6 7. 2. 1 Defi niti o n of S A E ................................................................................. 5 6 7. 2. 2 S A E re p orti n g ........................................................................................ 5 7 7. 3 Li ver saf et y m o nit ori n g ......................................................................................... 5 7 7. 4 Re p orti n g of st u d y treat me nt err ors i ncl u di n g mis use/a b use ................................ 5 8 7. 5 Pre g n a nc y r e p orti n g ............................................................................................... 5 9 8 Data re vi e w a n d d ata bas e ma na ge m e nt ............................................................................. 5 9 8. 1 Site m o nit ori n g ...................................................................................................... 5 9 8. 2 Data c ollecti o n ....................................................................................................... 6 0 8. 3 Data base m a na ge m e nt a n d q ualit y c o ntr ol ............................................................ 6 0 8. 4 Data M o nit ori n g C o m mittee .................................................................................. 6 1 8. 5 A dj u dicati o n C o m mittee ........................................................................................ 6 1 9 Data a n al ysis ...................................................................................................................... 6 2 9. 1 A nal ysis sets .......................................................................................................... 6 2 9. 2 Patie nt de m o gr a p hics a n d ot her baseli ne c har acteristics ....................................... 6 2 9. 3 Treat me nts ............................................................................................................. 6 3 9. 4 A nal ysis of t h e pri mar y v aria ble ............................................................................ 6 3 9. 4. 1 Varia bles ............................................................................................... 6 3 9. 4. 2 Statistical m o del, h y p ot h esis a n d met h o d of a nal ysis ........................... 6 3 9. 4. 3 Ha n dli n g of missi n g val u es/ earl y disc o nti n uati o ns.............................. 6 4 9. 4. 4 M ulti plicit y A dj ust me nt ........................................................................ 6 4 9. 4. 5 S u p p orti ve a nal ys es ............................................................................... 6 5 9. 5 A nal ysis of s ec o n dar y e n d p oi nts ........................................................................... 6 5 9. 5. 1 Efficac y vari a bles .................................................................................. 6 5 9. 5. 2 Safet y v aria bl es ..................................................................................... 6 7 6 8 6 8 6 8 6 8 6 8 9. 7 I nteri m a nal yses ..................................................................................................... 7 1 9. 8 Sa m ple size calc ulati o n .......................................................................................... 7 1 1 0 Et hical c o nsi derati o ns ........................................................................................................ 7 1 1 0. 1 Re g ulat or y a n d et hical c o m plia nce i nf or me d c o nse nt pr oce d ures ........................ 7 1"
4,page_4,"N o v arti s C o nfi d e nti al P a g e 5 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 1 0. 2 I nf or me d c o ns e nt pr oced ures ................................................................................. 7 2 1 0. 3 Res p o nsi bilities of t he i n vesti gat or a n d I R B/I E C .................................................. 7 2 1 0. 4 P u blicati o n of st u d y pr ot oc ol a n d res ults............................................................... 7 2 1 0. 5 Q ualit y C o ntr ol a n d Q u alit y Ass ura n ce ................................................................. 7 2 1 1 Pr ot oc ol a d here n ce ............................................................................................................ 7 3 1 1. 1 Pr ot oc ol a me n d me nts ............................................................................................. 7 3 1 2 Refere n ces ......................................................................................................................... 7 3 1 3 A p pe n di x 1: Li ver e v e nt a n d La b or at or y tri g ger Defi niti o ns a n d F oll o w- u p Re q uire me nts ..................................................................................................................... 7 6 1 4 A p pe n di x 2: S pir o metr y G ui da nce ................................................................................... 7 8 1 5 A p pe n di x 3: I nstr ucti o n f or Use of C o n ce pt 1 .................................................................. 8 1 1 6 A p pe n di x 4: I nstr ucti o n f or Use of Acc u h aler ®/ Dis k us® ................................................. 8 5 1 7 A p pe n di x 5: I nstr ucti o ns f or Use of t h e Res pi mat® ......................................................... 9 0 9 3 1 9 A p pe n di x 7: A Q L Q- S ........................................................................................................ 9 4 2 0 A p pe n di x 8: A C Q- 7 .......................................................................................................... 9 9 1 0 1 2 2 A p pe n di x 1 0: L o w, me di u m a n d hi g h D ail y D os es of I n hale d Gl u c oc ortic oster oi ds f or A d ults 1 ....................................................................................................................... 1 0 6 Li st of t a bl e s Ta ble 2 - 1 O bjecti ves a n d r elate d e n d p oi nts .......................................................... 1 7 Ta ble 5 - 1 St u d y Treat me nts .................................................................................. 3 4 Ta ble 5 - 2 Pr o hi bite d ast h ma- relate d me dicati o ns ................................................. 3 6 Ta ble 5 - 3 Pr o hi bite d Me dicati o ns ......................................................................... 3 7 Ta ble 5 - 4 Me dicati o ns all o we d u n d er certai n c o n diti o ns ...................................... 3 7 Ta ble 5 - 5 Assess me nts f or Patie nts w h o Disc o nti n ue St u d y Treat me nt ............... 4 0 Ta ble 6 - 1 Assess me nt sc he d ule ............................................................................. 4 2 Ta ble 6 - 2 Ti me d Assess me nts ............................... Err or! B o o k m ar k n ot defi ne d. Ta ble 7 - 1 G ui da nce f or ca pt uri n g t he st u d y tr eat me nt err ors i ncl u di n g mis use/a b use ......................................... Err or! B o o k m ar k n ot defi ne d. Ta ble 1 3 - 1 Li ver E ve nt a n d La b orat or y Tri g ger D efi niti o ns .................................. 7 6 Ta ble 1 3 - 2 F oll o w U p Re q uire me nts f or Li v er E v e nts a n d La b orat or y Tri g gers ... 7 6 Li st of fi g ur e s Fi g ure 3 - 1 St u d y d esi g n ......................................................................................... 2 0"
5,page_5,N o v arti s C o nfi d e nti al P a g e 6 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Li st of a b br e vi ati o n s A C Q -7 A st h m a C o ntr ol Q u e sti o n n air e -7 A E A d v er s e E v e nt A L T Al a ni n e A mi n otr a n sf er a s e A N C O V A A n al y si s of c o v ari a n c e A Q L Q ( S) A st h m a Q u alit y of Lif e Q u e sti o n n air e A S T A s p art at e A mi n otr a n sf er a s e A T S/ E R S A m eri c a n T h or a ci c S o ci et y/ E ur o p e a n R e s pir at or y S o ci et y B MI B o d y M a s s I n d e x B P H B e ni g n pr o st ati c h y p er pl a si a b.i. d. t wi c e a d a y C C V C ar di o v a s c ul ar a n d C er e br o v a s c ul ar C F R U S C o d e of F e d er al R e g ul ati o n s C O P D C hr o ni c O b str u cti v e P ul m o n ar y Di s e a s e C P O C o u ntr y P h ar m a Or g a ni z ati o n C R F C a s e R e p ort/ R e c or d F or m ( p a p er or el e ctr o ni c) C R O C o ntr a ct R e s e ar c h Or g a ni z ati o n D A L Y s Di s a bilit y - A dj u st e d Lif e Y e ar s D A R D o s e A d mi ni str ati o n R e c or d D PI Dr y P o w d er I n h al er E C G El e ctr o c ar di o gr a m E D C El e ctr o ni c D at a C a pt ur e E M A E ur o p e a n M e di ci n e s A g e n c y E R E m er g e n c y R o o m E U E ur o p e a n U ni o n F A S F ull a n al y si s s et F D C Fi x e d d o s e c o m bi n ati o n F E F 2 5 -7 5 F or c e d E x pir at or y Fl o w b et w e e n 2 5 % a n d 7 5 % of F or c e d Vit al C a p a cit y F E V 1 F or c e d E x pir at or y V ol u m e i n 1 s e c o n d F V C F or c e d Vit al C a p a cit y G C P G o o d Cli ni c al Pr a cti c e G E E G e n er ali z e d e sti m ati n g e q u ati o n GI N A Gl o b al I niti ati v e f or A st h m a G LI Gl o b al L u n g F u n cti o n I niti ati v e G G T/ γ G T G a m m a Gl ut a m yl Tr a n sf er a s e g M C P Gr a p h B a s e d M ulti pl e C o m p ari s o n Pr o c e d ur e s H C P H e alt h C ar e Pr a ctiti o n er I C H I nt er n ati o n al C o nf er e n c e o n H ar m o nis ati o n of T e c h ni c al R e q uir e m e nt s f or R e gi str ati o n of P h ar m a c e uti c al s f or H u m a n U s e I B I n v e sti g at or Br o c h ur e I C S/ L A B A C o m bi n ati o n of i n h al e d c orti c o st er oi d a n d l o n g a cti n g b et a a g o ni st I E C I n d e p e n d e nt Et hi c s C o m mitt e e
6,page_6,N o v arti s C o nfi d e nti al P a g e 7 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 I g E I m m u n o gl o b uli n E I M Intr a m u s c ul ar I R B I n stit uti o n al R e vi e w B o ar d I R T I nt er a cti v e R e s p o n s e T e c h n ol o g y I UD I ntr a ut eri n e d e vi c e I U S I ntr a ut eri n e s y st e m I V Intr a v e n o u s L A B A L o n g -a cti n g β a dr e n o c e pt or a g o ni st s L A M A L o n g A cti n g M u s c ari ni c A nt a g o ni st L F T Li v er f u n cti o n t e st L T R A L e u k otri e n e r e c e pt or a nt a g o ni st s M CI D Mi ni m al i m p ort a nt diff er e n c e M DI M et er e d d o s e i n h al er M e d D R A M e di c al D i cti o n ar y f or R e g ul at or y A cti viti e s M M R M M o d el f or r e p e at e d m e a s ur e NI N o n -i nf eri orit y O C S Or al c orti c o st er oi d O C/ R D C Or a cl e Cli ni c al/ R e m ot e D at a C a pt ur e o. d. o n c e a d a y P E F P e a k E x pir at or y Fl o w p. o. or al(l y) P P S P er pr ot o c ol s et P R O P ati e nt R e p ort e d O ut c o m e Q o L Q u alit y of Lif e S A B A S h ort A cti n g β 2 A g o ni st S A E S eri o u s A d v er s e E v e nt S A M A S h ort a cti n g a nti c h oli n er gi c s S A P St ati sti c al a n al y si s pl a n S C S S y st e mi c c orti c o st er oi d S D D PI Si n gl e d o s e dr y p o w d er i n h al er S U S A R S u s p e ct e d U n e x p e ct e d S eri o u s A d v er s e R e a cti o n s T B L T ot al bilir u bi n T D Tr e at m e nt Di s c o nti n u ati o n U L N U p p er li mit of n or m al W H O W orl d H e alt h Or g a ni z ati o n W o C Wit h dr a w al of C o n s e nt
7,page_7,"N o v arti s C o nfi d e nti al P a g e 8 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Gl o s s ar y of t er m s C o ntr ol dr u g Dr u g s( s) u s e d a s a c o m p ar at or t o r e d u c e a s s e s s m e nt bi a s, pr e s er v e bli n di n g of i n v e sti g ati o n al dr u g, a s s e s s i nt er n al st u d y v ali dit y, a n d/ or e v al u at e c o m p ar ati v e eff e ct s of t h e i n v e sti g ati o n al dr u g D o s a g e D o s e of t h e st u d y tr e at m e nt gi v e n t o t h e p ati e nt i n a ti m e u nit ( e. g. 1 0 0 m g o. d. , 7 5 m g b.i. d. ) El e ctr o ni c D at a C a pt ur e ( E D C) El e ctr o ni c d at a c a pt ur e ( E D C) i s t h e el e ctr o ni c a c q ui siti o n of cli ni c al st u d y d at a u si n g d at a c oll e cti o n s y st e m s, s u c h a s W e b -b a s e d a p pli c ati o n s, i nt er a cti v e v oi c e r e s p o n s e s y st e m s a n d cli ni c al l a b or at or y i nt erf a c e s E D C i n cl u d e s t h e u s e of El e ctr o ni c C a s e R e p ort F or m s ( e C R F s) w hi c h ar e u s e d t o c a pt ur e d at a tr a n s cri b e d fr o m p a p er s o ur c e f or m s u s e d at t h e p oi nt of c ar e E nr oll m e nt P oi nt/ti m e of p ati e nt e ntr y i nt o t h e st u d y at w hi c h i nf or m e d c o n s e nt m u st b e o bt ai n e d ( e. g. pri or t o st arti n g a n y of t h e pr o c e d ur e s d e s cri b e d i n t h e pr ot o c ol) P eri o d A p orti o n of t h e st u d y w hi c h s er v e s a s p e cifi c p ur p o s e. T y pi c al p eri o d s ar e: s cr e e ni n g/r e cr uit m e nt, w a s h -o ut, tr e at m e nt, a n d f oll o w -u p S y n o n y m o u s wit h t h e t er m “ E p o c h” I n v e sti g ati o n al dr u g T h e dr u g w h o s e pr o p erti e s ar e b ei n g t e st e d i n t h e st u d y ; t hi s d efi niti o n i s c o n si st e nt wit h U S C F R 2 1 S e cti o n 3 1 2. 3 a n d i s s y n o n y m o u s wit h “i n v e sti g ati o n al n e w dr u g” or “i n v e sti g ati o n al m e di ci n al pr o d u ct.” M e di c ati o n p a c k n u m b er A u ni q u e i d e ntifi er o n t h e l a b el of e a c h i n v e sti g ati o n al dr u g p a c k a g e P art A si n gl e c o m p o n e nt of a st u d y w hi c h c o nt ai n s diff er e nt o bj e cti v e s or p o p ul ati o n s wit hi n t h at si n gl e st u d y. C o m m o n p art s wit hi n a st u d y ar e: a si n gl e d o s e p art a n d a m ulti pl e d o s e p art, or a p art i n p ati e nt s/ s u bj e ct s wit h e st a bli s h e d di s e a s e a n d i n t h o s e wit h n e wl y -di a g n o s e d di s e a s e P ati e nt/ s u bj e ct I D A u ni q u e s u bj e ct i d e ntifi c ati o n (I D) n u m b er a s si g n e d t o e a c h p ati e nt u p o n si g ni n g t h e i nf or m e d c o n s e nt R a n d o mi z ati o n n u m b er A u ni q u e i d e ntifi er a s si g n e d t o e a c h r a n d o mi z e d p ati e nt, c orr e s p o n di n g t o a s p e cifi c tr e at m e nt ar m a s si g n m e nt S o ur c e D at a/ D o c u m e nt S o ur c e d at a r ef er s t o t h e i niti al r e c or d, d o c u m e nt, or pri m ar y l o c ati o n fr o m w h er e d at a c o m e s. T h e d at a s o ur c e c a n b e a d at a b a s e, a d at a s et, a s pr e a d s h e et or e v e n h ar d -c o d e d d at a, s u c h a s p a p er or e S o ur c e. St u d y dr u g/ tr e at m e nt A n y si n gl e dr u g or c o m bi n ati o n of dr u g s a d mi ni st er e d t o t h e p ati e nt a s p art of t h e r e q uir e d st u d y pr o c e d ur e s; i n cl u d e s i n v e sti g ati o n al dr u g ( s), pl a c e b o/ c o m p ar at or a cti v e dr u g r u n -i n s or b a c k gr o u n d t h er a p y St u d y Tr e at m e nt Di s c o nti n u ati o n ( T D) W h e n t h e p ati e nt p er m a n e ntl y st o p s t a ki n g st u d y tr e at m e nt pri or t o t h e d efi n e d st u d y tr e at m e nt c o m pl eti o n d at e V ari a bl e A m e a s ur e d v al u e or a s s e s s e d r e s p o n s e t h at i s d et er mi n e d i n s p e cifi c a s s e s s m e nt s a n d u s e d i n d at a a n al y si s t o e v al u at e t h e dr u g b ei n g t e st e d i n t h e st u d y Wit h dr a w al of c o n s e nt ( W o C) Wit h dr a w al of c o n s e nt fr o m t h e st u d y i s d efi n e d a s w h e n a p ati e nt d o e s n ot w a nt t o p arti ci p at e i n t h e st u d y a n y l o n g er, a n d d o e s n ot w a nt a n y f urt h er vi sit s or a s s e s s m e nt s, a n d d o e s n ot w a nt a n y f urt h er st u d y r el at e d c o nt a ct, a n d d o e s n ot all o w a n al y si s of alr e a d y o bt ai n e d bi ol o gi c m at eri al"
8,page_8,"N o v arti s C o nfi d e nti al P a g e 9 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 A m e n d m e nt 2 A m e n d m e nt r ati o n al e I n a p o p ulati o n wit h u nc o ntr olle d ast h ma it is t he i n vesti gat or’s res p o nsi bilit y t o e ns ur e t hat patie nts are treate d a d e q ua tel y. At t he ti me of r a n d o mizati o n, t he i n vesti gat or nee ds t o ma ke a n i nf or me d decisi o n a b o ut t he m ost a p pr o priate treat me nt f or eac h i n di vi d ual patie nt. If t h e m ost a p pr o priate tr eat me nt is n ot a L A B A + L A M A +I C S, t he patie nt s h o ul d be scree n -faile d a n d be treate d acc or di n g t o his/ her i n di vi d ual nee ds. T he p ur p ose of t his a me n d me nt is t o s u p p ort t his i nf or me d decisi o n ma ki n g b y a d di n g rele va nt assess m e nts at t he r u n-i n visit, i.e. meas ure me nt of bl o o d t otal Ig E a n d a nti ge n - s pecific I g E (Im m u n o C A P) f or c o m m o n per e n nial aer oaller ge ns. F urt her m ore , t his a m e n d me nt i ncl u des a c ha n ge i n t he h y p ot heses testi n g strate g y. T h e ke y sec o n dar y o bjecti ve ( T o e val uate effi cac y of Q V M 1 4 9 hi g h I C S d ose a n d Q V M 1 4 9 me di u m I C S d ose c o m pare d t o sal meter ol/ fl uticas one + ti otr o pi u m i n ter ms of Tr o u g h F E V 1 after 2 4 wee ks of treat me nt) will be treate d as a r e g ular sec o n dar y o bjecti ve. T h e testi n g strate g y will i ncl u de o nl y t h e pri mar y o bjecti ve ( T h e n o n-i nferi orit y of Q V M 1 4 9 hi g h I C S d ose a n d Q V M 1 4 9 me di u m I C S d ose c o m p are d t o sal meter ol/ fl uticas o ne + ti otr o pi u m free c o m bi nati o n i n ter ms of c ha n ge fr o m baseli ne i n A Q L Q total sc ore after 2 4 wee ks of treat me nt). I n a d diti o n, t he a me n d me nt will a d dress c o m me nts recei v e d fr o m t he Et hi cs C o m mittee a n d Healt h A ut h orit y i n G er ma n y t o cl arif y s o me pr o ce d ures a n d data pr otecti o n meas ures. Recr uit me nt f or t he st u d y h as n ot i nitiate d as of ti me of pr ot oc ol a me n d me nt fi nalizati o n. T hese c ha n ges will n ot i nfl ue nce t he st u d y p o p ul ati o n, t he res ults of t he st u d y n o r is t here a n y i m pact t o patie nt safet y. I R B s/I E C s A c o p y of t his a me n de d pr ot oc ol will be se nt t o t he I nstit uti o nal Re vie w B oar d (I R Bs)/I n d e pe n d e nt Et hics C o m mittee (I E Cs) a n d Healt h A ut h orities. T he c ha n ges descri b e d i n t his a me n de d pr ot oc ol re q uire I R B/I E C a p pr o val pri or t o i m ple me ntati o n. C h a n g e s t o t h e pr ot o c ol • U p date t o t he Pr ot oc ol s u m mar y , Secti o n 4 a n d Secti o n 9. 8 wit h a re d ucti o n i n t he n u m ber of patie nts i n t he st u d y p o p ulati o n • Re m o ve d ke y sec o n d ar y o bjecti ve a n d c o nsi deri n g it as o ne of t he sec o n d ar y o bjecti ves, Ta ble 2 - 1, O bjecti ves • U p date d patie nt i ncl usi o n criteria N o. 1 & 6, Secti o n 4. 1 t o e ns ure: • o nl y le gall y c o m p ete nt patie nts ca n be i ncl u d e d i n t he trial ( N o. 1) a n d • t he hist orical se ver e e x acer bati o n is base d o n d oc u me nte d data a n d n ot o n p atie nts recall o nl y ( N o. 6) • U p date d patie nt i ncl usi o n criteri o n N o. 8 i n Secti o n 4. 1 t o clarif y:"
9,page_9,"N o v arti s C o nfi d e nti al P a g e 1 0 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 • a p ositi ve re versi bilit y test or a hist oric p ositi ve re versi bilit y test perf or me d acc or di n g t o A T S/ E R S g ui deli nes will be acce pta ble at V 1 0 1 • Pr o vi de d detaile d i nstr ucti o ns f or t he i n vesti gat or re gar di n g t he n ee d t o pa use or ter mi nate c o nc o mita nt m e dicati o n f or p atie nt ra n d o mizati o n i nt o t he trial, Secti o n 5. 5. 8 Pr o hi bite d Me dicati o ns a n d Ta ble 5 - 3 Pr o hi bite d Me dicati o ns • Clarifie d defi niti o n of t he e n d of t he tri al, Secti o n 5. 6. 1 • A d de d ser u m t otal I g E a n d a nti ge n-s pecifi c I g E (I m m u n o C A P) assess me nts at r u n -i n p hase Ta ble 6 - 1 Assess m e nt Sc he d ule • A d de d s pir o metr y at Tri al Disc o nti n uati o n ( T D) visit as S pir o metr y is part of t he A C Q -7 assess me nt , Ta bl e 6 - 1 Assess me nt Sc he d ule • Re m o ve d ce ntr al re vie w of E C Gs b y ce ntr al la b or at or y a n d r e q uire me nt t o pri nt traci n gs i n d u plicate, Secti o n 6. 5. 5 • Descri be d m eas ur es f or d ata pr otecti o n t o a v oi d u n a ut h orize d access, t o e ns ure c o nfi de ntialit y of rec or ds a n d t o pre ve nt sec urit y breac h Secti o n 8. 2 • Re m o ve d t he ke y sec o n d ar y vari a ble (c h a n ge i n tr o u g h F E V 1 fr o m baseli n e t o wee k 2 4) usi n g o nl y t he pri mar y varia ble f or h y p ot heses testi n g a n d a dj usti n g f or m ulti plicit y. Testi n g strat e g y h as bee n c ha n ge d fr o m gl o bal Si mes test t o tri m me d Si mes test, Secti o n s 9. 4. 1 , 9. 4. 2 , 9. 4. 3 , 9. 4. 4 ,a n d 9. 4. 5 • I n cl u de d t he c h a n ge i n tr o u g h F E V 1 fr o m baseli n e t o wee k 2 4 as o ne of t h e sec o n dar y varia ble s a n d t h e c orres p o n di n g a n al ysis, Secti o n 9. 5. 1. 2 • C ha n ge d t h e sa m ple size calc ulati o ns a n d p o w er a dj ust me nts base d o n u p date d testi n g strate g y of usi n g o nl y t h e pri mar y e n d p oi nt, S ecti o n 9. 8 • C orrecte d f or c o nsiste nc y t hr o u g h o ut d oc u me nt; u p date d f or matti n g, t y p o gr a p hical err ors A m e n d m e nt 1 A m e n d m e nt r ati o n al e T he pri mar y reas o ns f or t his a me n d me nt are t o e ns ure c o nsiste nc y acr oss secti o ns of t he pr ot oc ol a n d t o u p date dr u g s u p pl y s o urci n g str ate gies a n d o per ati o nal details/ pr ocesses. Pr ot oc ol secti o ns ha ve b ee n har m o nize d wit h res pect t o t he es calati o n a n d de-es calati o n of c o ntr oller or mai nte n a n ce t hera p y all o we d d uri n g t h e tr eat me nt p eri o d. T he dr u g s u p pl y s o urci n g strate g y is u p date d as l ocal s ourci n g f or t he c o m par ati ve treat me nt ar m (sal meter ol/fl uticas o ne a n d ti otr o pi u m) a n d t he r u n-i n me dicati o n (sal meter ol/fl uticas o ne) ma y o cc ur, i n a d diti o n t o gl o bal s o ur ci n g. Recr uit me nt f or t he st u d y h as n ot i nitiate d as of ti me of pr ot oc ol a me n d me nt fi nalizati o n. T hese c ha n ges will n ot i nfl ue nce t he st u d y p o p ul ati o n, t he res ults of t he st u d y n or is t here a n y i m pact t o s u bject safet y. C h a n g e s t o t h e pr ot o c ol • C ha n ge d f or matti n g of i n cl usi o n criteria 1 -7 wit h n u meric n u m beri n g of criteria fr o m b ullets f or i nter nal c o nsiste nc y ( Secti o n 4. 1)."
10,page_10,"N o v arti s C o nfi d e nti al P a g e 1 1 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 • C orrecte d err or f or e x cl usi o n criteria 1 9 , E C G t o be perf or me d at Visit 1 0 1 a n d n ot V 1 ( Secti o n 4. 2). • C orrecte d t y p o f or e x cl usi o n 2 6, patie nts o n mai nte na nce i m m u n ot hera p y f or aller gies f or less t ha n 3 m o nt hs; c ha n ge d “ or” t o “f or ” ( Secti o n 4. 2). • A d de d o pe n- l a bel c o m parati ve treat me nts (sal met er ol/fl uticas o ne a n d ti otr o pi u m) a n d r u n-i n me dicati o n (sal meter ol/fl uticas o ne) w hi c h ma y b e s o urce d l ocall y fr o m c o m mercial s u p plies. ( Secti o n 5. 1. 1 a n d Secti o n 5. 1. 2 ) • Clarifie d t hat pac k a gi n g wit h 2 part la beli n g is a p plica ble f or gl o ball y s o ur ce d treat me nts; all la beli n g will c o m pl y wit h l ocal re g ulati o ns ( Secti o n 5. 5. 2) • Re m o ve d S m P C ( S u m mar y of Pr o d uct C haracteristics) as a refer e nce f or a p pr o priate us e of ste p - u p a n d ste p- d o w n t hera p y; refer t o l ocal a p pr o ve d la bel ( Secti o n 5. 5. 5) • A d de d f o ot n ote t o Ta ble 5 - 4, “ Me dicati o ns all o we d u n der certai n cir c u msta nces” t o ali g n wit h Secti o n 5. 5. 5 w hic h descri bes t he ste p- u p a n d/ or ste p d o w n of patie nt’s bac k gr o u n d me dicati o n (c o ntr oller or mai nte na nce) treat me nt o pti o ns all o we d d uri n g t he treat me nt p hase of t he trial. ( Secti o n 5. 5. 8) • Pr o vi de d clarificati o n t hat patie nts will be i nstr ucte d b y I n vesti gat ors t o c o ntact t he trial site w he n patie nt recei ves e Diar y n otificati o ns w h e n ast h ma w ors e ni n g crit eria is met. ( Secti o n 6. 4. 4). • A d de d descri pti o n of t he baseli ne refer e nce f or S A B A use i n r u n- i n a n d treat me nt peri o ds ( Secti o n 6. 4. 4). • Ali g ne d pr ot oc ol secti o ns wit h u p date d re gi o nal stratificati o n a n d statistical a nal ysis pla n ( Secti o n 9)."
11,page_11,"N o v arti s C o nfi d e nti al P a g e 1 2 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Pr ot o c ol s u m m ar y Pr ot o c ol n u m b er C Q V M 1 4 9 B 2 3 0 6 F ull Titl e A m ultice nter, partiall y - bli n de d, ra n d o mize d, 2 4-wee k, parallel - gr o u p, n o n- i nferi orit y, o p e n-la bel acti ve c o ntr olle d st u d y t o c o m par e t he efficac y a n d saf et y of Q V M 1 4 9 wit h a fr ee tri ple c o m bi nati o n of sal meter ol/fl uticas o ne + ti otr o pi u m i n patie nts wit h u nc o ntr olle d ast h ma Bri ef titl e Efficac y st u d y of Q V M 1 4 9 i n u nc o ntr olle d ast h ma patie nts S p o n s or a n d Cli ni c al P h a s e N o vartis 3 b I n v e sti g ati o n t y p e Dr u g St u d y t y p e I nter ve nti o nal P ur p o s e a n d r ati o n al e T he p ur p ose of t his trial is t o de m o nstrate t hat t he efficac y of t w o stre n gt hs of t he fi x e d -d ose c o m bi nati o n pr o d uct Q V M 1 4 9 (I N D/ G L Y/ M F 1 5 0/ 5 0/ 8 0 μ g a n d I N D/ G L Y/ M F 1 5 0/ 5 0/ 1 6 0 μ g) is n o n- i nferi or t o t he efficac y of t he free c o m bi n ati o n of sal meter ol xi naf oate /fl uticas o ne pr o pi o nate 5 0/ 5 0 0 μ g + ti otr o pi u m 5 μ g i n u nc o ntr olle d ast h matics. Pri m ar y O bj e cti v e( s) T o de m o nstrate n o n -i nf eri orit y of eit her Q V M 1 4 9 hi g h-d ose or Q V M 1 4 9 me di u m -d ose t o c o m parat or sal met er ol / fl uticas o ne + ti otr o pi u m after 2 4 wee ks of tr eat me nt i n ter ms of Ast h ma Q u alit y of Lif e Q uesti o n nair e . S e c o n d ar y O bj e cti v e s • T o e val uate effi cac y of Q V M 1 4 9 hi g h -d ose a n d Q V M 1 4 9 me di u m- d ose c o m pare d t o sal meter ol/ fl uticas o ne + ti ot r o pi u m i n ter ms of Tr o u g h F E V 1 after 2 4 wee ks of treat me nt . • T o e val uate effi cac y of Q V M 1 4 9 hi g h -d ose a n d Q V M 1 4 9 me di u m- d ose c o m pare d t o sal meter ol/ fl uticas o ne + ti otr o pi u m i n ter ms of Ast h ma Q ualit y of Life Q u esti o n naire o ver 2 4 wee ks of treat me nt. • T o e val uate effi cac y of Q V M 1 4 9 hi g h -d ose a n d Q V M 1 4 9 me di u m- d ose c o m pare d t o sal meter ol/ fl uticas o ne + ti otr o pi u m i n ter ms of Ast h ma C o ntr ol Q uesti o n naire o ver 2 4 wee ks of treat me nt. • T o e val uate efficac y of Q V M 1 4 9 hi g h- d os e a n d Q V M 1 4 9 me di u m- d ose c o m par e d t o sal meter ol/ fl uticas o ne + ti otr o pi u m i n ter ms of l u n g f u ncti o n o v er 2 4 wee ks of treat me nt. St u d y d e si g n T his st u d y uses a m ultice nter, p artiall y-bli n de d, ra n d o mize d, 2 4 -"
12,page_12,"N o v arti s C o nfi d e nti al P a g e 1 3 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 wee k, par allel -gr o u p, n o n -i nferi orit y, o pe n-la b el acti ve c o ntr olle d desi g n. T he st u d y will c o nsist of a scree ni n g peri o d of u p t o 1 -wee k, r u n -i n peri o d of 2 -wee ks, r a n d o mize d treat me nt peri o d of 2 4- wee ks, a n d a f oll o w-u p of peri o d of 1 -wee k. P o p ul ati o n T he st u d y p o p ul ati o n will c o nsist of a p pr o xi matel y 1 2 5 1 m ale a n d fe male patie nts wit h u nc o ntr olle d ast h ma a ge d 1 8 a n d a b o ve. K e y I n cl u si o n crit eri a • Writte n i nf or me d c o nse nt m ust be o btai ne d bef o re a n y st u d y- relate d ass ess me nt is perf or me d; o nl y f ull y le gall y c o m pete nt patie nts ca n be i ncl u d e d. • Male a n d f e male a d ult patie nt ≥ 1 8 years ol d. • Patie nts wit h a dia g n osis of ast h ma f or a peri o d of at least 6 m o nt hs pri or t o Visit 1 wit h c urre nt ast h ma se v erit y ≥ ste p 4 ( GI N A 2 0 1 7). • Patie nts w h o ha ve use d I C S/ L A B A c o m bi nati o ns f or ast h ma f or at least 3 m o nt hs a n d at sta ble me di u m or hi g h d os e of I C S/ L A B A f or at least 1 m o nt h pri or t o Visit 1. • Patie nts m ust be s y m pt o matic at scree ni n g des pite treat me nt wit h me di u m or hi g h sta ble d oses of I C S/ L A B A as defi ne d b y A C Q- 7 sc ore ≥ 1. 5 at visits 1 0 1 a n d 2 0 1 (ra n d o mizati o n visit). • Patie nts wit h hist or y of at least o ne se ver e ast h ma e x acer bati o n (see Secti o n 6. 4. 5 ) w hic h re q uire d me di cal care fr o m a p h ysicia n, E mer ge nc y R o o m ( E R) visit ( or l ocal e q ui vale nt str uct ure) or h os pitalizati o n i n t he 1 2 m o nt hs pri or t o Visit 1 a n d re q uire d s yste mic c ortic oster oi ds ( S C S) treat me nt f or at least 3 da ys i ncl u di n g p h ysicia n g ui de d self-ma n a ge me nt tr eat me nt wit h oral c ortic oster oi ds ( O C S) as part of writte n ast h ma acti o n pla n. • Pre -br o nc h o dilat or F E V 1 of < 8 5 % of t h e pre dict e d n or mal val ue f or t he p atie nt after wit h h ol di n g br o nc h o dilat ors pri or t o s pir o metr y at b ot h Visit 1 0 1 a n d Visit 2 0 1. • Patie nts w h o de m o nstrate a n i ncr ease i n F E V 1 of ≥ 1 2 % a n d 2 0 0 m L. K e y E x cl u si o n crit eri a • Patie nts w h o ha ve a s m o ki n g hist or y of gr eater t h a n 2 0 pac k years. • Patie nts dia g n ose d wit h C hr o nic O bstr ucti ve P ul m o nar y Diseas e ( C O P D). • Patie nts w h o ha ve ha d a n ast h ma attac k/e x acer bati o n re q uiri n g s yste mic ster oi ds or h os pitalizati o n or e mer ge n c y r o o m visit wit hi n 6 wee ks of Visit 1 ( Scree ni n g). • Patie nts treate d wit h a L A M A f or ast h ma wit hi n 3 m o nt hs pri or t o Visit 1. • Patie nts w h o ha ve ha d a res pirat or y tr act i nfecti o n or cli nical"
13,page_13,
14,page_14,"N o v arti s C o nfi d e nti al P a g e 1 5 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 1 I ntr o d u cti o n 1. 1 B a c k gr o u n d Ast h ma is a c hr o nic i nfla m mat or y dis or der of t he air wa ys ass ociate d wit h air wa ys h y per res p o nsi ve ness t hat lea ds t o rec urre nt e pis o d es of w heezi n g, br eat hless ness, c hest ti g ht ness, a n d c o u g hi n g, partic ularl y at ni g ht or i n t he earl y m or ni n g. T hese e pis o des are us uall y ass ociate d wit h wi d es pr ea d b ut varia ble airfl o w o bstr ucti o n t hat is ofte n re versi ble eit her s p o nta ne o usl y or wit h treat me nt. Airfl o w li mitati o n occ urs as a r es ult of o bstr ucti o n or narr o wi n g of t he air w a ys, w he n e x p ose d t o preci pitati n g f act ors. E x acer bati o ns of ast h ma ar e e pis o dic w her eas i nfla m mati o n is c hr o nic ( GI N A 2 0 1 7 ). Des pite e xisti n g t hera pies t here are still si g nifica nt u n met me dical nee ds i n ast h ma, wit h a n esti mate d 3 0 0 milli o n pe o ple affecte d w orl d wi d e. T he Gl o bal B ur d e n of Ast h ma Re p ort esti mates t hat 1 5 milli o n disa bilit y– a dj uste d lif e years ( D A L Ys) are l ost a n n uall y d ue t o ast h ma, re prese nti n g 1 % of t he t otal gl o bal b ur de n. A n n u al w orl d wi de deat hs ha v e b ee n esti mate d at 2 5 0, 0 0 0 ( Mas oli, 2 0 0 4 ). Ma n y patie nts wit h ast h ma fail t o ac hie v e a d e q u ate c o ntr ol of s y m pt o ms a n d e x acer bati o ns w he n treate d wit h i n hale d c ortic oster oi ds (I C S) or c o m bi nati o ns of I C S a n d l o n g -acti n g b eta-a g o nists ( L A B A). Fail ure t o res p o n d t o i n hale d t hera p y ma y b e d ue t o m ulti ple fact ors, i ncl u di n g p o or a d h er e nce, i na de q uate i n hal er tec h ni q ue or c ortic oster oi d resista nce. T i otr o pi u m ( S piri va ® Res pi mat ®) has bee n a p pr o ve d i n Eur o pea n U ni o n ( E U) as a n a d d -o n mai nte na nce br o nc h o dilat or treat me nt i n a d ult patie nts ( ≥ 1 8 years) wit h ast h ma w h o ar e c urre ntl y treate d wit h t he mai nte na nce c o m bi nati o n of i n hale d c ortic oster oi ds ( ≥ 8 0 0 μ g b u des o ni de/ da y or e q ui v ale nt) a n d l o n g -acti n g β 2- a g o nists a n d w h o e x perie nce d o n e or m or e se vere e x acer b ati o ns i n t he pre vi o us year. F oll o wi n g ti otr o pi u m re g ulat or y a p pr o val i n ast h ma, GI N A g ui deli ne ( 2 0 1 7) rec o m me n ds ti otr o pi u m as a ne w a d d-o n o pti o n o n t o p of I C S/ L A B A for ste ps 4 a n d 5 i n patie nts wit h a hist or y of e x acer bati o ns (i n ste p 4 i n t h e list of ot h er c o ntr oller o pti o ns a n d i n ste p 5 i n t h e list of pref err e d c o ntr oller c h oice s). Q V M 1 4 9 is a fi x e d -d ose c o m bi nati o n of i n dacater ol acetat e (i n hale d L A B A wit h 2 4 h o ur d urati o n of acti o n), gl yc o p yrr o ni u m br o mi de (i n hale d L A M A wit h 2 4 h o urs d urati o n of acti o n), a n d m o metas o ne f ur oate ( M F, I C S wit h 2 4 h o ur d urati o n of acti o n) i n de vel o p me nt f or o nce-dail y mai nte na n ce treat me nt of ast h ma GI N A ste p ≥ 4. All t hree m o n o -c o mp o ne nts ha ve pre vi o usl y b ee n de vel o pe d as i n di vi d ual dr u gs f or eit her C O P D (i n dacater ol maleat e a n d gl yc o p yrr o ni u m br o mi de) or Ast h ma ( m o metas o n e f ur oate). N o vartis is de vel o pi n g Q V M 1 4 9 ( L A B A/ L A M A/I C S) fi xe d d ose c o m bi nati o n ( F D C) as a lact ose-ble n d e d i n halati o n p o w der t o be deli vere d via C o nce pt 1 ( Breez haler ®), a si n gle d ose dr y p o w der i n haler ( S D D PI) f or mai nte na nce tr eat me nt f or se ver e ast h ma ( GI N A 2 0 1 7 Ste p ≥ 4). D at a fr o m m o n o -c o m p o n e nt s: Q V M 1 4 9 is bei n g de vel o pe d i n parallel wit h Q M F 1 4 9 (i n dacater ol acetat e/ m o metas o ne f ur oate). E xisti n g efficac y a n d saf et y d ata f or t he t hr ee m o n o -c o m p o ne nts (i n dacater ol/ m o metas o ne/ gl yc o p yrr o ni u m ) of t he Q V M 1 4 9 F D C as well as f or t he t w o"
15,page_15,"N o v arti s C o nfi d e nti al P a g e 1 6 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 c o m bi nati o ns i n dacater ol/ m o metas o ne ( Q M F 1 4 9) a n d gl yc o p y rr o ni u m/i n d acater ol ( Ulti br o ®) s u p p ort i n vesti gati o n i n P hase III. I n d acat er ol maleate, d eli vere d via C o nce pt 1, a si n gle d os e dr y p o w d er i n haler ( S D D PI) ( O n brez ® Br eez haler ®), is a p pr o ve d i n o ver 1 1 0 c o u ntries w orl d wi de f or t he o nce dail y mai nte na nce br o nc h o dilat or treat me nt of airfl o w o bstr ucti o n i n patie nts wit h C O P D. Treat me nt g ui d eli nes stat e t hat L A B As ar e m ost effecti ve w he n c o m bi ne d wit h a n I C S ( GI N A 2 0 1 7 ). T he P hase III cli nical de vel o p me nt of i n dacater ol maleate t hat i ncl u de d st u dies i n patie nts wit h ast h ma ( w h o were recei vi n g bac k gr o u n d I C S t hera p y), de m o nstrate d t hat i n dacater ol maleate was effecti ve a n d well-t oler ate d. A st u d y i n a d oles ce nt a n d a d ult patie nts wit h m o derate t o se vere persiste nt ast h ma s h o we d t hat d oses of u p t o 6 0 0 μ g o. d. o ver a 2 4-wee k tr eat me nt p e ri o d ( w he n a d mi nistere d wit h c o nc o mita nt I C S t hera p y) was well-t olerat e d a n d res ulte d i n effecti ve br o nc h o dilati o n w hic h was s u peri or t o t hat pr o vi de d b y sal meter ol ( C Q A B 1 4 9 B 2 3 3 8). St u dies c o m pari n g t he i n dacater ol maleate salt wit h t h e acetate s alt f o u n d t hat t he alter nati ve salts were ass ociate d wit h a l o wer i nci de nce of p ost-i n halati o n c o u g h ( C Q A B 1 4 9 B 2 1 0 2) wit h n o i m pact o n efficac y, safet y or s yste mic e x p os ure ( C Q A B 1 4 9 D 2 3 0 1). Gl yc o p yrr o ni u m br o mi de ( 5 0 μ g o nce dail y i n a lact ose- b ase d f or m ulati o n) is r e gistere d i n t he E U si nce 2 0 1 2 as S ee bri ® Breez haler ® ( C o nce pt 1) f or t h e treat me nt of C O P D. Gl yc o p yrr o ni u m br o mi de 5 0 μ g has de m o nstrate d cli nicall y m ea ni n gf ul a n d statisticall y si g nifica nt i m pr o ve m e nts i n l u n g f u ncti o n i n C O P D patie nts w hic h is s ustai ne d o ver 2 4 h o urs a n d pr o vi des si g nifica nt s y m pt o matic be nefits wit h a fa v ora ble s afet y a n d t olera bilit y pr ofile. T he fi x e d d ose c o m bi n ati o n of i n dacater ol maleate a n d gl yc o p yrr o ni u m br o mi de is als o registere d i n t he E U as Ulti br o ® Breez haler ®. Gl yc o p yrr o ni u m br o mi de has bee n st u die d i n a d ults a n d de m o nstrat e d o pti mal br o nc h o dilati o n fr o m t he first d ose a n d efficac y w as mai ntai ne d o n o nce -dail y d osi n g f or tr eat me nt p eri o ds of u p t o a year, wit h g o o d s afet y a n d t olera bilit y. M F is mar k ete d i n i n hal ati o n, nasal, crea m, oi nt me nt a n d l oti o n f or m ulati o ns. T he i n halati o n p o w der f or m ulati o n w hic h ma y be a d mi nistere d o nce or t wice dail y is mar kete d as a m ulti d ose dr y p o w der i n haler ( M D D PI) calle d As ma ne x ® T wist haler ® f or t he treat me nt of ast h ma. As ma ne x ® T wist haler ® is c urre ntl y a p pr o ve d i n t he U nite d States f or t he treat me nt of ast h ma i n a d ults a n d c hil dre n ≥ 4 years of a ge a n d is a p pro ve d i n o ver 5 5 c o u ntries w orl d wi de f or t he treat me nt of ast h ma i n a d ults a n d a d olesce nts ≥ 1 2 years of a ge. 1. 2 P ur p o s e T he p ur p ose of t his trial is t o de m o nstrate t hat t he efficac y of t w o stre n gt hs of t he fi x e d - d ose c o m bi nati o n pr o d uct Q V M 1 4 9 (I N D/ G L Y/ M F 1 5 0/ 5 0/ 8 0 μ g a n d I N D/ G L Y/ M F 1 5 0/ 5 0/ 1 6 0 μ g) is n o n- i nferi or t o t he efficac y of t he free c o m bi nati o n of sal meter ol/ fl uticas o ne 5 0/ 5 0 0 μ g + ti otr o pi u m 5 μ g i n u nc o ntr olle d ast h matics. 2 St u d y o bj e cti v e s a n d e n d p oi nt s All o bjecti ves will c o nsi der t he f oll o wi n g 2 c o m p aris o n gr o u ps:"
16,page_16,N o v arti s C o nfi d e nti al P a g e 1 7 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Q V M 1 4 9 1 5 0/ 5 0/ 8 0 μ g o. d. deli ver e d via C o n ce pt 1 c o m pare d wit h o p e n la bel s al meter ol xi naf oate/fl uticas o ne pr o pi o n ate 5 0/ 5 0 0 μ g b.i. d. deli vere d via Acc u haler ® + ti otr o pi u m 5 μ g o. d. deli vere d via Res pi mat ® Q V M 1 4 9 1 5 0/ 5 0/ 1 6 0 μ g o. d. deli vere d via C o nce pt 1 c o m pare d wit h o pe n la bel sal meter ol xi naf oate/fl uticas o ne pr o pi o nate 5 0/ 5 0 0 μ g b.i. d. deli vere d via Acc u haler ® + t i otr o pi u m 5 μ g o. d. deli vere d via Res pi mat ® 2. 1 St u d y O bj e cti v e s a n d E n d p oi nt s T a bl e 2- 1 O bj e cti v e s a n d r el at e d e n d p oi nt s O bjecti ve(s) E n d p oi nt(s) Pri m ar y O bjecti ve • T o de m o nstrate n o n- i nf eri orit y of eit her Q V M 1 4 9 hi g h -d ose or Q V M 1 4 9 me di u m- d ose t o c o m parat or sal meter ol/ fl uticas o ne + ti otr o pi u m i n ter ms of Ast h ma Q ualit y of L if e Q uesti o n nair e ( A Q L Q) E n d p oi nt f or pri m ar y o bjecti ve • C ha n ge fr o m baseli ne i n Ast h ma Q uali t y of Life Q uesti o n nair e ( A Q L Q) t otal sc ore after 2 4 w ee ks of tr eat me nt Sec o n d ar y O bjecti ve s • T o e val uate efficac y of Q V M 1 4 9 hi g h - d ose a n d Q V M 1 4 9 me di u m - d ose c o m pare d t o sal meter ol/ fl uticas o ne + ti otr o pi u m i n ter ms of Tr o u g h F E V 1 • T o e val uate efficac y of Q V M 1 4 9 hi g h - d ose a n d Q V M 1 4 9 me di u m - d ose c o m pare d t o sal meter ol/ fl uticas o ne + ti otr o pi u m i n ter ms of Ast h ma Q ualit y of Lif e Q uesti o n nair e • T o e val uate efficac y of Q V M 1 4 9 hi g h - d ose a n d Q V M 1 4 9 me di u m - d ose c o m pare d t o sal meter ol/ fl uti cas o ne + ti otr o pi u m i n ter ms of Ast h ma C o ntr ol Q uesti o n naire • T o e val uate efficac y of Q V M 1 4 9 hi g h - d ose a n d Q V M 1 4 9 me di u m - d ose c o m pare d t o sal meter ol/ fl uticas o ne + ti otr o pi u m i n ter ms of l u n g f u n cti o n E n d p oi nts f or sec o n d ar y o bjecti ves • C ha n ge fr o m baseli ne i n Tr o u g h F E V 1 after 2 4 w ee ks of treat me nt • C ha n ge fr o m baseli ne i n Ast h ma C o ntr ol Q uesti o n naire ( A C Q - 7) t otal sc ore o ver 2 4 wee ks of tr eat me nt • C ha n ge fr o m baseli ne i n Ast h m a Q ualit y of Life Q uesti o n nair e ( A Q L Q) t otal sc ore o ver 2 4 wee ks of tr eat me nt • Perce nta ge of patie nts ac hie vi n g t he mi ni mal i m p orta nt differe nce ( M C I D) decrease fr o m baseli ne A C Q - 7 ≥ 0. 5 o ver 2 4 wee ks of treat me nt (res p o n der rate) • Perce nta ge of patie nts ac hie vi n g t he mi ni mal i m p orta n t differe nce ( MC I D) c ha n ge fr o m baseli ne A Q L Q ≥ 0. 5 o ver 2 4 wee ks of tr eat me nt (r es p o n der rate) • C ha n ge fr o m bas eli ne i n F V C o ver 2 4 wee ks of tr eat me nt • C ha n ge fr o m bas eli ne i n F orce d E x pirat or y Fl o w b et wee n 2 5 % a n d 7 5 % of F or ce d Vital Ca pacit y ( F E F 2 5 -7 5)
17,page_17,"N o v arti s C o nfi d e nti al P a g e 1 8 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 3 I n v e sti g ati o n al pl a n 3. 1 St u d y d e si g n T his st u d y uses a m ulti ce nter, p artiall y -bli n de d, ra n d o mize d, 2 4 -wee k, parallel -gr o u p, n o n - i nferi orit y, o p e n-la b el acti ve c o ntr olle d desi g n."
18,page_18,"N o v arti s C o nfi d e nti al P a g e 1 9 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 T he st u d y will c o nsist of a scr ee ni n g peri o d of u p t o 1 -wee k, r u n -i n peri o d of 2 -w ee ks, ra n d o mize d treat me nt peri o d of 2 4- wee ks, a n d a f oll o w- u p of peri o d of 1 -wee k. At Visit 1, i nf or me d c o nse nt will be o btai n e d bef or e a n y st u d y r elat e d assess me nts or pr oce d ur es are p erf or m e d. All patie nts si g ni n g i nf or me d c o ns e nt m ust be re gister e d i n t he I nteracti ve Res p o nse Tec h n ol o g y (I R T). Ast h m a me dicati o ns a n d eli gi bilit y criteria will be re vie we d. All patie nts m ust ha ve use d i n hale d L A B A + I C S f or at least 3 m o nt hs a n d bee n o n sta ble me di u m or hi g h d ose L A B A + I C S f or at l east 1 m o nt h pri or t o Visit 1. If n ecessar y, arra n ge me nts will be ma de t o a dj ust c o nc urre nt a n d pr o hi bite d me dicati o ns (Ta ble 5 - 2, Ta ble 5- 3 , a n d T a ble 5- 4) b ef ore m o vi n g f or war d t o Visit 1 0 1. O nce c o nc urre nt me dicati o ns c o m pl y wit h t he re q uire me nts of t he st u d y patie nts will c o n d uct Visit 1 0 1. Visit 1 a n d Visit 1 0 1 ma y b e perf or m e d o n t he sa me d a y if c o nc urr e nt me dicati o ns c o m pl y wit h t he re q uire me nts of t he st u d y ( L A B A + I C S m ust n ot be use d wit hi n 1 2 h o urs f or t wice dail y a n d 2 4 h o urs f or o nce dail y b ef ore Visit 1 0 1) . Visit 1 a n d Visit 1 0 1 s h o ul d be c o n d ucte d as cl ose t o get her as p ossi ble base d o n a dj ust me nts of pr o hi bite d me dicati o ns. All patie nts t hat meet eli gi bilit y criteria at Visit 1 will be pr o vi de d a s h ort -acti n g β- 2 a g o nist (sal b uta m ol) f or use as a resc u e i n haler o n a n “as nee de d ” basis t hr o u g h o ut t he st u d y; f or m ore details o n res c ue m e dicati o n please ref er t o Secti o n 5. 5. 6 . At Visit 1 0 1 all a d diti o nal scree ni n g ass ess me nts, i ncl u di n g a r e versi bilit y test t o assess eli gi bilit y (see A p pe n di x 2 S pir o metr y), a n d a n E C G t o e val uate pati e nts’ car di o vasc ular safet y, m ust be c o n d ucte d. Patie nts w h o q ualif y will e nter a 2-wee k r u n-i n p eri o d . Patie nts will be s u p plie d wit h o pe n- la bel L A B A/I C S sal meter ol /fl uticas o ne 5 0/ 2 5 0 μ g b.i. d. or 5 0/ 5 0 0 μ g b.i. d, t o matc h t heir bac k gr o u n d me dicati o n , w hic h will be use d t hr o u g h o ut t he R u n- i n a n d st o p pe d at Visit 2 0 1 . Patie nts will al s o be s u p plie d wit h a n el ectr o nic di ar y (e Diar y) c o m bi ne d wit h Pea k Fl o w meter t o rec or d ast h ma s y m pt o ms, resc ue me dicati o n use, a n d P E F. U p o n c o m pleti o n of t he r u n -i n p eri o d at Visit 2 0 1 patie nts will r et ur n t o t he cli nic. All patie nts w h o meet t he eli gi bilit y criteria will be ra n d o mize d i n a 1: 1 : 1 rati o t o o ne of t he t hree treat me nt ar ms (Secti o n 5. 2 ). Patie nts will be stratifie d at Visit 2 0 1 ra n d o mizati o n acc or di n g t o t he I C S d ose c o m p o ne nt of bac k gr o u n d I C S/ L A B A ( m e di u m or hi g h d ose) a n d r e gi o n. T he first d ose of st u d y me dicati o n will be a d mi nistere d at t he cli nic i n t he e ve ni n g ( bet wee n 5: 0 0 a n d 8: 0 0 p m) at Visit 2 0 1 ( Da y 1). Ra n d o mi ze d pat ie nts will e nter t he 2 4 wee k treat me nt peri o d d uri n g w hic h v isits m ust be sc h e d ule d t o all o w ra n d o mize d st u d y treat me nt t o be t a ke n i n t he e ve ni n g at t he cli ni c. Patie nts m ust be i nstr ucte d n ot t o ta ke t heir e v e ni n g d os e of st u d y me dicati o n pri or t o all f ut ure cli nic visits, as t hese d oses will be a d mi nistere d i n cli nic after all pre -d ose assess me nts ha ve bee n perf or me d. All treat me nt peri o d visits s h o ul d be c o n d ucte d at a p pr o xi matel y t he sa me ti me t hr o u g h o ut t he st u d y t o e ns ure pr e- d ose s pir o metr y is per f or me d a n d st u d y treat me nt is ta ke n at a p pr o xi matel y t he s a me ti me. All ra n d o mize d patie nts will be c o ntacte d ( b y t ele p h o ne) 7 da ys f oll o wi n g t he l ast d ose of st u d y me dicati o n or l ast visit, w hic he ver is later, f or Visit 3 0 1 ( Safet y F oll o w- u p)."
19,page_19,"N o v arti s C o nfi d e nti al P a g e 2 0 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Fi g ur e 3- 1 St u d y d e si g n 3. 2 R ati o n al e f or st u d y d e si g n A m ultice nter, partiall y - bli n de d, ra n d o mize d, 2 4-wee k, par allel -gr o u p, n o n -i nferi orit y, o p e n - la bel acti ve c o ntr olle d st u d y i n patie nts wit h u nc o ntr olle d ast h ma o n me di u m t o hi g h d ose IC S/ L A B A was c h ose n t o e val uate t he effi cac y a n d safet y of 2 stre n gt hs of t he fi x e d tri ple c o m bi nati o n treat me nt Q V M 1 4 9 vs t he fr ee tri ple c o m bi nati o n tr eat me nt sal meter ol/ fl uticas o ne + ti otr o pi u m. T he ge n eral desi g n is well-esta blis he d i n r es pirat or y cli nical trials a n d e na bles t he st u d y treat me nts t o be gi ve n f or a n a p pr o priate a n d practical le n gt h of ti me t o assess t he effi cac y a n d s afet y of t he treat me nts. T he st u d y has a n o p e n-la bel c o m p o ne nt (fr ee tri ple c o m bi nati o n of sal meter ol/fl uticas o ne + ti otr o pi u m f or w hic h i n vesti gat ors a n d patie nts will ha ve f ull k n o wle d ge of treat me nt all ocati o n. H o we ver, i n or der t o mi ni mize t he p ote ntial i m pact, meas ures will be ta ke n t o bli n d t he s p o ns or tea m fr o m k no wle d ge of treat me nt all ocati o n. I n a d diti o n, wit hi n t he t w o Q V M 1 4 9 treat me nt ar ms all parties i ncl u di n g patie nts a n d i n vesti gat ors will r e mai n bli n de d t o t he act ual d ose. T he i de ntit y of t he Q V M1 4 9 stre n gt hs will be c o nceale d b y t he use of st u d y dr u gs t hat ar e all i de ntical i n pac ka gi n g, la beli n g, sc h e d ule of a d mi nistrati o n, a p peara n ce, taste a n d o d or. T he o pe n -la bel desi g n of t he st u d y will re d uce t he b ur de n of a tri ple d u m m y tr eat me nt re gi me n f or p artici pati n g patie nts. A n i m pr o ve me nt of 0. 5 p oi nts i n A Q L Q sc ore is c o nsi dere d t o be t h e mi ni mall y cli nicall y i m p orta nt differe n ce ( M CI D) i n ast h ma. A n o n-i nferi orit y m ar gi n of 0. 2 5 p oi nts re d ucti o n i n A Q L Q sc ore h as bee n desi g nate d f or t h e st u d y bas e d u p o n 5 0 % of t he M CI D. If t he M CI D of 0. 5 p oi nts re d ucti o n i n t he A Q L Q is c o nsi der e d cli nicall y i m p orta nt, it is reas o n a ble t o use a n o n- i nferi orit y mar gi n of o ne- half of t his diff ere n ce, w hic h is 0. 2 5 p oi nts."
20,page_20,"N o v arti s C o nfi d e nti al P a g e 2 1 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 3. 3 R ati o n al e f or d o s e/r e gi m e n, r o ut e of a d mi ni str ati o n a n d d ur ati o n of tr e at m e nt Selecti o n of t he Q V M 1 4 9 c o m bi nati o n pr o d uct stre n gt hs ( 1 5 0/ 5 0/ 8 0 μ g o. d. a n d 1 5 0/ 5 0/ 1 6 0 μ g o. d.) f or e val u ati o n i n t his P hase III b st u d y are t he sa m e as t h ose use d i n t he P hase III pr o gra m a n d bas e d o n t h e d oses of t he c o nstit ue nt m o n ot hera pies w hic h h a ve bee n a p pr o v e d f or eit her C O P D or ast h ma. I n d a c at er ol a c et at e: I n d acat er ol maleate at a d ose of 1 5 0 μ g o. d. is mar kete d f or t he mai nte na nce treat me nt of C O P D. A d ose -r a n gi n g st u d y of i n dacat er ol maleate i n ast h matic p atie nts de m o nstrate d t hat a d ose of 1 5 0 μ g o. d. w as safe a n d eff ecti ve ( St u d y C Q A B 1 4 9 B 2 3 5 7). T he acetate salt of i n dacater ol was f o u n d t o res ult i n a l o wer i nci de nce of t he p ost-i n h alati o n c o u g h, o bs er ve d f or i n dacater ol maleate, wit h o ut i m pact o n efficac y or safet y C Q A B 1 4 9 D 2 3 0 1. T he d ose of i n dacater ol acetat e 1 5 0 μ g was als o c o nfir me d i n St u d y C Q M F 1 4 9 E 2 2 0 3 i n a d ult ast h ma patie nts w here i n dacater ol acetate 1 5 0 μ g a n d 7 5 μ g deli vere d via C o nce pt 1 t o place b o wer e i n vesti gate d. I n d acat er ol acetate 1 5 0 μ g s h o we d p ositi ve tre n ds i n ter ms of tr o u g h F E V 1, P E F a n d resc u e me dicati o n use c o m pare d wit h i n dacater ol acet ate 7 5 μ g. I n st u d y Q M F 1 4 9 A 2 2 1 0, Q M F 1 4 9 1 5 0/ 1 6 0 μ g o. d. s h o we d be n eficial eff ects o n ast h ma e x acer bati o ns i n ter ms of t he ti me t o first e x acer bati o n a n d t he c u m ulati ve i nci d e nce of s eri o us ast h ma e x acer bati o ns. T heref ore, a d ose of i n dacater ol acet ate 1 5 0 μ g o. d. has bee n selecte d f or use i n t he Q V M 1 4 9 pr o gra m. M o m et a s o n e f ur o at e: Si nce a vaila ble data f or t he M F c o m p o ne nt e xists i n t he T wist haler ® de vice, a 3 ste p bri d gi n g a p pr oac h was c o n d uct e d t o deter mi ne M F d ose f or C o nce pt 1 w hi c h is c o m para ble t o eac h of t he re gistere d d ail y d os es of As ma ne x T wist haler ® ( m o metas o ne f ur o ate, i n halati o n p o w der). T his is d ue t o differe nce i n de vice perf or m a nce c haract eristics bet wee n t he T wist haler ® a n d C o nce pt 1 de vices. Ste p 1: p har mac o ki netic bri d gi n g utilizi n g p har mac o ki netic c haracterizati o n i n st u d y C Q M F 1 4 9 E 2 1 0 1 ( Vai d ya S et al, 2 0 1 2) f oll o w e d b y i n -vitr o fi ne particle mass a dj ust me nt (ste p 2) a n d fi nall y p har mac o d y n a mic e val uati o n of efficac y i n ast h ma patie nts i n st u d y C Q M F 1 4 9 E 2 2 0 1 (ste p 3). F or Ste p 1 a n d 2, t he d ata of st u d y C Q M F 1 4 9 E 2 1 0 1 ( Vai d ya S et al, 2 0 1 2), al o n g wit h i n vitr o fi ne particle m ass a dj ust me nts ha ve le d t o t he selecti o n of 8 0, 1 6 0 a n d 3 2 0 μ g as d os es of M F i n C o nce pt 1 de vice t hat are c o m para ble t o t he a p pr o ve d d oses 2 0 0 μ g, 4 0 0 μ g a n d 8 0 0 μ g ( 2 x 4 0 0 μ g) M F i n T wist haler ®. F or Ste p 3, t w o of t he M F d oses i n T wist haler ® a n d C o nce pt 1 were f urt her e val uat e d f or p har mac o d y n a mic a n d cli nical c o m para bilit y i n a 4 -wee k st u d y ( C Q M F 1 4 9 E 2 2 0 1) i n patie nts wit h persiste nt ast h ma. M F d oses of 8 0 μ g a n d 3 2 0 μ g deli vere d o nce dail y via C o nce pt 1 s h o we d c o m para ble efficac y i n tr o u g h F E V 1 a n d sli g htl y l o w er s yste mic e x p os ure c o m pare d t o M F d oses of 2 0 0 μ g a n d 8 0 0 μ g ( 2 x 4 0 0 μ g) deli vere d o nce dail y via T wist haler ® c o nfir mi n g t h e selecte d d oses f or M F C o nce pt 1 ar e a p pr o priate f or f urt her Q M F 1 4 9 C o nce pt 1 de vel o p me nt."
21,page_21,"N o v arti s C o nfi d e nti al P a g e 2 2 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 I n s u m mar y, M F d oses of 2 0 0 μ g o. d, 4 0 0 μ g o. d. a n d 4 0 0 μ g b.i. d. deli vere d b y T wist haler ® are c o m para ble wit h M F d oses of 8 0 μ g o. d, 1 6 0 μ g o. d. a n d 3 2 0 μ g o. d., res pecti vel y i n Q M F 1 4 9 deli ver e d b y C o nce pt 1. F or Q V M 1 4 9 pr o gr a m, as a r es ult of a c o m p o n e nt i nteracti o n, a n i ncr ease i n t he M F fi ne particle mass ( F P M) i n t he Q V M 1 4 9 c o m bi nati o n pr o d uct c o m pare d t o t he c orr es p o n di n g sa me n o mi nal M F d os e i n Q M F 1 4 9 ( m atc he d t o As ma ne x ® T wist haler ®) was o bser v e d. T o a dj ust f or t his, t he n o mi nal d oses of M F has bee n re d uce d t o, 8 0 μ g o. d. a n d 1 6 0 μ g o. d. t o e ns ure t hat t he fi n e particle mass ( F P M, i n -vitr o aer os ol p erf or ma nce) i n t he lact ose ble n d f or m ulati o n f or t he tri ple F D C is c o m para ble t o t he n o mi nal M F d oses of 8 0 μ g o. d., 1 6 0 μ g o. d. a n d 3 2 0 μ g o. d. f or Q M F 1 4 9 pr o gra m, res pecti vel y. T heref or e 4 0 0 μ g M F via T wist haler ® is c o m para ble w it h 1 6 0 μ g M F i n Q M F i n C o nce pt 1 a n d wit h 8 0 μ g Q V M 1 4 9 vi a C o nce pt 1; all pr o vi de si milar fi ne particle mass a n d t here b y e x pecte d t o pr o vi de si milar l u n g a n d s yste mic e x p os ure, si nce or al bi oa vaila bilit y of M F is l o w. Gl y c o p yrr o ni u m br o mi d e: T he d ose c h ose n f or gl yc o p yrr o ni u m br o mi de of 4 4 μ g ( e x presse d as d ose a cti ve m oiet y deli ver y b y t he m o ut h piece of t he i n haler) is t he o ne first a p pr o ve d i n t he E U o n 2 8 - Se p - 2 0 1 2 f or t he i n dicati o n of m ai nte na nce br o nc h o dilat or treat me nt t o relie ve s y m pt o ms i n a d ult patie nts wit h C O P D. O utsi de t he E U, t he d ose of See bri ® Br ee z haler ® is ge n erall y e x presse d as t he d ose of acti ve m oiet y i n t he ca ps ule, i.e. 5 0 μ g. E xte nsi ve data fr o m t h e P hase III de v el o p me nt pr o gra m i n C O P D s u p p orts t he efficac y a n d safet y of gl yc o p yrr o ni u m br o mi de 5 0 μ g o nce dail y. It has de m o nstrate d cli nicall y mea ni n gf ul a n d statisticall y si g nifica nt i m pr o ve me nts i n l u n g f u n cti o n i n C O P D patie nts w hic h wer e s ustai ne d o ver 2 4 h o urs a n d pr o vi de d si g nifica nt s y m pt o matic be nefits wit h a fa v ora ble saf et y a n d t olera bilit y pr ofile. L u n g f u n cti o n i m pr o ve me nts were c o m para bl e t o ti otr o pi u m 1 8 μ g a d mi nistere d via Ha n di H aler ®. Ti otr o pi u m 5 μ g o nce d ail y has bee n a p pr o ve d i n E ur o pe f or treat me nt of ast h ma as a d d o n t o hi g h d ose L A B A/I C S i n patie nts wit h a hist or y of e x acer bati o ns. T his is e q ui vale nt t o t he d ose a p pr o ve d i n C O P D. It is rec o m me n de d b y GI N A g ui deli ne ( 2 0 1 7) as a n a d d-o n o pti o n ( o n t o p of t he pref err e d c o ntr oller c h oice) f or Ste ps 4 a n d 5 i n patie nts wit h a hist or y of e x acer b ati o ns. Base d o n h ea d t o hea d c o m parati ve d ata c o n d uct e d i n p atie nts wit h C O P D, it is e x pecte d t hat gl yc o p yrr o ni u m br o mi d e 5 0 μ g o n ce- dail y will pr o vi de si milar efficac y i n a n ast h ma p o p ulati o n. T he t w o L A M As, gl yc o p yrr o ni u m a n d ti otr o pi u m b ot h de m o nstrate si milar ki netic selecti vit y f or M 3 o v er M 2 rece pt ors, w hic h is i m p ort a nt f or t h eir si milar l o n g a n d s ustai ne d br o nc h o dilat or effects ( T esti 2 0 1 4). Base d o n t h e a vaila ble d ata gl yc o p yrr o ni u m br o mi de 5 0 μ g is c o nsi dere d a n a p pr o pri ate d os e t o bri n g f or war d i nt o P hase III/III b ast h ma pr o gra m as part of tri ple F D C Q V M 1 4 9 ( L A B A/ L A M A/I C S)."
22,page_22,"N o v arti s C o nfi d e nti al P a g e 2 3 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 3. 4 R ati o n al e f or c h oi c e of c o m p ar at or Sal meter ol/fl uticas o ne is wi del y use d sta n dar d of care i n ast h ma treat me nt. Sal meter ol /fl uticas o ne hi g h d ose 5 0/ 5 0 0 μ g b.i. d. d eli vere d b y D PI ( dr y-p o w der i n h aler) is m ar ket e d as Sereti de ® Acc u haler ® or Sereti de ® Dis k us ® de p e n di n g o n t he c o u ntries f or t he treat me nt of ast h ma i n a d ults a n d a d ol esce nts 1 2 years a n d ol der. Ti otr o pi u m 5 μ g o. d. has bee n a p pr o v e d i n E ur o p e f or treat me nt of ast h m a as a d d-o n t o hi g h d ose L A B A/I C S i n patie nts wit h a hist or y of e x acer bati o ns a n d is mar kete d as S piri va ® Res pi mat ® S oft Mist ™ . Ti otr o pi u m is t he o nl y a p pr o v e d L A M A f or t his i n dicati o n w orl d wi de. It is r ec o m me n de d b y GI N A g ui deli n e ( 2 0 1 7 ) as a n a d d-o n o pti o n ( o n t o p of t he preferre d c o nt r oller c h oice) f or Ste ps 4 a n d 5. T he i nte nti o n of t his trial is t o c o m par e a fi x e d d ose c o m bi nati o n of L A B A/ L A M A/I C S i n t w o differe nt d ose stre n gt hs wit h t he acti ve c o m parat or l o ose c o m bi nati o n of t hese 3 c o m p o ne nts ( L A B A, L A M A, a n d I C S). T he acti ve c o m parat or is b ase d o n t he GI N A g ui deli ne rec o m me n dati o n s i n t his p o p ulati o n a n d re prese nts t he sta n dar d of care. T he acti ve c o m parat or free c o m bi nati o n of sal meter ol/fl uticas o ne pl us ti otr o pi u m als o re pres e nts t he m ost c o m m o nl y us e d dr u gs w hic h ca n f or m t he free tri ple c o m bi nati o n. T heref ore , it is of scie ntific i nterest t o c o n d uct a direct c o m p aris o n st u d y t o de m o nstrate t hat t he fi x e d tri ple c o m bi nati o n Q V M 1 4 9 is n o n -i nferi or t o t he fr ee tri ple c o m bi nati o n of sal meter ol/fl uticas o ne pl us ti otr o pi u m. 3. 5 P ur p o s e a n d ti mi n g of i nt eri m a n al y s e s/ d e si g n a d a pt ati o n s N o i nteri m a nal ysis f or efficac y is pla n ne d. 3. 6 Ri s k s a n d b e n efit s D ual br o nc h o dilati o n wit h I C S c o ntr oller w o ul d be e x pecte d t o ac hie ve g o o d s y m pt o m c o ntr ol, mi ni mize airfl o w o bstr ucti o n, mi ni mize ris k of e x acer bati o ns, a n d h os pitalizati o ns i n t his p o p ulati o n. Use of m ulti ple, ofte n differe nt de vices re pres e nts a si g nifica nt b ur de n f or ast h ma patie nts. A v aila bilit y of t hr ee eff ecti ve o nce -dail y c o ntr oller m e dicati o ns i n a si n gle de vice ma y offer a d va nta ges i n ter ms of i m pr o ve d a d here n ce a n d c o n ve ni e nce. T h e a vaila ble ast h ma cli nical trial data s u g gest t hat a L A M A ma y c o nfer br o nc h o dilat or effects i n ter ms of i m pr o ve d l u n g f u ncti o n w he n use d i n a d diti o n t o I C S al o ne or i n c o nj u ncti o n wit h L A B A/I C S (i.e., “free c o m bi nati o n” or “l o ose” tri ple t her a p y) ( Far d o n 2 0 0 7, Peters 2 0 1 0, Bate ma n 2 0 1 1, Kerstje ns 2 0 1 1, Kerstje ns 2 0 1 2, G u yer 2 0 1 3). A re vie w e val uati n g t he efficac y pr ofile of a L A M A (ti otr o pi u m) as a d d -o n t hera p y t o I C S or L A B A/I C S i n p atie nts wit h u nc o ntr olle d m o derat e t o se v er e persiste nt ast h ma c o ncl u d e d t hat t he a d diti o n of a L A M A res ulte d i n si g nifica nt i m pr o ve me nts i n l u n g f u ncti o n ( F E V 1 a n d pea k e x pirat or y fl o w) ( Befe ka d u 2 0 1 4). T he be nefit of a d di n g a m uscari nic a nta g o nist i n t he treat me nt of u n c o ntr olle d ast h ma is s u p p orte d b y t w o re plicate st u dies w hic h c o m pare d ti otr o pi u m t o place b o ( Kerstje ns 2 0 1 2). Kerstje ns et al s h o we d t h at ti otr o pi u m o n t o p of hi g h d ose I C S/ L A B A i m pr o ve d l u n g f u n cti o n a n d si g nifica ntl y pr ol o n ge d ti me t o first s e ver e e x acer b ati o n ( K er stje ns 2 0 1 2). T he a d diti o n of"
23,page_23,"N o v arti s C o nfi d e nti al P a g e 2 4 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 ti otr o pi u m i ncrease d t he ti me t o t he first se vere e x acer bati o n ( 2 8 2 da ys vs. 2 2 6 da ys), wit h a n o verall re d u cti o n of 2 1 % i n t he ris k of a se vere e x acer bati o n. A d diti o n of L A M A (ti otr o pi u m 5 μ g Res pi mat ®) t o I C S/ L A B A is n o w a rec o m me n d e d treat me nt o pti o n i n GI N A g ui deli ne ( 2 0 1 7) f or ste p 4 o n war ds. As gl yc o p yrr o ni u m a n d ti otr o pi u m ( Ha n di Haler ®) de m o nstrate d c o m p ara ble effi cac y a n d saf et y i n C O P D, it is reas o na bl e t o e x pect t hat b ot h dr u gs w o ul d s h o w si milar ris k/ be nefit pr ofiles i n ast h ma ( C ha p ma n 2 0 1 4). O verall, as c o ncl u d e d fr o m t he cli nical st u dies gl yc o p yrr o ni u m br o mi de o. d. was safe a n d well t olerate d b y t he C O P D patie nts a n d c o m para ble t o o pe n la bel ti otr o pi u m. Re p orti n g rates f or k n o w n cl ass effect A Es f or a nti-c h oli ner gic dr u gs w ere l o w a n d ge n er all y c o nsiste nt wit h t h ose e x pecte d f or t his class (i.e. c o nsti pati o n, uri nar y rete nti o n, gl a uc o m a, dr y m o ut h). N o e n ha nce d ris k of car di o - or cere br o vasc ul ar e ve nts relati ve t o place b o was a p pare nt, a n d t h e deat h rat e i n gl yc o p yrr o ni u m br o mi de at all d oses was l o wer t h a n t hat o bser ve d i n t he place b o gr o u p. I n s u m mar y, as t he be nefit ris k pr ofile of gl yc o p yrr o ni u m br o mi de has s h o w n t o be p ositi ve i n C O P D patie nts i n w hic h t here are m or e c o m or bi dities t ha n ast h matic patie nts. T he saf et y pr ofile i n a n ast h ma p o p ulati o n ( w hic h is ge nerall y y o u n ger wit h less c o-m or bi dities) is e x pecte d t o als o be p ositi ve. I n t his c urr e nt P hase III b st u d y, t w o Q V M 1 4 9 stre n gt hs will be c o m p are d t o s al meter ol/ fl uticas o ne + ti otr o pi u m d uri n g 2 4 wee ks of tr eat me nt. Partici pati n g p atie nts i n t his st u d y will be ra n d o mize d t o recei v e eit her o ne of t he t w o stre n gt hs/d oses of Q V M 1 4 9 or sal meter ol / fl uticas o ne + ti otr o pi u m. T he use of ot her c o ntr oller me dicati o ns, i.e. s ustai ne d rel ease t he o p h ylli ne, le u k otri e ne m o difiers a n d a nti I g E ( X olair ®) i n sta ble d oses will be per mitte d d u e t o t he se verit y of t he disease a n d p er treat me nt g ui deli ne ( GI N A 2 0 1 7). T he e x pecte d p ote ntial be nefit f or t he patie nt i ncl u de a n i m pr o ve me nt i n t he p ul m o nar y f u ncti o n, better ast h ma c o ntr ol s uc h as re d ucti o ns i n s y m pt o ms, resc ue me dicati o n use a n d l o wer fre q u e nc y/ se verit y of ast h ma e x acer b ati o ns, a n d i m pr o ve d q ualit y of life. A t h or o u g h me dical e val u ati o n of t he patie nts’ diseas e a n d cl ose cli nical m o nit ori n g f or t he d ur ati o n of t he st u d y will pr o vi de a d diti o nal be nefit t o t he patie nt care. Fre q u e nt a n d re g ular c o ntacts will occ ur i n ter ms of cli nic visits a n d tele p h o ne c o ntacts w he n nee de d , t o eac h patie nt t hr o u g h o ut t h e 2 4-w ee k tr eat me nt. I n a d diti o n, safet y m o nit ori n g (e. g. s y m pt o m c ollecti o n a n d resc ue me dicati o n use via electr o nic diar y), a n d P E F ( dail y) meas ure me nts at re g ular i nter vals t hr o u g h o ut t he st u d y will hel p assess stat us of t he patie nt’s ast h ma s y m pt o m c o ntr ol. T heref or e, i n vesti gat ors ma y h a ve a n earl y i n dicati o n of w orse ni n g s y m pt o ms a n d will be a ble t o m o nitor t he patie nt cl osel y t hr o u g h o ut t he st u d y. I n li ne wit h c urre nt m e dical treat me nt g ui deli nes, all patie nts partici pati n g i n t h e st u d y will recei v e acti ve “c o ntr oller” treat me nt f or t heir ast h ma t hr o u g h o ut t he 2 4-wee k treat me nt peri o d. I n a d diti o n, pr o vi d i n g t he patie nts wit h r esc ue me dicati o n f or us e as n ee de d t o tr eat a n y s u d de n c o nstricti o n hel ps miti gate t hese ris ks. At n o ti me, will a n y patie nt be wit h o ut treat me nt f or ast h ma."
24,page_24,"N o v arti s C o nfi d e nti al P a g e 2 5 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 T he ris k t o t he patie nts i n t he st u d y is t hat Q V M 1 4 9 is u n der de vel o p me nt i n ast h ma a n d t heref or e it is p ossi ble t hat u ne x pecte d safet y iss ues ma y be i de ntifie d a n d t he ris k will be mi ni mize d b y c o m plia nce wit h t he eli gi bilit y criteria a n d cl ose cli nical m o nit ori n g of patie nts. T he ris ks of si de eff ects fr o m t he st u d y me dicati o n are t h ose k n o w n f or t he i n di vi d ual c o m p o ne nts i n dacat er ol acetat e, gl yc o p yrr o ni u m br o mi de a n d m o met as o ne f ur o ate. N o a d diti o nal ris ks ha ve b ee n i de ntifie d w hi c h mi g ht occ ur w he n t h e t hr ee c o m p o n e nts ar e a d mi nistere d c o nc urre ntl y or fr o m t he sa me i n haler. D etaile d ris k -b e nefit i nf or mati o n ca n be o btai ne d fr o m t he Q V M 1 4 9 I n v esti gat or’s Br oc h ure. G ui da nce t o ma na ge p ote ntial w orse ni n g of ast h ma s y m pt o ms will be pr o vi de d t o i n vesti gat ors c o nsiste nt wit h g ui deli ne r ec o m me n dati o ns ( GI N A 2 0 1 7 ). Patie nts will receive writte n i nstr ucti o ns as t o h o w t o c o ntact t he i n vesti gat or i n t he e ve nt of w orse ni n g of t heir ast h ma s y m pt o ms . T he i n vesti gat or s h o ul d disc o nti n ue st u d y tr eat me nt f or a gi ve n p atie nt if, o n bala nce, h e/s he belie v es t hat c o nti n uati o n w o ul d be detri me ntal t o t he p atie nt’s well- bei n g. Patie nts are als o i nstr uct e d t hat t he y ca n disc o nti n ue st u d y tr eat me nt at a n y ti me, a n d f or a n y reas o n. I n s u m mar y, base d o n a v aila ble data of c o m p o ne nts, it is a ntici pate d t hat Q V M 1 4 9 1 5 0/ 5 0/ 8 0 μ g a n d Q V M 1 4 9 1 5 0/ 5 0/ 1 6 0 μ g wil l ha ve a fa v ora ble be nefit t o ris k pr ofile i n patie nts wit h u nc o ntr olle d ast h ma. 4 P o p ul ati o n T he st u d y p o p ulati o n will c o nsist of a p pr o xi matel y 1 2 5 1 m ale a n d fe male patie nts wit h u nc o ntr olle d ast h ma a ge d 1 8 a n d a b o ve. It is a ntici pate d t hat a p pr o xi matel y 2 5 0 0 pati e nts will nee d t o be s cree n e d i n or der t o ra n d o mize a p pr o xi matel y 1 2 5 1 patie nts i nt o t he t hree treat me nt gr o u ps of t he st u d y wit h a ra n d o mizati o n rati o of 1: 1: 1, (i.e. a p pr o xi matel y 4 1 7 patie nts i n eac h of t h e treat me nt gr o u ps). Dr o p -o uts after ra n d o mizati o n will n ot be re place d. T his st u d y will e nr oll m ulti -nati o nall y a n d patie nts will be stratifie d b y pr e vi o us I C S d ose c o m p o ne nt of I C S/ L A B A t hera p y ( me di u m or hi g h) a n d re gi o n. 4. 1 I n cl u si o n crit eri a 1. Writte n i nf or me d c o nse nt m ust be o btai ne d bef ore a n y st u d y- relate d assess me nt is perf or me d. O nl y f ull y l e gall y c o m p ete nt patie nts ca n be i ncl u d e d ( patie nts t hat are n ot a ble t o c o nse nt ca n n ot be recr uite d i n t his trial). 2. Male a n d f e male a d ult patie nt ≥ 1 8 years ol d. 3. Patie nts wit h a dia g n osis of ast h ma f or a peri o d of at least 6 m o nt hs pri or t o Visit 1 wit h c urre nt ast h ma se verit y ≥ ste p 4 ( GI N A 2 0 1 7). 4. Patie nts w h o ha ve use d I C S/ L A B A c o m bi nati o ns f or ast h ma f or at least 3 m o nt hs a n d at sta ble me di u m or hi g h d ose of I C S/ L A B A f or at least 1 m o nt h pri or t o Visit 1 (A p pe n di x 1 0 ). 5. Patie nts m ust be s y m pt o matic at scree ni n g des pite treat me nt wit h m e di u m or hi g h sta ble d oses of I C S/ L A B A as d efi ne d b y A C Q - 7 s c ore ≥ 1. 5 at visits 1 0 1 a n d 2 0 1 (ra n d o mizati o n visit)."
25,page_25,"N o v arti s C o nfi d e nti al P a g e 2 6 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 6. Patie nts wit h hist or y of at least o ne se ver e ast h ma e x acer bati o n ( Secti o n 6. 4. 5 ) w hic h re q uire d me di cal care fr o m a p h ysicia n, E R visit ( or l ocal e q ui vale nt str u ct ure) or h os pitalizati o n i n t he 1 2 m o nt hs pri or t o Visit 1 a n d re q uire d s yste mic c ortic oster oi d ( S C S) treat me nt f or at least 3 da ys i n cl u di n g p h ysicia n g ui d e d self-ma n a ge me nt treat me nt wit h oral c ortic oster oi ds as part of writte n ast h ma acti o n pla n . • Pre vi o us se vere ast h m a e x acer bati o n i n t his c o nte xt m ust be s u p p orte d b y d oc u me ntati o n (i.e. s uc h as i n s o urce n otes, p har mac y r ec or ds, h os pital rec or ds, or c hart r ec or ds) of u n pla n ne d nee d f or me dical care at a n y pri mar y car e p h ysici a n, p ul m o n ol o gist, e mer ge n c y r o o m a n d h os pital d ue t o a n a g gra v ati o n of ast h ma s y m pto ms a n d treat me nt wit h s yste mic c ortic oster oi ds d ue t o s e v ere ast h ma e x acer bati o n i ncl u di n g p h ysicia n g ui de d self-ma na ge me nt treat me nt wit h oral c ortic oster oi ds as part of writte n ast h ma acti o n pla n . 7. Pre -br o nc h o dilat or F E V 1 of < 8 5 % of t h e pre dict e d n or ma l val ue f or t he patie nt after wit h h ol di n g br o nc h o dilat ors pri or t o s pir o metr y (Ta ble 5 - 2) at b ot h Visit 1 0 1 a n d Visit 2 0 1. • Re peat testi n g is all o w e d o nce at eac h visit ( b y res c he d uli n g t h e visit). Re peat of Visit 1 0 1 s h o ul d be sc he d ule d o n a date t hat w o ul d pr o vi de s ufficie nt ti me t o recei ve c o nfir mati o n fr o m t he s pir o metr y ce ntr al re vie wer bef ore ra n d o mizati o n. • Re -scree ni n g is all o we d o nce if patie nt f ails t o meet t he criteria at t he r e peat visit. 8. Patie nts w h o de m o nstrate a n i ncr eas e i n F E V 1 of ≥ 1 2 % a n d 2 0 0 m L 1 5 t o 3 0 mi n utes after a d mi nistrati o n of 4 0 0 μ g sal b uta m ol or 3 6 0 μ g al b uter ol (e q ui val e nt d ose) t hr o u g h a s pacer d e vice at Visit 10 1 . Patie nts nee d t o de m o nstrate re v ersi bilit y at V 1 0 1 b y eit her a p ositi ve re versi bil it y test or wit h hist orical e vi de nce of re v ersi bilit y or p ositi ve br o nc hial pr o v ocati o n test t hat was perf or me d wit hi n 5 years pri or t o Visit 1 a n d acc or di n g t o A T S/ E R S g ui deli nes . If r e versi bilit y is n ot de m o nstrate d at Visit 1 0 1 t he re versi bilit y test ma y b e re p eate d o n ce. If re versi bility is n ot de m o nstrate d at Visit 1 0 1 ( or after r e peat ) a n d hist orical e vi de nce of re versi bilit y is n ot a vaila ble ( or w as n ot perf or me d acc or di n g t o t he A T S/ E R S g ui deli nes ) t he patie nts m ust be scree n faile d. 4. 2 E x cl u si o n crit eri a Patie nts f ulfilli n g a n y of t he f oll o wi n g criteria ar e n ot eli gi ble f or i n cl usi o n i n t his st u d y. N o a d diti o nal e x cl usi o ns ma y be a p plie d b y t he i n vesti gat or, i n or d er t o e ns ure t hat t h e st u d y p o p ulati o n will be re pres e ntati ve of all eli gi ble patie nts. 1. Patie nts w h o ha ve a s m o ki n g hist or y of gr eater t h a n 20 pac k years ( N ote: 1 pac k is e q ui vale nt t o 2 0 ci gar ettes. 1 0 pac k years = 1 p ac k / da y x 1 0 yrs., or ½ pac k/ da y x 2 0 yrs.). 2. Patie nts dia g n ose d wit h C hr o nic O bstr ucti ve P ul m o nar y Diseas e ( C O P D). 3. Patie nts w h o ha ve ha d a n ast h ma attac k/e x acer bati o n re q uiri n g s yst e mic ster oi ds or h os pitalizati o n or e mer ge nc y r o o m visit wit hi n 6 wee ks of Visit 1 ( Scr ee ni n g). If patie nts e x perie nce a n ast h ma att ac k/e x acer b ati o n re q uiri n g s yste mic ster oi ds or h os pitalizati o n or e mer ge n c y r o o m v isit bet wee n Visit 1 a n d Visit 2 0 1 t he y ma y b e re-scr ee n e d 6 wee ks after r ec o v er y fr o m t he e x acer bati o n."
26,page_26,"N o v arti s C o nfi d e nti al P a g e 2 7 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 4. Patie nts w h o ha ve e ver r e q uire d i nt u bati o n f or a s e vere ast h ma attac k/ e x acer bati o n. 5. Patie nts w h o ha ve a cli ni cal c o n diti o n w hic h is li kel y t o be w orse n e d b y I C S a d mi nistrati o n (e. g. gl a uc o ma, catar act a n d fra gilit y fract ur es) w h o are acc or di n g t o i n vesti gat or’s m e dical j u d g me nt at ris k p artici pati n g i n t he st u d y. 6. Patie nts treate d wit h a L A M A f or ast h ma wit hi n 3 m o nt hs pri or t o Visit 1. 7. Patie nts wit h narr o w -a n gle gla u c o ma, s y m pt o matic be ni g n pr ostatic h y per plasia ( B P H) or bl a d der- n ec k o bstr ucti o n or se ver e re n al i m pair me nt or uri nar y r ete nti o n. B P H patie nts w h o are sta bl e o n treat m e nt ca n be c o nsi der e d . 8. Patie nts w h o ha ve ha d a res pirat or y tr act i nfecti o n or cli nical si g nifi ca nt ast h ma w orse ni n g as defi ne d b y I n vesti gat or wit h i n 4 wee ks pri or t o Visit 1 or bet wee n Visit 1 a n d Visit 20 1. Patie nts ma y be re -s cree ne d 4 wee ks after rec o ver y fr o m t heir r es pirat or y tract i nfecti o n or ast h ma w orse ni n g. 9. Patie nts wit h a n y c hr o nic c o n diti o ns affecti n g t he u p per res pir at or y tract (e. g. c hr o nic si n usitis) w hic h i n t he o pi ni o n of t he i n vesti gat or ma y i nterfer e wit h t he st u d y e v al uati o n or o pti mal partici pati o n i n t he st u d y. 1 0. Patie nts wit h a hist or y of c hr o nic l u n g diseases ot her t ha n ast h ma, i ncl u di n g ( b ut n ot li mite d t o) sarc oi d osis, i nterstitial l u n g disease, c ystic fi br osis, cli nicall y si g nifica nt br o nc hiectasis a n d acti ve t u berc ul osis. 1 1. Patie nts wit h u nc o ntr olle d T y pe I or T y p e II dia b etes. 1 2. Patie nts w h o ha ve a cli ni call y si g nifica nt la b orat or y a b n or malit y at Visit 1 0 1. 1 3. Use of ot her i n v esti gati o nal dr u gs wit hi n 3 0 da ys or 5 half- li ves of e nr oll me nt, u ntil t he e x pecte d p har mac o d y na mics effect has ret ur ne d t o baseli ne, w hic he v er is l o n ger. 1 4. Patie nts w h o, i n t he j u d g me nt of t he i n vesti gat or, ha ve cli nicall y si g nifica nt c o n diti o n s uc h as ( b ut n ot li mite d t o) u nsta ble isc he mic heart disease, Ne w Y or k H eart Ass ociati o n ( N Y H A) Class III/I V l eft ve ntric ular f ail ure, arr h yt h mia, u nc o ntr olle d h y p erte nsi o n, cere br o vasc ul ar diseas e, ps yc hiatric diseas e, ne ur o de ge ner ati ve diseas es, or ot her ne ur ol o gi cal diseas e, u nc o ntr olle d h y p o- a n d h y pert h yr oi dis m a n d ot her a ut oi m m u ne diseases, h y p o kale mia, h y p er a dr e ner gi c state, or o p ht hal m ol o gic dis or der or patie nts wit h a me dical c o n diti o n t hat mi g ht c o m pr o mise patie nt safet y or c o m plia nce, i nterfer e wit h e val uati o n , or pr ecl u de c o m pleti o n of t he st u d y. 1 5. Patie nts wit h par o x ys mal (e. g., i nter mitte nt) atrial fi brillati o n are e x cl u de d. Patie nts wit h persiste nt atrial fi brillati o n as defi ne d b y c o nti n u o us atrial fi brillati o n f or at least 6 m o nt hs a n d c o ntr olle d wit h a r at e c o ntr ol strate g y (i.e., s electi ve beta bl oc k ers, calci u m c ha n nel bl oc ker, pace ma k er place me nt, di g o xi n or a blati o n t hera p y) f or at least 6 m o nt hs ma y be c o nsi dere d f or i ncl usi o n. I n s u c h patie nts, atrial f i brillati o n m ust be prese nt at Visit 1 0 1 wit h a resti n g v e ntric ular rate < 1 0 0/ mi n. 1 6. Patie nts wit h a hist or y of m y ocar dial i nfarcti o n wit hi n 1 2 m o nt hs pri or t o Visit 1 . 1 7. C o nc o mita nt use of a ge nts k n o w n t o pr ol o n g t he Q T i nter val u nless it ca n be per ma n e ntl y disc o nti n ue d f or t he d ur ati o n of st u d y. 1 8. Patie nts wit h a hist or y of l o n g Q T s y n dr o m e or w h ose Q Tc meas ure d at Visit 1 0 1 ( Fri dericia met h o d) is pr ol o n ge d ( > 4 5 0 msec f or males a n d > 4 6 0 msec f or fe males). T hese patie nts s h o ul d n ot be rescree n e d."
27,page_27,"N o v arti s C o nfi d e nti al P a g e 2 8 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 1 9. Patie nts w h o ha ve a cli ni call y si g nifica nt E C G a b n or malit y at Visit 1 0 1 ( E C G e vi de nce of m y ocar dial i nfarcti o n at Visit 1 0 1 s h o ul d be cli nicall y assesse d b y t he i n v esti gat or wit h s u p p orti ve d oc u me ntati o n). 2 0. Hist or y of m ali g na n c y of a n y or ga n s yste m ( ot her t ha n l ocalize d basal cell carci n o ma of t he s ki n or i n-sit u cer vical ca ncer), treate d or u ntr eate d, wit hi n t he past 5 ye ars, re gar dless of w het her t h ere is e vi d e nce of l ocal rec urr e nce or metastases. 2 1. Patie nts wit h a hist or y of h y perse nsiti vit y t o lact ose, a n y of t he st u d y dr u gs or its e x ci pie nts , or t o si milar dr u gs wit hi n t he cl ass i ncl u di n g u nt o war d reacti o ns t o s y m pat h o mi metic a mi nes or i n hale d me dicati o n or a n y c o m p o ne nt t here of. 2 2. Patie nts w h o ha ve n ot ac hie ve d a n acce pta ble s pir o metr y res ult at Visit 1 0 1 (c o nfir me d b y o ver rea d ) a n d Visit 2 0 1 (s pir o meter) i n acc or da n ce wit h A T S / E R S criteria f or acce pta bilit y a n d re peata bilit y. (R e peat is all o we d o nce f or eac h visit, sc he d ule d as cl ose as p ossi ble b ut n ot o n t he sa me da y). If t he patie nt fails t he re peat assess me nt, t he patie nt ma y b e res cree ne d o nce). 2 3. Patie nts recei vi n g a n y m e dicati o ns i n t he classes liste d i n Ta ble 5- 3. 2 4. Patie nts recei vi n g a n y ast h ma -relat e d me dicati o ns i n t he classes s pecifi e d i n Ta ble 5- 2. 2 5. Patie nts recei vi n g me dicati o ns i n t he classes liste d i n Ta ble 5 - 4 s h o ul d be e x cl u de d u nless t he me dicatio n has bee n sta bilize d f or t he s pecifie d peri o d a n d t he state d c o n diti o ns ha ve bee n met. 2 6. Patie nts o n mai nte na nce i m m u n ot hera p y ( dese nsitizati o n) f or aller gies f or l ess t ha n 3 m o nt hs pri or t o Visit 1 0 1 or patie nts o n Mai nte na n ce I m m u n ot her a p y f or m ore t ha n 3 m o nt hs pri or t o Visit 1 0 1 b ut e x pecte d t o c ha n ge t hr o u g h o ut t he c o urse of t he st u d y. 2 7. Patie nts w h o are ser vi n g a c ust o dial se nte nce, d o n ot ha ve a per ma ne nt r esi de nce or w h o are det ai ne d u n der l ocal me ntal healt h le gislati o n/re g ulati o ns. 2 8. Patie nts w h o are directl y ass ociate d wit h a n y me m bers of t he st u d y tea m or t heir fa mil y me m bers. 2 9. Patie nts u na ble t o use t he C o nce pt 1 dr y p o w der i n haler, Acc u haler ®/ Dis k us ®, Res pi mat ® or a meter e d d ose i n haler. S pacer de vi ces are n ot p er mitte d f or use wit h st u d y treat me nt. 3 0. Hist or y of alc o h ol or ot h er s u bsta nce a b use t hat b ase d o n j u d ge me nt of t he i n vesti gat or w o ul d i nterfer e wit h st u d y c o n d u ct. 3 1. Patie nts wit h a k n o w n hist or y of n o n-c o m plia nce t o me dicati o n or w h o were u na ble t o c o m plete a patie nt e Diar y, use electr o ni c Pea k Fl o w Meter , or c o m plete q uesti o n naires ( P R Os). 3 2. Patie nts w h o d o n ot mai ntai n re g ular d a y/ ni g ht, w a ki n g/slee pi n g c ycles ( e. g., i nc o nsiste nt ni g ht s hift w or kers). C o nsiste nt ni g ht s hift w or kers ma y b e c o nsi dere d f or i ncl usi o n. 3 3. Pre g n a nt or n ursi n g (lactati n g) w o m e n, w here pr e g na n c y is defi ne d as t he state of a f e male after c o nce pti o n a n d u ntil t he ter mi nati o n of gestati o n, c o nfir me d b y a p ositi ve h C G la b orat or y test. 3 4. W o me n of c hil d- beari n g p ote ntial, defi ne d as all w o me n p h ysi ol o gicall y ca pa ble of bec o mi n g pre g na nt, u nless t he y are usi n g hi g hl y effecti ve m et h o ds of c o ntr ace pti o n d uri n g d osi n g of st u d y tr eat me nt a n d f oll o w- u p p eri o d. Hi g hly Effective c o ntr ace pti o n met h o ds i ncl u de:"
28,page_28,"N o v arti s C o nfi d e nti al P a g e 2 9 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 • T otal a bsti ne nce ( w he n t his is i n li ne wit h t he preferre d a n d us ual lifest yle of t he s u bject). Peri o dic a bsti ne nce (e. g., cale n d ar, o v ulati o n, s y m pt o m-t her mal, p ost o v ulati o n met h o ds) a n d wit h dra wal are n ot acce pta ble met h o ds of c o ntrace pti o n. • Fe male sterilizati o n ( ha ve ha d s ur gical bilateral o o p h orect o m y wit h or wit h o ut h yster ect o m y) , t otal h yst erect o m y or t u b al li gati o n at least si x wee ks bef or e ta ki n g st u d y treat me nt. I n cas e of o o p h orect o m y al o n e, o nl y w he n t h e re pr o d ucti ve stat us of t he w o ma n has bee n c o nfir me d b y f oll o w u p h or m o ne le vel assess me nt. • Male sterilizati o n (at least 6 m o nt hs pri or t o scree ni n g). F or f e male s u bjects o n t he st u d y, t he vas ect o mize d male part ner s h o ul d be t he s ole part ner f or t hat s u bject. • Use of or al, i njecte d or i m pla nte d h or m o nal met h o ds of c o ntrace pti o n or ot her f or ms of h or m o nal c o ntrace pti o n t hat ha ve c o m para ble efficac y (f ail ure r ate < 1 %), f or e x a m ple h or m o ne va gi nal ri n g or tr a ns der mal h or m o ne c o ntrace pti o n. • Place me nt of a n i ntr a uteri ne de vice (I U D) or i ntra uteri ne s yste m (I U S) . I n case of use of oral c o ntrace pti o n, w o me n s h o ul d ha ve bee n sta ble o n t he sa me pill f or a mi ni m u m of 3 m o nt hs bef ore Visit 2 0 1 ( Ra n d o mizati o n / Start of treat me nt peri o d ). W o me n are c o nsi der e d p ost- me n o pa usal a n d n ot of c hil d- beari n g p ot e ntial if t he y h a ve ha d 1 2 m o nt hs of nat ural (s p o nta ne o us) a m e n orr h ea wit h a n a p pr o priate cli nical pr ofile (e. g. a ge a p pr o pri ate, hist or y of vas o m ot or s y m pt o ms) or ha ve h a d s ur gical bilateral o o p h orect o m y ( wit h or wit h o ut h ysterect o m y) or t u bal li gati o n at least si x wee ks a g o. I n t he case of o o p h orect o m y al o n e, o nl y w he n t he r e pr o d ucti ve stat us of t he w o ma n has bee n c o nfir me d b y f oll o w- u p h or m o ne le v el assess me nt is s he c o nsi dere d n ot of c hil d beari n g p ote ntial. 5 Tr e at m e nt 5. 1 St u d y tr e at m e nt 5. 1. 1 I n v e sti g ati o n al a n d c o ntr ol dr u g s T he I n vesti gati o nal treat me nts are as f oll o ws: • Q V M 1 4 9 (i n dacater ol acetate/ gl yc o p yrr o ni u m br o mi de/ M F) 1 5 0/ 5 0/ 8 0 μ g o. d. deli vere d as p o w der i n har d ca ps ules via C o nce pt 1 • Q V M 1 4 9 (i n dacater ol acetate/ gl yc o p yrr o ni u m br o mi de/ M F) 1 5 0/ 5 0/ 1 6 0 μ g o. d. deli vere d as p o w der i n har d ca ps ules via C o nce pt 1 T he C o m parati ve tr eat me nt is: • O pe n la bel sal meter ol xi naf oate /fl uticas o n e pr o pi o nate 5 0/ 5 0 0 μ g b.i. d. deli vere d as p o w der via A cc u h aler ® + ti otr o pi u m 5 μ g o. d deli vere d via Res pi mat ® U n der n o circ u mst a n ces is a n alter n ati ve i n h al ati o n de vice t o be use d f or t he a d mi nistr ati o n of t he i n vesti g a ti o n al or ref ere nce t her a pies d uri n g t he tre at me nt peri o d. Q V M 1 4 9 will be pr o vi de d as gl o bal cli nical bli n de d s u p plies a n d will be pac ke d a n d la bele d u n der t h e res p o nsi bilit y of N o v artis, Dr u g S u p pl y M a na ge me nt • T he C o m parati ve tr eat me nts, sal meterol xi naf oate /fl uticas o ne pr o pi o nate 5 0/ 5 0 0 μ g deli vere d as p o w der via Acc u hal er ® + ti otr o pi u m 5 μ g deli ver e d via Res pi mat ® , will"
29,page_29,"N o v arti s C o nfi d e nti al P a g e 3 0 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 eit her be s o ur ce d as l o cal c o m mercial s u p pl y b y N o vartis or pr o vi de d gl o bal l y b y N o vartis as cli nical o pe n la b el s u p plies. 5. 1. 2 A d dit i o n al tr e at m e nt Starti n g wit h Visit 1 p atie nts will recei ve s h ort acti n g b eta a g o nist (sal b uta m ol or al b uter ol ) i n haler t o use as r esc ue me dicati o n o n a n “as n ee de d” basis. At Visit 1 0 1 patie nts will als o be s u p plie d wit h o pe n la bel r u n -i n me dicati o n, salmeter ol / fl uticas o ne 5 0/ 2 5 0 μ g b.i. d. or 5 0/ 5 0 0 μ g b.i. d. t o mat c h t heir b ac k gr o u n d m e dicati o n vi a I R T . It is r e q uire d f or all patie nts t o ta k e t he o pe n-la bel r u n-i n me dicati o n, sal meter ol / fl uticas o ne t wice d ail y fr o m Visit 10 1 t o Visit 2 0 1. T h e resc u e me di cati o n will be pr o vi de d as nee de d t o t he patie nts f or t he d ur ati o n of t he st u d y. M ore d etails re gar di n g res c ue me di cati o n are i n Secti o n 5. 5. 6 O pe n -la bel r u n i n me dicati o n, sal meter ol xi naf oate /fl uticas o ne pr o pi o nate 5 0/ 2 5 0 μ g or 5 0/ 5 0 0 μ g deli vere d as p o w der via Acc u h aler ® will eit her be s o urce d as l ocal c o m mercial s u p pl y or pr o vi de d as gl o bal cli nical o pe n l a b el s u p plies b y N o vartis. Sal b uta m ol resc ue me dicati o n will eit her be s u p plie d t o t he i n vesti gat or sites l ocall y b y N o vartis or pr o vi de d b y t he st u d y ce nter a n d rei m b urse d b y N o vartis. 5. 2 Tr e at m e nt ar m s Patie nts will be ra n d o mize d t o o ne of t he f oll o wi n g t hree treat me nt ar ms i n a rati o of 1: 1: 1 : • Q V M 1 4 9 1 5 0/ 5 0/ 8 0 μ g o. d. deli vere d via C o nce pt 1 • Q V M 1 4 9 1 5 0/ 5 0/ 1 6 0 μ g o. d. deli vere d via C o nce pt 1 • Sal meter ol xi naf oate /fl uticas o ne pr o pi o nat e 5 0/ 5 0 0 μ g b.i. d. (i n t he m or ni n g a n d i n t he e ve ni n g) deli vere d via A cc u haler ® pl us ti otr o pi u m 5 μ g o. d deli vere d vi a Res pi mat ® 5. 3 Tr e at m e nt a s si g n m e nt a n d r a n d o mi z ati o n At Visit 2 0 1 all eli gi ble patie nts will be ra n d o mize d via I nteracti ve R es p o nse Tec h n ol o g y (I R T) t o o ne of t he treat me nt ar ms. T he i n vesti gat or or his/ her dele gate will c o ntact t he I R T after c o nfir mi n g t hat t h e patie nt f ulfills all t he i ncl usi o n/e x cl usi o n criteria. T h e I R T will assi g n a ra n d o mizati o n n u m ber t o t he patie nt, w hic h will be use d t o li n k t he patie nt t o a treat me nt ar m a n d will s pecif y a u ni q ue me dicati o n n u m ber f or t he first pac ka ge of i n vesti gati o nal treat me nt t o be dis pe nse d t o t he patie nt. T he ra n d o mizati o n n u m ber will n ot be c o m m u nicate d t o t he call er. T he ra n d o mizati o n n u m bers will be ge nerate d usi n g t he f oll o wi n g pr o ce d ure t o e ns ure t hat treat me nt assi g n m e nt is u n biase d a n d c o nceale d fr o m patie nts a n d i n vesti gat or staff. A patie nt ra n d o mizati o n list will be pr o d uce d b y t he I R T pr o vi der usi n g a vali date d s yste m t hat a ut o mates t he ra n d o m assi g n me nt of patie nt n u m bers t o ra n d o mizati o n n u m bers. T hese ra n d o mizati o n n u m bers are li n ke d t o t he differe nt treat me nt ar ms, w hic h i n t ur n are li n ke d t o me dicati o n n u m bers. A se parat e me dicati o n list will be pr o d uce d b y or u n der t he res p o nsi bilit y of N o vartis Dr u g S u p pl y Ma n a ge m e nt usi n g a v ali date d s yste m t hat a ut o mates t he ra n d o m assi g n me nt of me dicati o n n u m bers t o pac ks c o ntai ni n g t he i n vesti gati o nal dr u g(s). Ra n d o mizati o n will be stratifie d b y pr e vi o us I C S d ose of I C S/ L A B A t hera p y ( me di u m or hi g h d ose) a n d r e gi o n."
30,page_30,"N o v arti s C o nfi d e nti al P a g e 3 1 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 T he ra n d o mizati o n sc he me f or patie nts will be re vie we d a n d a p pr o ve d b y a me m ber of t he Ra n d o mizati o n Gr o u p. 5. 4 Tr e at m e nt bli n di n g T he st u d y is partiall y bli n de d. T he free tri ple c o m bi nati o n of sal meter ol/fl uticas o ne + ti otr o pi u m is o pe n-la bel f or w hic h i n vesti gat ors a n d patie nts will ha ve f ull k n o wle d ge of treat me nt all ocati o n. H o we ver, i n or d er t o mi ni mize t he p ote ntial i m pact, meas ures will b e ta ke n t o bli n d t he s p o ns or tea m, i ncl u di n g d ata a nal ysts, fr o m k n o wle d ge of treat me nt all ocati o n b y usi n g t he f oll o wi n g met h o ds: ( 1) Ra n d o mizati o n data a n d treat me nt c o des are ke pt strictl y c o nfi d e ntial u ntil t he ti me of u n bli n di n g, a n d will n ot be accessi ble b y a n y o n e else i n v ol ve d i n t he st u d y ( 2) Case Re p ort F or ms t hat re veal t he treatme nt ar m will be bli n de d fr o m t he s p o ns or tea m. S pecificall y w it hi n t he t w o Q V M 1 4 9 treat me nt ar ms patie nts, i n vesti gat or staff, pers o ns perf or mi n g t h e ass ess me nts, a n d data a nal ysts will re mai n bli n d t o t he i de ntit y of t he Q V M 1 4 9 treat me nt d os e fr o m t he ti me of ra n d o mizati o n u ntil data base l oc k, usi n g t he f oll o wi n g a d diti o nal met h o d: ( 3) T he i de ntit y of t he Q V M 1 4 9 treat me nt d ose will be c o nceale d b y t he us e of st u d y dr u gs t hat are all i de ntical i n pac k a gi n g, la beli n g, sc h e d ule of a d mi nistrati o n, a p pear a n ce, taste, a n d o d or. U n bli n di n g will o nl y occ ur i n t he case of p atie nt e mer ge n cies (s ee Secti o n 5. 5. 9 ) a n d at t he c o ncl usi o n of t he st u d y. 5. 5 Tr e ati n g t h e p ati e nt S p o ns or q ualifie d me di cal pers o n nel will b e r ea dil y a v aila ble t o a d vise o n trial rel ate d me dica l q uesti o ns or pr o ble ms. 5. 5. 1 P ati e nt n u m b eri n g Eac h p atie nt is u ni q uel y i d e ntifie d b y a S u bject N u m ber w hic h is c o m p ose d b y t he site n u m ber assi g ne d b y N o vartis a n d a se q u e ntial n u m ber assi g ne d b y t he i n vesti gat or. O n ce assi g ne d t o a patie nt, t he S u bject N u m ber will n ot be re use d. U p o n si g ni n g t he i nf or m e d c o nse nt f or m, t he patie nt is assi g ne d t h e ne xt se q ue ntial n u m ber b y t he i n vesti gat or. T he i n vesti gat or or his/ her staff will c o ntact t he I R T a n d pr o vi de t he re q ueste d i d e ntif yi n g i nf or mati o n f or t he p atie nt t o re gister t he m i nt o t he I R T s yste m. T he site s h o ul d select t he e- Case Re p ort F or m (e-C R F) b o o k wit h a matc hi n g S u bject N u m ber fr o m t he E D C s yste m t o e nter data. If t he patie nt fails t o be ra n d o mize d f or a n y r eas o n, t he I R T m ust be n otifie d wit hi n 2 da ys t hat t he patie nt was a scr ee ni n g/r u n -i n fail ure. T h e reas o n f or scree ni n g/r u n-i n fail ure will be e ntere d o n t he a p plica ble St u d y P eri o d Dis p ositi o n e C R F. Re -scree ne d patie nts will be assi g ne d a ne w se q ue nti al patie nt n u m ber a n d t he i n vesti gat or or staff will re gister t he m i nt o t he I R T s yste m."
31,page_31,"N o v arti s C o nfi d e nti al P a g e 3 2 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 5. 5. 2 Di s p e n si n g t h e st u d y dr u g Eac h st u d y site will be s u p plie d b y N o vartis wit h i n vesti gati o nal treat me nt i n pac ka gi n g of i de ntical a p pear a nce. All N o vartis gl o ball y s u p plie d treat me nts will ha ve st u d y dr u g pac ka gi n g wit h a 2-part la bel. A u ni q ue me dicati o n n u m ber is pri nte d o n eac h part of t his la bel w hic h c orres p o n ds t o o ne of t he t hr ee tr eat me nt ar ms. I n vesti gat or staff will i de ntif y t h e st u d y dr u g pac k a ge(s) t o dis pe nse t o t he patie nt b y c o ntacti n g t he I R T a n d o btai ni n g t he me dicati o n n u m ber(s). I m me diatel y bef ore dis pe nsi n g t he pac ka ge t o t he patie nt, i n vesti gat or staff will detac h t he o ut er part of t h e la bel fr o m t he pac ka gi n g a n d affi x it t o t he s o urce d oc u me nt ( Dr u g La bel F or m) f or t hat patie nt’s u ni q ue s u bject n u m ber. All st u d y tr eat me nt l a bels will c o m pl y wit h t he le gal re q uir e me nts of eac h c o u ntr y, i n cl u di n g l ocall y s o ur ce d tr eat me nts. 5. 5. 3 H a n dli n g of st u d y a n d a d diti o n al tr e at m e nt 5. 5. 3. 1 H a n dli n g of st u d y tr e at m e nt St u d y treat me nt m ust be recei v e d b y a desi g nate d pers o n at t he st u d y site, ha n dle d a n d st ore d safel y a n d pr o p erl y, a n d ke pt i n a sec ure d l ocati o n t o w hic h o nl y t he i n vesti gat or a n d desi g nees ha v e access. U p o n recei pt, all st u d y treat me nt m ust be st ore d acc or di n g t o t h e i nstr ucti o ns s pecifie d o n t he la bels. Cli nical s u p plies are t o be dis pe nse d o nl y i n acc or da nce wit h t he pr ot oc ol. Tec h nical c o m plai nts are t o be re p orte d t o t he res p ecti v e N o vartis C o u ntr y P har ma Or ga nizati o n Q u alit y Ass ur a nce. Me dicati o n la bels will be i n t he l ocal la n g u a ge a n d c o m pl y wit h t he le gal re q uire m e nts of eac h c o u ntr y. T he y will i ncl u de st ora ge c o n diti o ns f or t he st u d y treat me nt b ut n o i nf or mati o n a bo ut t he patie nt e x ce pt f or t he me dicati o n n u m ber . T he i n vesti gat or m ust m ai ntai n a n acc urate rec or d of t he s hi p me nt a n d dis pe nsi n g of st u d y treat me nt i n a dr u g acc o u nta bilit y l o g. M o nit ori n g of dr u g acc o u nta bilit y will be perf or me d b y m o nit ors d uri n g site visits or r e m otel y a n d at t he c o m pleti o n of t he trial. Patie nts will be as ke d t o ret ur n all u n use d st u d y tr eat me nt a n d pac ka gi n g at t he e n d of t he st u d y or at t h e ti me of disc o nti n uati o n of st u d y treat me nt. At t he c o n cl usi o n of t he st u d y, a n d as a p pr o priate d uri n g t h e c o urs e of t h e st u d y, t he i n vesti gat or will r et ur n all u n use d st u d y treat me nt, pac ka gi n g, dr u g l a bels, a n d a c o p y of t he c o m plete d dr u g acc o u nt a bilit y l o g t o t he N o vartis m o nit or or t o t he N o vartis a d dress pr o vi de d i n t he i n vesti gat or f ol d er at eac h site. 5. 5. 3. 2 H a n dli n g of a d diti o n al tr e at m e nt T he f oll o wi n g n o n- i n vesti gati o nal treat me nt has t o be m o nit ore d as f oll o ws: T he n o n -i n vesti gati o nal treat me nt m ust be recei v e d b y a desi g nat e d pers o n at t he st u d y site, ha n dle d a n d st ore d safel y a n d pr o perl y, a n d k e pt i n a sec ure d l ocati o n t o w hic h o nl y t he i n vesti gat or a n d desi g n ees ha v e access. Cli nical s u p plies are t o b e dis pe nse d o nl y i n acc or d a nce wit h t he pr ot oc ol. T he i n vesti gat or m ust m ai ntai n a n acc urate rec or d of t he s hi p me nt a n d dis pe nsi n g of t he n o n - i n vesti gati o nal treat me nt i n a dr u g acc o u nta bilit y l o g. M o nit ori n g of dr u g acc o unta bilit y will"
32,page_32,"N o v arti s C o nfi d e nti al P a g e 3 3 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 be perf or me d b y m o nit ors d uri n g site visits or r e m otel y a n d at t h e c o m pleti o n of t he trial. Patie nts will be as ke d t o ret ur n all u n use d n o n - i n vesti gati o nal treat me nt a n d pac ka gi n g at t he e n d of t he r u n -i n f or t h e r u n-i n me dicati o n a n d at t he e n d of t he st u d y or at t he ti me of disc o nti n uati o n of i n vesti gati o nal tr eat me nt f or t h e resc ue m e dicati o n. T hese me dicati o ns are: • Sal b uta m ol ( 1 0 0 μ g) or al b uter ol ( 9 0 μ g) us e d as r esc ue me dicati o n • Sal meter ol xi naf oate /fl uticas o ne pr o pi o nat e 5 0/ 2 5 0 μ g b.i. d. or 5 0/ 5 0 0 μ g b.i. d. via Acc u hal er ® use d as r u n-i n me dicati o n Details are d escri b e d i n t he C R F c o m pleti o n g ui d eli nes. 5. 5. 4 I n str u cti o n s f or pr e s cri bi n g a n d t a ki n g st u d y tr e at m e nt At Visit 1 all patie nts will be i nstr ucte d o n h o w t o use a Met ere d De vice I n hal er ( M DI ) t o a d mi nister res c ue m e dicati o n, sal b uta m ol. Patie nts will be i nstr ucte d t o ta ke r esc u e me dicati o n o n a n “as nee de d ” basis t hr o u g h o ut t he st u d y. I n or der t o sta n d ar dize meas ure me nts, p atie nts will be i nstr ucte d t o a bstai n fr o m ta ki n g res c ue me dicati o n wit hi n 6 h o urs of t he start of eac h visit u nless a bs ol utel y n ecessar y. At Visit 1 0 1 patie nts will be trai ne d o n h o w t o pr o perl y us e o pe n -la b el r u n-i n me dicati o n sal meter ol/fl uticas o ne vi a Acc u h aler ® a n d will be i nstr ucte d t o ta ke b.i. d. per instr ucti o ns i n A p pe n di x 4 . At Visit 2 0 1 patie nts will be trai n e d o n h o w t o pr o perl y use t h e C o nce pt 1 i n haler d e vice or t h e Acc u hal er ® pl us Res pi m at ® i n haler d e vices base d o n t he r a n d o mize d treat me nt ar m pr o vi de d b y I R T. Patie nts w h o are u na ble t o use t he assi g ne d de vice (s) c orr ectl y at Visit 2 0 1 will n ot c o nti n ue i n t he st u d y. At cli nic visits t he i n vesti gat or s h o ul d c hec k t he patie nt’s use of t he i n halati o nal de vices t o e ns ure t hat t he y ar e usi n g eac h de vice c orr ectl y. Ad diti o nal de vice trai ni n g s h o ul d be pr o vi d e d as re q uir e d. Q V M 1 4 9 Tre at me nt ar ms o nce d ail y e ve ni n g d ose: Pati e nts will be i nstr ucte d t o i n hale 1 Q V M 1 4 9 ca ps ule usi n g t h e pr o vi de d C o nce pt 1 de vice (pac k beari n g o nl y a m o o n pict o gra m ) i n t he e ve ni n g bet wee n 5: 0 0 a n d 8: 0 0 p m. Q V M 1 4 9 st u d y tr eat me nt m ust o nl y be ta ke n o nce a d a y i n t h e e v e ni n g. T h e first d ose will be a d mi nistere d i n t he cli nic at Visit 2 0 1 . O pe n l a bel s al meter ol /fl utic as o ne t wice d ail y + ti otr o pi u m o nce d ail y e ve ni n g d ose: Patie nts will be i nstr ucte d t o ta ke: • M O R NI N G bet w ee n 5: 0 0 a n d 8: 0 0 a m: 1 i n halati o n fr o m t he Acc u haler ® de vice c ontai ni n g sal met er ol/fl uticas o ne ( pac ka ge beari n g b ot h a s u n a n d m o o n pict o gr a m ) • E V E NI N G b et wee n 5: 0 0 a n d 8: 0 0 p m: 1 i n halati o n fr o m t he Ac c u haler ® d e vice c o ntai ni n g sal met er ol/fl uticas o ne ( pac ka ge beari n g b ot h a s u n a n d m o o n pict o gr a m ) f oll o we d directl y b y 2 i n halati o ns fr o m t he Res pi mat ® de vice c o ntai ni n g ti otr o pi u m (pac ka ge beari n g o nl y a m o o n pict o gra m ). Ti otr o pi u m via Res pi mat ® m ust o nl y be ta ke n o nce a da y i n t he e ve ni n g. T h e first d ose will be a d mi nistere d i n t he cli nic at Visit 2 0 1."
33,page_33,"N o v arti s C o nfi d e nti al P a g e 3 4 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 T a bl e 5- 1 St u d y Tr e at m e nt s Tre at me nt ar m M or ni n g E ve ni n g Q V M 1 4 9 1 5 0/ 5 0/ 8 0 µ g or Q V M 1 4 9 1 5 0/ 5 0/ 1 6 0 µ g N o d ose 1 ca ps ule via C o nce pt 1 Sal meter ol xi naf oate/fl uticas o ne pr o pi o nate 5 0/ 5 0 0 µ g + Ti otr o pi u m 5 μ g o. d 1 i n halati o n via Acc u haler® 1 i n halati o n via Acc u haler® + 2 i n halati o ns via Res pi mat® Patie nts will be i nstr ucte d t o ri nse t heir m o ut h after i n halati o n of st u d y dr u g ( 2 ti mes wit h a p pr o xi matel y 3 0 m L w ater). Water use d f or m o ut h ri nsi n g s h o ul d be s pat o ut a n d s h o ul d N O T be s w all o we d. W he n se q ue ntial i n halati o ns of st u d y dr u gs fr o m t w o de vices ar e req uire d, m o ut h ri nsi n g s h o ul d be d o ne after t he last i n halati o n. Patie nts will als o be i nstr ucte d t o ta ke me dicati o n at a p pr o xi matel y t he sa me desi g nate d ti me w hile at h o me i n bet wee n visits. I nstru cti o ns f or use of t he C o nce pt 1, Acc u h aler ® , a n d Res pi mat ® de vices are gi v e n i n A p pe n di x 3 , A p pe n di x 4 , a n d A p pe n di x 5 . T he st u d y treat me nt ca n be ta ke n wit h o ut re gar d t o slee p, meals, a n d ot her acti vities. O n da ys of sc he d ule d cli nic visits, patie nts s h o ul d ta ke t heir e ve ni n g d ose of st u d y treat me nt at t he cli nic. T he d ur ati o n of acti ve tr eat me nt is 2 4 wee ks, wit h t he last d os e of st u d y treat me nt o cc urri n g at Visit 2 0 4. All kits of i n vesti gati o nal treat me nt assi g n e d b y t he I R T will b e r ec or d e d i n t he I R T . All use d a n d u n use d st u d y me di cati o n/ pac ka gi n g (e x ce pt use d ca ps ules) m ust be ret ur n e d b y t he patie nt at eac h st u d y visit a n d/ or at t he ti me of disc o nti n uati o n. T he i n vesti gat or s h o ul d pr o m ote c o m plia nce b y i nstr ucti n g t he patie nt t o ta ke t he st u d y treat me nt e x actl y as pres cri be d a n d b y stati n g t h at c o m plia nce is necessar y f or t h e patie nt’s safet y a n d t he vali dit y of t he st u d y. T he patie nt s h o ul d be i nstr ucte d t o c o ntact t he i n vesti gat or if he/s he is u na ble f or a n y r eas o n t o ta ke t h e st u d y treat me nt as pr escri be d. If a n y fa ults ar e i de ntifie d wit h eit her t he de vi ce a n d/ or t he blisters, t hese s h o ul d be ret ur ne d t o N o vartis Dr u g S u p pl y Ma na ge me nt wit h t he c o m plete d De vice Ret ur n F or m. The f or ms will be s u p plie d t o eac h i n vesti gat or site b y t he Fi el d M o nit or. 5. 5. 5 P er mitt e d d o s e a dj u st m e nt s a n d i nt err u pti o n s of st u d y tr e at m e nt I n v esti gati o nal treat me nt d ose a dj ust me nts a n d/ or i nterr u pti o ns are n ot p er mitte d u nless t he i n vesti gat or c o nsi ders a n i nterr u pti o n is necessar y f or t he treat me nt of a n a d verse e v e nt. A n y i nterr u pti o n of st u d y m e dicati o n s h o ul d be f or t he s h ortest ti me peri o d p ossi ble. E ver y i nterr u pti o n d ue t o a n a d verse e v e nt m ust be rec or de d i n t he D osa ge A d mi nistrati o n Rec or d C R F (e -C R F). I nt err u pti o ns of m ore t ha n 5 da ys f or ot her r eas o ns m ust als o be rec or de d i n t he D osa ge A d mi nistrati o n Rec or d C R F ( e-C R F)."
34,page_34,
35,page_35,
36,page_36,"N o v arti s C o nfi d e nti al P a g e 3 7 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Cl a s s of m e di c ati o n Mi ni m u m w a s h o ut p eri o d pri or t o S cr e e ni n g ( Vi sit 1), R u n -i n ( Vi sit 1 0 1) a n d R a n d o mi z ati o n ( Vi sit 2 0 1) 1, 2, 3 I ntr a-m u s c ul ar d e p ot c orti c o st er oi d s M u st n ot b e u s e d wit hi n 3 m o nt h s pri or t o Vi sit 1 0 1 1 Tr e at m e nt f or r e c or d e d a st h m a e x a c er b ati o n a s d efi n e d i n S e cti o n 6. 4. 5 i s all o w e d O N L Y u ntil t h e a st h m a e x a c er b ati o n i s r e s ol v e d 2 T hi s t a bl e i s n ot c o n si d er e d all -i n cl u si v e. M e di c ati o n s s h o ul d b e a s s e s s e d f or a d h er e n c e t o t h e i n di c ati o n a n d ot h er i n cl u si o n/ e x cl u si o n crit eri a . 3 T h e s e m e di c ati o n s ar e al s o pr o hi bit e d if a d mi ni st er e d f or ot h er i n di c ati o n s. 4 St u d y s u p pli e d r e s c u e m e di c ati o n ( s al b ut a m ol/ al b ut er ol r e s c u e m e di c ati o n) pr o vi d e d at Vi sit 1 i s all o w e d d uri n g tr e at m e nt b ut s h o ul d b e wit h h el d f or at l e a st 6 h o ur s pri or t o s pir o m etr y m e a s ur e m e nt s at cli ni c vi sit s. Cli ni c vi sit s m a y b e r e s c h e d ul e d if r e s c u e m e di c ati o n w er e t a k e n l e s s t h a n 6 h o ur s pri or t o t h e s pir o m etr y a s s e s s m e nt s . T a bl e 5- 3 Pr o hi bit e d M e di c ati o n s Cl a s s of m e di c ati o n 1 Mi ni m u m c e s s ati o n p eri o d pri or t o R u n -i n ( Vi sit 1 0 1) N o n -p ot a s s i u m s p ari n g di ur eti c s ( u nl e s s a d mi ni st er e d a s a fi x e d -d o s e c o m bi n ati o n wit h a p ot a s si u m c o n s er vi n g dr u g ) 7 d a y s N o n -s el e cti v e s y st e mi c β – bl o c ki n g a g e nt s 7 d a y s C ar di a c a nti -arr h yt h mi c s Cl a s s I a 7 d a y s C ar di a c a nti -arr h yt h mi c s Cl a s s III 7 d a y s, a mi o d ar o n e 3 m o nt h s Ot h er dr u g s wit h p ot e nti al t o si g nifi c a ntl y pr ol o n g t h e Q T i nt er v al ( e. g. mi z ol a sti n a n d t erf e n a di n e) 1 4 d a y s or 5 h alf -li v e s, w hi c h e v er i s l o n g er All a nti p s y c h oti c a g e nt s (fir st, s e c o n d a n d t hir d g e n er ati o n, i n cl u si v e of at y pi c al a nt i p s y c h oti c s). C o m bi n ati o n s of a nti p s y c h oti c a g e nt s wit h a nti d e pr e s s a nt s ar e pr o hi bit e d 1 4 d a y s S er ot o ni n N or a dr e n ali n e R e u pt a k e I n hi bit or s ( S N RI s) 1 4 d a y s M o n o a mi n e -o xi d a s e i n hi bit or s 1 4 d a y s S y st e mi c a nti c h oli n er gi c s 7 d a y s Str o n g i n hi bit or s of c yt o c hr o m e P 4 5 0 3 A e. g. k et o c o n a z ol e 7 d a y s Tri c y cli c a nti d e pr e s s a nt s ( Pl e a s e n ot e t h at t etr a c y cli c s w hi c h ar e si mil ar i n cl a s s wit h r e g ar d s t o dr u g i nt er a cti o n ar e al s o t o b e e x cl u d e d) 1 4 d a y s Ot h er i n v e sti g ati o n al dr u g s 3 0 d a y s or 5 h alf -li v e s, w hi c h e ver i s l o n g er N or a dr e n ali n e r e u pt a k e i n hi bit or s 7 d a y s Li v e att e n u at e d v a c ci n e 3 0 d a y s 1 T hi s t a bl e i s n ot c o n si d er e d all -i n cl u si v e. M e di c ati o n s s h o ul d b e a s s e s s e d f or a d h er e n c e t o t h e i n di c ati o n a n d ot h er i n cl u si o n/ e x cl u si o n crit eri a. B ef or e st arti n g w a s h -o ut of a n y of t h e li st e d pr o hi bit e d m e di c ati o n s i n t hi s t a bl e, t h e i n v e sti g at or h a s t o a s s e s s t h e b e n efit a n d ri s k c ar ef ull y f or e a c h i n di vi d u al p ati e nt. T er mi n ati n g a n y m e di c ati o n s ol el y f or t h e p ur p o s e of m e eti n g i n cl u si o n/ e x cl u si o n crit eri a i s n ot a c c e pt a bl e. T a bl e 5- 4 M e di c ati o n s all o w e d u n d er c ert ai n c o n diti o n s Cl a s s of m e di c ati o n C o n diti o n"
37,page_37,"N o v arti s C o nfi d e nti al P a g e 3 8 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Cl a s s of m e di c ati o n C o n diti o n M o n o cl o n al a nti b o d y: I g E i n hi bit or s ( e. g. o m ali z u m a b), I L -5 i n hi bit or s ( e. g. m e p oli z u m a b) ** All o w e d if at st a bl e d o s e f or at l e a st 3 m o nt h s pri or t o Vi sit 1 Or al c orti c o st er oi d s * ** All o w e d if at st a bl e d o s e f or at l e a st 1 m o nt h pri or t o Vi sit 1 L e u k otri e n e A nt a g o ni st a n d l e u k otri e n e s y nt h e si s i n hi bit or s ** All o w e d if at st a bl e d o s e f or at l e a st 1 m o nt h pri or t o Vi sit 1 L o n g -a cti n g t h e o p h ylli n e ( m et h yl x a nt hi n e) pr e p ar ati o n s ** If st a bili z e d f or at l e a st 4 w e e k s pri or t o Vi sit 1 a n d t hr o u g h o ut t h e tri al. N ot a d mi ni st er e d wit hi n 2 4 h pri or t o st u d y vi sit. S h o rt- a cti n g t h e o p h ylli n e ( m et h yl x a nt hi n e) ** If st a bili z e d f or at l e a st 4 w e e k s pri or t o Vi sit 1 a n d t hr o u g h o ut t h e tri al. N ot a d mi ni st er e d wit hi n 1 2 h pri or t o st u d y vi sit. M u c ol yti c a g e nt s n ot c o nt ai ni n g br o n c h o dil at or s If st a bili z e d f or at l e a st 4 w e e k s pri or t o Vi sit 1 a n d t hr o u g h o ut t h e tri al S y st e mi c m a st c ell st a bili z er s e. g. cr o m o gl y c at e, n e d cr o mil, k et otif e n If st a bili z e d f or at l e a st 4 w e e k s pri or t o Vi sit 1 a n d t hr o u g h out t h e tri al S el e cti v e S er ot o ni n R e u pt a k e I n hi bit or s ( m u st h a v e n o d o c u m e nt e d eff e ct o n a n y ot h er n e ur otr a n s mitt er s or ot h er bi ol o gi c al p at h w a y s. E. g. m u s c ari ni c p at h w a y) Tr e at m e nt r e gi m e n i s st a bl e f or at l e a st o n e m o nt h at Vi sit 1 I n a cti v at e d i nfl u e n z a v a c ci n ati o n, p n e u m o c o c c al v a c ci n ati o n or a n y ot h er i n a cti v at e d v a c ci n e N ot a d mi ni st er e d wit hi n 4 8 h o ur s pri or t o a st u d y vi sit I ntr a-n a s al c orti c o st er oi d s St a bl e d o s e f or at l e a st 4 w e e k s pri or t o Vi sit 1 0 1. I n t h e c a s e of a s n e e d e d, pr o vi d e d a n e st a bli s h e d p att er n of u s e h a s b e e n d o c u m e nt e d. T o pi c al c orti c o st er oi d s f or t h e tr e at m e nt of e c z e m a I n r e c o m m e n d e d d o s e s a n d d o s a g e r e gi m e n s M ai nt e n a n c e i m m u n ot h er a p y f or all er gi e s St a bl e d o s e f or at l e a st 3 m o nt h s pri or t o Vi sit 1 0 1 a n d t hr o u g h o ut t h e tri al . * Or al c orti c o st er oi d s m a y b e c o nti n u e d at a l o w st a bl e d o s e aft er a c o ur s e of st er oi d t a p er f or e x a c er b ati o n s at t h e di s cr eti o n of t h e i n v e sti g at or. **D uri n g t h e tr e at m e nt p eri o d, “ st e p u p” or a d d-o n a s w ell a s “ st e p -d o w n” or d e -e s c al ati o n of m ai nt e n a n c e tr e at m e nt s ar e all o w e d , a s d e s cri b e d b el o w a n d i n S e cti o n. 5. 5. 5. T h e s e tr e at m e nt s m u st b e u s e d a c c or di n g t o a p pr o v e d l o c al l a b el s . If i n dicate d f or t he tr eat me nt of a n ast h ma e x acer bati o n, a n y treat me nt dee me d necessar y b y t he treati n g p h ysicia n f or t he saf et y of t he p atie nt is all o we d fr o m t he start of t he ast h ma e x acer bati o n e ve nt ( defi n e d as per pr ot oc ol Secti o n 6. 4. 5 ) u ntil t he ast h ma e x acer bati o n e ve nt is res ol ve d. If dee me d necessar y, t he treati n g p h ysicia n ma y “ste p-u p ” patie nt’s bac k gr o u n d me dicati o n a n d/ or a d d -o n mai nte na nce tr eat me nt o pti o ns if t he y re m ai n u nc o ntr olle d or e x perie nce se v ere ast h ma e x acer b ati o ns , refer t o Secti o n 5. 5. 5 . Patie nts ma y N O T self -me dicate ( ot h er t ha n a d mi nistrati o n of resc u e me dicati o n) or a d j ust t hera p y wit h o ut per missi o n/ g u i da nce fr o m treati n g p h ysici a n."
38,page_38,"N o v arti s C o nfi d e nti al P a g e 3 9 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 5. 5. 9 E m er g e n c y br e a ki n g of a s si g n e d tr e at m e nt c o d e E mer ge nc y c o d e brea ks m ust o nl y be u n derta k e n w he n it is re q uire d t o i n or der t o treat t he patie nt safel y. M ost oft e n, st u d y tr eat me nt disc o nti n uati o n a n d k n o wle d ge of t he p ossi ble treat me nt assi g n me nts ar e s uffici e nt t o treat a st u d y p atie nt w h o pr ese nts wit h a n e mer ge nc y c o n diti o n. E mer ge nc y treat me nt c o de brea ks are p erf or me d usi n g t h e I R T. W he n t he i n vesti gat or c o nt acts t he s yste m t o brea k a treat me nt c o de f or a patie nt, h e/s he m ust pr o vi de t he re q ueste d p atie nt i de ntif yi n g i nf or mati o n a n d c o nfir m t he necessit y t o brea k t he tr eat me nt c o de f or t he patie nt. T h e i n vesti gat or will t he n recei v e det ails of t he i n vesti gati o nal dr u g treat me nt f or t he s pecifie d patie nt a n d a fa x or e m ail c o nfir mi n g t his i nf or mati o n. T he s yst e m will a ut o maticall y i nf or m t he N o vartis m o nit or f or t he site a n d t he St u d y Tea m t hat t he c o de has bee n br o k e n. It is t h e i n vesti gat or’s res p o nsi bilit y t o e ns ure t hat t here is a de p e n da ble pr oce d ure i n place t o all o w access t o t he I R T/ c o de brea k car ds at a n y ti me i n case of e mer ge n c y. T h e i n vesti gat or will pr o vi de: • pr ot oc ol n u m ber • st u d y dr u g na m e • patie nt n u m ber I n a d diti o n, oral a n d writte n i nf or mati o n t o t he s u bject m ust be pr o vi de d o n h o w t o c o ntact his/ her bac k u p i n cases of e mer ge nc y, or w he n he/s he is u na vaila ble, t o e ns ure t hat u n -bli n di n g ca n b e perf or me d at a n y ti me. St u d y tr eat me nt m ust be disc o nti n ue d if t he treat me nt c o de of Q V M 1 4 9 treat me nt ar m has bee n br o ke n (act ual d ose of Q V M 1 4 9 u n bli n de d) after e mer ge n c y u n bli n di n g or i na d v erte ntl y br o ke n. T his d oes n ot a p pl y t o t he fr ee tri ple tr eat me nt ar m ( sal meter ol xi naf oate / fl uticas o ne pr o pi o nate + ti otr o pi u m) w hic h is o pe n la bel f or in vesti gat ors a n d p atie nts. 5. 6 St u d y C o m pl eti o n a n d Di s c o nti n u ati o n 5. 6. 1 St u d y c o m pl eti o n , p o st -st u d y tr e at m e nt a n d e n d of tri al A patie nt will be c o nsi dere d t o ha v e c o m plete d t h e st u d y w he n t he patie nt has c o m plete d t h e last visit pla n ne d i n t he pr ot oc ol ( Visit 3 0 1). C o nti n ui n g car e s h o ul d be pr o vi de d b y i n vesti gat or a n d/ or ref erri n g p h ysicia n b ase d o n patie nt a vaila bilit y. F or all ra n d o mize d pati e nts, a safet y f oll o w -u p V isit 3 0 1 s h o ul d be c o n d ucte d b y t ele p h o ne 7 da ys after last visit . T he i nf or mati o n t o be c ollecte d at t his f oll o w u p visit i ncl u des a d verse e ve nts a n d s ur vi val stat us. T he e ntire trial will be c o m plete d w he n t he last ra n d o mize d patie nt c o m pletes t he last visit ( Visit 3 0 1) of t his pr ot oc ol. I n case t he last patie nt ra n d o mize d disc o nti nues treat me nt pre mat urel y (see Secti o n 5. 6. 2 ) or v ol u ntaril y wit h dra ws c o nse nt ( see Secti o n 5. 6. 3 ) t he fi nalizati o n of t he trial is c o nsi dere d at patie nt’s l ast visit. T he trial will als o e n d if N o vartis is ter mi nati n g t he trial d u e t o reas o ns r elate d t o be n efit/ris k assess me nt (see Secti o n 5. 6. 5 )."
39,page_39,"N o v arti s C o nfi d e nti al P a g e 4 0 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 5. 6. 2 Di s c o nti n u ati o n of St u d y Tr e at m e nt Disc o nti n uati o n of st u d y treat me nt f or a patie nt o cc urs w he n st u d y dr u g is st o p pe d earlier t ha n t he pr ot oc ol pla n n e d d ur ati o n, a n d ca n b e i nitiate d b y eit her t he patie nt or t he i n vesti gat or. I n s uc h cas es t he p atie nt s h o ul d be as ke d t o c o nti n u e i n t he trial t hr o u g h t he sc he d ule d fi n al visit i n or der t o e ns ur e t he sci e ntific i nte grit y of t he tri al. T he i n vesti gat or m ust disc o nti n ue st u d y treat me nt f or a gi ve n patie nt if, o n bala nce, h e/s he belie ves t hat c o nti n uati o n of st u d y tr eat me nt w o ul d ne gati vel y i m pact t he ris k/ be nefit of trial partici pati o n. St u d y treat me nt m ust be disc o nti n ue d u n der t he f oll o wi n g circ u msta n ces: • Patie nt wis h • Pre g n a nc y • A n y sit uati o n i n w hic h st u d y treat me nt mi g ht r es ult i n a safet y ris k t o t he p atie nt If disc o nti n uati o n of st u d y tr eat me nt o cc urs, t he p atie nt s h o ul d N O T b e c o nsi dere d wit h dr a w n fr o m t he st u d y. F or t his st u d y it is ver y i m p orta nt t o c o nti n ue c ollecti n g data o n all patie nts t hat disc o nti n ue treat me nt, es peci all y f or pri mar y e n d p oi nt a n d saf et y. The patie nt s h o ul d ret ur n t o t he cli nic as s o o n as p ossi ble, after disc o nti n uati o n of st u d y dr u g, f or a st u d y treat me nt disc o nti n uati o n visit. Treat me nt disc o nti n uati o n visit assess me nts detaile d i n Ta bl e 6- 1 s h o ul d be c o m plete d a n d rec or de d i n t he e C R F. T he i n vesti gat or m ust deter mi ne t he pri mar y reas o n f or t he patie nt’s pre mat ure disc o nti n uati o n of st u d y treat me nt a n d rec or d t his i nf or mati o n i n t he E n d of St u d y Tr eat me nt e C R F. T he i n vesti gat or a n d st u d y staff m ust als o disc uss c o nti n ue d partici pati o n wit h t he patie nt. Patie nts w h o disc o nti n ue st u d y treat me nt pre m at urel y s h o ul d c o nti n ue wit h li mite d st u d y assess me nts. T he y s h o ul d ret ur n t o t h e cli nic f or eac h sc h e d ule d visit d uri n g t h e treat me nt peri o d a cc or di n g t o Assess me nt Sc he d ule T a ble 6 - 1 b ut o nl y c o n d u ct t he assess me nts i n dicate d i n Ta ble 5 -5 Assess me nts f or Patie nts w h o Disc o nti n ue St u d y Treat me nt . Patie nts s h o ul d als o c o n d uct t he safet y f oll o w-u p Visit 3 0 1 ( via tele p h o ne) after c o m pleti n g t he i nte n de d treat me nt peri o d. T a bl e 5- 5 A s s e s s m e nt s f or P ati e nt s w h o Di s c o nti n u e St u d y Tr e at m e nt A s s e s s m e nt A Q L Q1 S pir o m etr y1 R e c or d A E s R e c or d S A E s R e c or d A st h m a E x a c er b ati o n s R e vi e w C o n c o mit a nt M e di c ati o n R e vi e w S ur g er y a n d Pr o c e d ur e s 1 P R O s s h o ul d b e c o m pl et e d b ef or e a n y ot h er a s s e s s m e nt . A Q L Q a n d S pir o m etr y m u st b e p erf or m e d pr e-d o s e f or st a n d ar d of c ar e tr e at m e nt. T he i n vesti gat or m ust als o c o ntact t he I R T t o re gister t he patie nt’s disc o nti n uati o n fr o m st u d y treat me nt. If st u d y dr u g disc o nti n uati o n occ urs beca use tr eat me nt c o d e of Q V M 1 4 9 treat me nt ar m has bee n br o ke n (act ual d ose of Q V M 1 4 9 u n bli n de d), please r ef er t o Secti o n 5. 5. 9 ."
40,page_40,"N o v arti s C o nfi d e nti al P a g e 4 1 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 5. 6. 3 Wit h dr a w al of i nf or m e d c o n s e nt Patie nts ma y v ol u ntaril y wit h dra w c o ns e nt t o partici pate i n t he st u d y f or a n y reas o n at a n y ti me. Wit h dra wal of c o ns e nt ( W o C) occ urs o nl y w h e n a patie nt d o es n ot w a nt t o partici pate i n t h e st u d y a n y m ore a n d d oes n ot wa nt a n y f urt her visits or assess me nts a n d d oes n ot wa nt a n y f urt her st u d y relat e d c o ntacts a n d d oes n ot all o w a nal ysis of alrea d y o btai ne d bi ol o gic material. A patie nt is N O T c o nsi dere d t o ha ve wit h dra w n c o nse nt if t he y a gr ee t o f oll o w - u p visits. If a patie nt wit h dra ws c o nse nt, t he i n vesti gat or m ust ma ke e ver y eff ort (e. g. tele p h o ne, e-mail, letter) t o d eter mi ne t he pri mar y r eas o n f or t his decisi o n a n d rec or d t his i nf or mati o n. St u d y treat me nt m ust be disc o nti n ue d a n d n o f urt her ass ess me nts c o n d ucte d. All bi ol o gical materi al t hat has n ot bee n a nal yz e d at t he ti me of wit h dra wal m ust n ot be use d. F urt her atte m pts t o c o ntact t he patie nt are n ot all o we d u nless safet y fi n di n gs re q uire c o m m u nicati n g or f oll o w- u p. 5. 6. 4 L o st t o f oll o w -u p F or ra n d o mize d patie nts w h o are l ost t o f oll o w -u p (i.e. t h ose patie nts w h ose stat us is u nclear beca use he/s he fails t o a p pear f or st u d y visits wit h o ut stati n g a n i nte nti o n t o wit h dra w), t he i n vesti gat or s h o ul d s h o w "" d ue dili ge n ce"" b y ma ki n g a p pr o priate eff orts t o re-esta blis h c o nt act wit h patie nt a n d atte m pts t o c o ntact t he patie nt s h o ul d be d oc u me nte d i n t he s o urce d oc u me nts, e. g. dates of tele p h o ne calls/e mails, re gistere d letters, etc. If c o ntact has n ot bee n re-esta blis he d, all eff orts s h o ul d still be ma de t o l ocate t he patie nt a n d o btai n i nf or mati o n at t he e n d of t he 2 4 wee ks i nte n de d treat me nt a n d at t he safet y f oll o w-u p visit ( Visit 3 0 1 ). A patie nt ca n n ot be c o nsi dere d as l ost t o f oll o w -u p u ntil t he ti me p oi nt of his/ her sc he d ule d e n d of st u d y visit has passe d. 5. 6. 5 E arl y st u d y t er mi n ati o n b y t h e s p o n s or T he st u d y ca n be ter mi nate d at a n y ti me f or a n y reas o n b y N o v artis. S h o ul d t his be necessar y, t he patie nt s h o ul d be see n as s o o n as p ossi ble a n d treate d f or a pre mat ur el y wit h dra w n patie nt. T he i n vesti gat or ma y be i nf or me d of a d diti o nal pr oce d ur es t o be f oll o we d i n or der t o e ns ure t hat a de q uat e c o nsi derati o n is gi ve n t o t he pr otecti o n of t he patie nt’s i nterests. T he i n vesti gat or will be r es p o nsi ble f or i nf or mi n g t he I nstit uti onal Re vie w B oar d/I n de pe n d e nt Et hics C o m mittee (I R Bs/I E Cs) of t he earl y ter mi n ati o n of t he trial. 6 Vi sit s c h e d ul e a n d a s s e s s m e nt s Ta ble 6- 1 lists all t he assess me nts t o be perf or m e d f or t he st u d y a n d i n dicates wit h a n “ X” t h e visits at w hic h t he y will be perf or m e d. Patie nts s h o ul d be see n f or all visits o n t he desi g nate d da y or as cl ose as p ossi ble t o t hat date. Visits d uri n g t he treat me nt pe ri o d s h o ul d be perf or me d wit hi n +/ - 7 da ys of t he desi g nate d da y or as cl ose as p ossi ble. All data o btai ne d f or t hes e assess me nts m ust be s u p p orte d i n t he patie nts’ s o urce d oc u m e ntati o n. T he f oll o wi n g ass ess me nts are sc he d ule d t o be perf or me d i n or der as f oll o ws: Patie nt re p orte d o utc o me ( P R O) q u esti o n naires (i.e. A Q L Q , A C Q, ), E C G, Vit al si g ns ( p ulse rat e a n d bl o o d press ure), bl o o d sa m ple/ uri ne sa m ples, f oll o we d b y s pir o metr y i n a ma n ner t hat t he"
41,page_41,"N o v arti s C o nfi d e nti al P a g e 4 2 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 s pir o metr y m eas ur e me nts occ ur at t he sc he d ul e d ti me p oi nt ( See Ta ble 6- 2 f or Ti me d Assess me nts). W he ne ver ot her assess me nts are sc h e d ule d at t he sa me ti me -p oi nt, s pir o metr y m ust ta ke prece d e nce s uc h t hat it occ urs at t he s c he d ule d ti me p oi nt or as near as p ossi ble. As re q uire d, ot her assess me nt s ca n be d one after s pir o metr y. T a bl e 6- 1 A s s e s s m e nt s c h e d ul e P eri o d S cr e e ni n g R u n -i n Tr e at m e nt F oll o w -u p St u d y C o m pl eti o n Vi sit n u m b er 1 1 0 1 2 0 1 2 0 2 2 0 3 2 0 4 T D 3 0 14 D a y -2 1 t o -1 4 -1 4 1 5 7 1 1 3 1 6 9 1 7 6 W e e k - 3 t o -2* - 2 0 8 1 6 2 4 2 5 O bt ai n I nf or m e d c o n s e nt X C o nt a ct I R T (I V R S/I W R S) S S S S S S S S Pri or a n d C urr e nt m e di c ati o n r e vi e w/ a dj u st m e nt X R e vi e w C o n c o mit a nt m e di c ati o n X X X X X X R e vi e w S ur g er y a n d Pr o c e d ur e s X X X X X X I n cl u si o n/ E x cl u si o n crit eri a r e vi e w X X X R el e v a nt M e di c al Hi st or y, D e m o gr a p h y X Hi st or y of A st h m a E x a c er b ati o n X P h y si c al e x a mi n ati o n S S S S m o ki n g hi st or y a n d st at u s X I s s u e/ c oll e ct r e s c u e m e di c ati o n a s r e q uir e d a n d r e vi e w u s e S S S S S S Pr e g n a n c y t e st ( s er u m)1 X X X Pr e g n a n c y t e st ( uri n e)1 X X X A nti g e n -S p e cifi c I g E (I m m u n o c a p) X S er u m T ot al I g E X Vit al si g n s X X X E C G X X X H ei g ht X W ei g ht X X X"
42,page_42,"N o v arti s C o nfi d e nti al P a g e 4 3 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 P eri o d S cr e e ni n g R u n -i n Tr e at m e nt F oll o w -u p St u d y C o m pl eti o n Vi sit n u m b er 1 1 0 1 2 0 1 2 0 2 2 0 3 2 0 4 T D 3 0 14 D a y -2 1 t o -1 4 -1 4 1 5 7 1 1 3 1 6 9 1 7 6 W e e k - 3 t o -2* - 2 0 8 1 6 2 4 2 5 R e v er si bilit y S pir o m etr y t e st( S A B A)3 X S pir o m etr y X X X X X S af et y L a b a s s e s s m e nt s ( h a e m at ol o g y, cli ni c al c h e mi str y, uri n al y si s, bl o o d e o si n o p hil c o u nt) X X X I s s u e a n d tr ai n o n e Di ar y / S S S S S S R e vi e w e Di ar y / S S S S S A c c u h al er ® d e vi c e tr ai ni n g S Di s p e n s e R u n -i n m e di c ati o n vi a I R T S I s s u e R u n -i n m e di c ati o n X R a n d o mi z ati o n vi a I R T S Di s p e n s e st u d y tr e at m e nt vi a I R T S S S C o n c e pt 1 or A c c u h al er® + R e s pi m at® d e vi c e tr ai ni n g S S S St u d y Tr e at m e nt C o m pli a n c e X X X X St u d y tr e at m e nt a d mi ni str ati o n at vi sit X X X X A E s r e c or di n g X2 X X X X X X X S A E s r e c or di n g X X X X X X X X A C Q - 7 X X X X X A Q L Q X X X X S ur vi v al St at u s X * Ti m e b et w e e n Vi sit 1 a n d 1 0 1 c a n b e s h ort e n e d / a d a pt e d a c c or di n g t o t h e r e q uir e d w a s h-o ut fr o m pr e vi o u s a st h m a m e di c ati o n. T D: Tri a l di s c o nti n u ati o n S: T h e s e a s s e s s m e nt s ar e s o ur c e d o c u m e nt ati o n o nl y a n d will n ot b e e nt er e d i nt o t h e e -C R F X: A s s e s s m e nt t o b e r e p ort e d i n t h e cli ni c al d at a b a s e"
43,page_43,"N o v arti s C o nfi d e nti al P a g e 4 4 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 1 F or f e m al e s of c hil d -b e ari n g p ot e nti al o nl y u nl e s s s ur gi c all y st eril e. 2 If p ati e nt i s s cr e e n f ail ur e, a n y n o n-s eri o u s A E s m u st o nl y b e r e c or d e d i n t h e s o ur c e d o c u m e nt ati o n ( S) 3 If r e v er si bilit y f ail s o n t h e fir st att e m pt at V 1 0 1 , hi st ori c al r e v er si bilit y or br o n c h o pr o v o c ati o n w o ul d b e a c c e pt a bl e a s s p e cifi e d i n S e cti o n 4. 1 4 I nf or m ati o n a b o ut p ati e nt s’ st at u s will b e o bt ai n e d b y a t el e p h o n e c all, 7 d a y s aft er t h e p ati e nt’ s l a st d o s e of st u d y dr u g f or c o m pl et e d p ati e nt s or at a n y ti m e d uri n g t h e st u d y tr e at m e nt p eri o d w h e n i n di c at e d. F or p ati e nt s w h o wit h dr a w e arl y, pl e a s e r ef er t o di s c o nti n u ati o n of st u d y tr e at m e nt a n d pr e m at ur e p ati e nt wit h dr a w al s e cti o n . T a bl e 6 -2 Ti m e d A s s e s s m e nt s Vi sit ( D a y) Ti m e p oi nt1 P R O s ( A Q L Q, A C Q -7, ) S pir o m etr y4 ( F E V 1, F V C) L a b s ( H e m at ol o g y, C h e mi str y , Uri n al y si s ) Uri n e Pr e g n a n c y T e st3 E C G Vit al s2 Vi sit 2 0 1 ( D a y 1) > -4 5 mi n X X -4 5 mi n X -1 5 mi n X 0 mi n E V E NI N G D O S E Vi sit 2 0 2 ( D a y 5 7) > -4 5 mi n X -4 5 mi n X -1 5 mi n X 0 mi n E V E NI N G D O S E Vi sit 2 0 3 ( D a y 1 1 3) > -4 5 mi n X X -4 5 mi n X -1 5 mi n X 0 mi n E V E NI N G D O S E Vi sit 2 0 4 ( D a y 1 6 9) > -4 5 mi n X X - 4 5 mi n X - 4 5 t o -2 0 mi n X 5, 6 -1 5 mi n X 0 mi n E V E NI N G D O S E 1 St u d y dr u g ti m e d d o s e s. All st u d y m e di c ati o n d o s e s t o b e a d mi ni st er e d i n t h e cli ni c. Ti m e r el at e s t o t h e d o s e gi v e n fr o m fir st d e vi c e at vi sit . >- 4 5 r ef er s t o a n y ti m e b ef or e t h e -4 5 s pir o m etr y ti m e p oi nt. A s s e s s m e nt s s c h e d ul e d -4 5 t o -2 0 mi n c a n b e d o n e at a n y ti m e pr e -d o s e if m or e c o n v e ni e nt or effi ci e nt. 2 S y st oli c a n d di a st oli c bl o o d pr e s s ur e a n d h e art r at e (r a di al p ul s e) 3 Uri n e pr e g n a n c y t e st c a n b e d o n e at a n y ti m e pr e-d o s e if m or e c o n v e ni e nt or effi ci e nt. 4 A mi ni m u m of 3 mi n ut e s r e st m u st b e o b s er v e d pri or t o t h e st art of s pir o m etr y at e a c h ti m e -p oi nt. A mi ni m u m of 1 mi n ut e r e st i s t o b e o b s er v e d b et w e e n e a c h s pir o m etr y m a n e u v er. 5 Uri n e a n al y si s i s t o b e d o n e o nl y if t h e uri n e di p sti c k i s a b n or m al, a n d o nl y d o n e pr e -d o s e 6 S er u m pr e g n a n c y t e st d o n e wit h s af et y l a b s at Vi sit 2 0 4 6. 1 I nf or m ati o n t o b e c oll e ct e d o n s cr e e ni n g f ail ur e s All patie nts w h o ha v e si g ne d i nf or me d c o nse nt b ut n ot e nter e d i nt o t he r u n-i n peri o d will ha v e t he scree ni n g dis p ositi o n pa ge f or t he scr ee ni n g p eri o d , de m o gr a p hics, eli gi bilit y criteria, a n d seri o us a d verse e ve nts ( S A E) data c ollect e d. A d verse e ve nts t hat ar e n ot S A Es will be f oll o we d b y t he i n vesti gat or a n d c ollecte d o nl y i n t he s o urce d ata o nl y."
44,page_44,"N o v arti s C o nfi d e nti al P a g e 4 5 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 All patie nts w h o are e ntere d i nt o t he r u n -i n peri o d of t he st u d y will a d diti o nall y ha ve all a d verse e ve nts occ urri n g after i nf or me d c o ns e nt is si g ne d rec or de d o n t he A E pa ge a n d ha ve t he r u n-i n dis p ositi o n pa ge f or r u n-i n peri o d c ollecte d. 6. 2 P ati e nt d e m o gr a p hi c s/ ot h er b a s eli n e c h ar a ct eri sti c s P ati e nt d e m o gr a p hi c a n d b a s eli n e c h ar a ct eri sti c d at a t o b e c oll e ct e d o n all p ati e nt s i n cl u d e: • Date of birt h ( w her e all o we d b y l ocal le gislati o n) • A ge (calc ulate d) • Se x • Race a n d et h nicit y • Patie nts i nitials ( w here all o we d b y l o cal le gislati o n) • Hei g ht a n d Wei g ht • B MI ( calc ulat e d) • Baseli ne p h ysical e x a mi nati o n ( n ot data bases ot her t ha n i n t he c o nte xt of rele va nt me dical hist or y) • Vital si g ns • E C G • Date of dia g n osis of ast h ma • Rele va nt me dical hist or y/ c urre nt me dical c o n diti o n prese nt bef ore si g ni n g t he i nf or me d c o nse nt • S m o ki n g hist or y a n d st at us • Ast h ma Q ualit y of Life ( A Q L Q) • Ast h ma C o ntr ol ( A C Q- 7) • Pri or c o nc o mita nt me dicati o n ( B ot h ast h m a r elate d a n d n o n- ast h ma r elate d) • Pre a n d p ost- br o nc h o dilat or s pir o metr y ( r u n-i n s pir o metr y a n d r e versi bilit y testi n g) 6. 3 Tr e at m e nt e x p o s ur e a n d c o m pli a n c e St u d y tr eat me nt c o m plia nce s h o ul d be assess e d b y t he i n vesti gat or a n d/ or site pers o n nel at all visits. W here necessar y, t he I n vesti gat or will disc uss c o m plia nce iss ues wit h t he patie nt. 6. 4 Effi c a c y T he f oll o wi n g assess me nts of efficac y will be perf or me d: • H ealt h Stat us (P R Os: A Q L Q , A C Q - 7, ) • S pir o metr y"
45,page_45,"N o v arti s C o nfi d e nti al P a g e 4 6 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 6. 4. 1 H e alt h St at u s ( P ati e nt R e p ort e d O ut c o m e s) A patie nt - re p orte d o utc o me ( P R O) is a n y re p ort of t he stat us of a patie nt’s healt h c o n diti o n t hat c o mes directl y fr o m t he patie nt, wit h o ut i nter pretati o n of t he p atie nt’s res p o nse b y a cli nicia n or a n y o ne else. Patie nt -re p orte d o utc o m es ma y pr o vi de q u a ntitati ve i nf or mati o n f or patie nts re gar di n g t he ‘i m pact o n dail y life’, w hic h is of ke y i m p orta nce, f or patie nts a n d t heir p h ysicia ns a n d als o f or healt h tec h n ol o g y ass ess me nts. I n t his st u d y, t he mai n efficac y vari a ble is a P R O t o assess t he i m pact of u nc o ntr olle d ast h ma a n d t he disease’s ma na ge me nt be y o n d l u n g f u ncti o n. All P R Os s h o ul d al wa ys be c o m plete d bef ore a n y ot h er assess me nts are perf or me d t o a v oi d i nfl ue nci n g t he res p o nses. W he n occ urri n g at t h e sa me visit t he y ar e t o be c o m plete d i n t he f oll o wi n g or d er: A Q L Q-S, A C Q - 7, 6. 4. 1. 1 A st h m a Q u alit y of Lif e Q u e sti o n n air e ( A Q L Q -S) T he A Q L Q is a 3 2 -ite m ast h ma s pecific q uesti o n naire desi g n e d t o meas ure f u n cti o nal i m pair me nts t hat are m ost i m p orta nt t o patie nts wit h ast h ma (A p pe n di x 7 ). It c o nsists of 4 d o mai ns: s y m pt o ms, e m oti o ns, e x p os ure t o e n vir o n me ntal sti m uli a n d acti vit y li mitati o n. Patie nts are as ke d t o recall t heir e x perie nces d uri n g t he pre vi o us 2 wee ks a n d t o sc ore eac h ite m o n a 7-p oi nt scale (J u ni per 1 9 9 2, J u ni per 1 9 9 3). T he o verall A Q L Q sc ore is t he m ea n res p o nse t o all 3 2 q uesti o ns. Cli nicall y i m p orta nt differe nces i n sc ores bet wee n a n y t w o assess me nts ha ve bee n d eter mi ne d b y t h e a ut h ors of t he A Q L Q. C ha n ges i n sc ores of 0. 5 are c o nsi dere d cli nicall y mea ni n gf ul; c h a n ges of 1. 0 are c o nsi dere d as m o derate a n d > 1. 5 as lar ge c h a n ges f or a n y i n di vi d ual d o mai n or f or t he o verall s u m mar y sc or e (J u ni per 1 9 9 4). A Q L Q s h o ul d be c o m plete d b y t he patie nt (self -a d mi nistere d) at t he cli nic as per Assess me nt Sc he d ule Ta ble 6 - 1. 6. 4. 1. 2 A st h m a C o ntr ol Q u e sti o n n air e ( A C Q -7) I n t his st u d y, t he A C Q-7 ( A p pe n di x 8 ) will be use d t o assess i m pr o ve me nts i n ast h ma s y m pt o m c o ntr ol. T he A C Q-7 (J u ni per 1 9 9 9; J u ni per 2 0 0 5; J u ni per 2 0 0 6) is a se ve n -ite m disease -s pecific i nstr u me nt de vel o pe d a n d vali date d t o assess ast h ma c o ntr ol i n patie nts i n cli nical trials as well as i n i n di vi d uals i n cli nical practice. T he A C Q -7 q uesti o n naire will be pr o vi de d t o t he site. T h e A C Q -7 q u esti o n naire c o nsists of fi ve ite ms t o assess s y m pt o ms a n d acti vit y li mitati o ns, o ne q uesti o n t o assess res c ue me dicati o n use, a n d o ne q uesti o n t o assess air wa y cali ber ( F E V 1% pre dicte d). All se ve n ite ms are sc ore d o n a 7 - p oi nt Li kert scale, wit h 0 i n dicati n g t otal c o ntr ol a n d 6 i n dicati n g p o or c o ntr ol. T he q uesti o ns ar e e q uall y w ei g ht e d a n d t he t otal sc ore is t he mea n of t he se ve n ite ms. T he pr o p orti o n of patie nts w h o ac hie ve an i m pr o ve me nt of at least 0. 5 i n A C Q-7 (i.e. decrease of A C Q -7 sc or e of at least 0. 5 fr o m baseli ne) at p ost -b aseli ne visits will als o be a nal yz e d. T he first 6 q uesti o ns of t he A C Q-7 s h o ul d be c o m plete d b y t he patie nt b ase d o n o ne recall o ver t he pri or wee k. T h e last q uesti o n s h o ul d be c o m plete d b y t he i n v esti gat or at t he site usi n g data fr o m t he s pir o meter. T he A C Q -7 s h o ul d be c o m plete d at t he cli nic as per Assess me nt Sc he d ule Ta ble 6 - 1."
46,page_46,N o v arti s C o nfi d e nti al P a g e 4 7 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 6. 4. 2 S pir o m e tr y T he f oll o wi n g s pir o m etric assess me nts will be ma de: • F orce d e x pirat or y v ol u me i n o ne sec o n d ( F E V 1) • F orce d Vital Ca pacit y ( F V C) • F orce d E x pirat or y Fl o w bet wee n 2 5 % a n d 7 5 % of F or ce d Vital Ca pacit y ( F E F 2 5 -7 5) S pir o metric assess me nts will be perf or me d per Assess me nt Sc he d ule Ta ble 6 -1 a n d Ti me d Assess me nts Ta ble 6 - 2. Tr o u g h F E V 1 f or Q V M 1 4 9 1 5 0/ 5 0/ 8 0 μ g a n d Q V M 1 4 9 1 5 0/ 5 0/ 1 6 0 μ g o. d. d eli vere d via C o nce pt 1 is t he mea n of t he t w o F E V 1 val ues meas ures at -4 5 mi n a n d -1 5 mi n pri or t o e ve ni n g d ose. Tr o u g h F E V 1 f or t he ‘free’ tri ple c o m bi nati o n of sal met er ol/fl uticas o ne 5 0/ 5 0 0 μ g b.i. d. deli ver e d as p o w der via Acc u haler ® + ti otr o pi u m 5 μ g o. d deli v ere d via Res pi mat ® is t he mea n of t he t w o F E V 1 val ues meas ures at - 4 5 mi n a n d - 1 5 mi n pri or t o e ve ni n g d os e. Please ref er t o t he S pir o metr y G ui d a nce i n A p p e n di x 2 .
47,page_47,N o v arti s C o nfi d e nti al P a g e 4 8 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 6. 4. 4 W or s e ni n g of a st h m a I n v esti gat ors a n d patie nts will be i nstr ucte d h o w t o deal wit h w orse ni n g of ast h ma s y m pt o ms. T he data ca pt ure d i n t h e patie nt di ar y a n d site s pir o meter will b e use d t o alert t he patie nt a n d/ or i n vesti gat or t o p ossi ble si g ns of w orse ni n g ast h ma. T he patie nt e D iar y will i nstr uct t he patie nt t o c o ntact t he st u d y site if a n y ast h ma w orse ni n g criteria is met. T he i n vesti gat or will i nstr uct t he patie nt t o c o ntact t he i n vesti gat or if at a n y ti me d uri n g t he trial fr o m t he r u n-i n o n war ds o ne or m ore of t he f oll o wi n g criteria of w orse ni n g ast h ma de vel o ps: Ast h m a W o rs e ni n g Criteri a : 1. > 2 0 % decrease i n F E V 1 fr o m baseli ne val ue (t his criteri o n a p plies t o I n vesti gat or re vie w at t he ti me of a st u d y visit or via s pir o metr y re p ort) 2. > 5 0 % i ncr ease i n S A B A use a n d > 8 p uffs per da y o n 2 o ut of a n y 3 c o nsec uti ve da ys c o mpare d t o bas eli ne 3. ≥ 2 0 % decr ease i n m or ni n g ( A M ) or e ve ni n g ( P M ) P E F fr o m baseli ne o n 2 o ut of a n y 3 c o nsec uti ve da ys c o m par e d t o baseli ne 4. < 6 0 % of pr e dicte d or pers o nal best P E F c o m pare d t o bas eli ne 5. Ni g ht ti me a w a ke ni n gs r e q uiri n g S A B A us e o n at least 2 o ut of a n y 3 c o nsec uti ve ni g hts
48,page_48,"N o v arti s C o nfi d e nti al P a g e 4 9 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 6. Ur ge nt u nsc he d ul e d cli nic visit d ue t o ast h ma relate d det eri orati o n N ote: T he ref ere n ce f or t he w orse ni n g of ast h ma d uri n g t he r u n -i n peri o d w o ul d be t he F E V 1 a n d P E F ta ke n at Visit 1 0 1 . T he b aseli ne F E V 1, a n d P E F f or t he tr eat me nt peri o d is ta k e n at treat me nt Da y 1 ( Visit 20 1 ). T he b aseli ne f or S A B A use d uri n g t he r u n -i n peri o d will be > 8 p uffs a n d t he bas eli ne f or t he tr eat me nt peri o d is t a ke n fr o m t he a ver a ge of t he 7 da ys pri or t o V 2 0 1. If a n y of t he a b o ve criteria (i ncl u di n g t he alert fr o m e-diar y) are met w hile a p atie nt is i n t h e r u n-i n or treat me nt peri o d , t he i n vesti gat or s h o ul d assess t he patie nt’s c o n diti o n. If t his occ urs d uri n g r u n -i n peri o d a n d it is co nsi dere d a cli nicall y si g nifica nt ast h ma w orse ni n g i n t he i n vesti gat or’s o pi ni o n, t he patie nt s h o ul d be treate d as a p pr o priate a n d disc o nti n ue d pri or t o ra n d o mizati o n. O nce t he c o n diti o n is res ol ve d, if eli gi bilit y criteria ar e m et, t he patie nt ma y be rec o nsi d ere d f or r escr ee ni n g. If patie nts de v el o p a n y of t he a b o ve criteri a d uri n g treat me nt, t he patie nt s h o ul d n otif y t he i n vesti gat or a n d be e v al u ate d b y t he i n vesti gat or a n d treate d as cli nicall y a p pr o priate. W orse ni n g of ast h ma s y m pt o ms ma y re q uire u nsc he d ule d e val uati o n b et wee n visits. St u d y site pers o n nel m ust be a vaila ble t o m o nit or a n d d oc u me nt patie nt’s pr o gr ess u ntil ast h ma c o ntr ol is re gai ne d. 6. 4. 5 A st h m a E x a c er b ati o n A se vere ast h m a e x acer bati o n ( Dr aft n ote f or g ui da nce o n cli nical i n vesti gati o n of me d i ci nal pr o d ucts f or treat me nt of ast h ma C H M P/ E W P/ 2 9 2 2/ 0 1 Re v. 1) is defi ne d as a n a g gr a vati o n of ast h ma s y m pt o ms (li ke s h ort ness of br eat h, c o u g h, w heezi n g, or c h est ti g ht ness) t hat re q uires S yste mic C ortic oster oi d ( S C S) f or at least t hree c o nsec uti ve d a ys a n d/ or a nee d f or a n E R visit ( or l ocal e q ui vale nt str uct ure), h os pitalizati o n d ue t o ast h ma or deat h d ue t o ast h ma. Start date a n d e n d d ate: • I n case of t he use of S C Ss f or at least t hree da ys, t he first da y of tr eat me nt will deter mi ne t he o nset date of t he e ve nt w hile t he last da y of treat me nt will defi ne t he st o p date. • I n t he e ve nt t hat a n E R visit a n d/ or h os pitalizati o n d ue t o ast h ma e x acer b ati o n were n ot ass ociate d wit h a c o urse of S C Ss as descri be d a b o ve, start a n d e n d d ates w o ul d be defi ne d b y t he c or r es p o n di n g d ates e nter e d b y t he I n vesti gat or i n t he C R F. A m o der ate ast h m a e x acer bati o n i n t his pr ot oc ol is defi n e d as t he o cc urre nce of t w o or m or e of t he f oll o wi n g: 1. Pr o gr essi ve i ncr ease of at least o ne of t h e ast h ma s y m pt o ms li ke s h ort ness of breat h, c o u g h, w heezi n g, or c hest ti g ht ness. T he s y m pt o ms s h o ul d be o utsi de t he patie nt’s us ual ra n ge of da y- t o- da y ast h ma a n d s h o ul d last at least t w o c o nsec uti ve da ys. 2. I n crease d use of “r esc ue” i n hale d br o n c h o dilat ors defi ne d b y: • ≥ 5 0 % i ncreas e i n S A B A use a n d > 8 p uffs o n 2 o ut of a n y 3 c o nsec uti ve da ys c o m pare d t o bas eli ne ca pt ure d Or • Ni g ht ti me a w a ke ni n gs r e q uiri n g S A B A use o n at least 2 o ut of a n y 3 c o ns ec uti ve ni g hts"
49,page_49,"N o v arti s C o nfi d e nti al P a g e 5 0 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 3. Deteri or ati o n i n l u n g f u ncti o n, w hic h last f or t w o da ys or m ore b ut us u all y n ot se ver e e n o u g h t o w arr a nt S C Ss f or m ore t ha n 2 d a ys or h os pitalizati o n. T his deteri orati o n w o ul d be defi ne d b y: • ≥ 2 0 % decr ease i n F E V 1 fr o m baseli ne val u e Or • ≥ 2 0 % decr ease i n m or ni n g ( A M) or e v e ni n g ( P M) P E F fr o m bas eli ne o n 2 o ut of a n y 3 c o nsec uti ve da ys c o m p are d t o bas eli ne. Or • < 6 0 % of pr e dicte d P E F c o m pare d t o bas eli ne A mil d ast h m a e x acer bati o n is defi ne d as t he occ urre nce of o ne of t he f oll o wi n g criteria: 1. Deteri or ati o n of at least o ne ast h ma s y m pt o ms li ke s h ort ness of breat h, c o u g h, w h eezi n g or c hest ti g ht n ess. 2. I n crease d use of “r esc ue” i n hale d br o nc h o dilat ors 3. Deteri or ati o n i n l u n g f u n cti o n, w hic h last f or t w o da ys or m ore b ut us uall y n ot se vere e n o u g h t o w arr a nt S C Ss or h os pitalizati o n. T his deteri orati o n w o ul d be d efi ne d b y: • ≥ 2 0 % decr ease i n F E V 1 fr o m baseli ne val u e Or • ≥ 2 0 % decr ease i n m or ni n g ( A M) or e v e ni n g ( P M) P E F fr o m bas eli ne o n 2 o ut of a n y 3 c o nsec uti ve da ys c o m p are d t o bas eli ne. Or • < 6 0 % of pr e dicte d P E F c o m pare d t o bas eli ne “ Start a n d e n d dates ” of eac h r e p orte d e ve nt i n t he C R F will be use d t o deter mi ne w het h er t w o c o nsec uti vel y re p ort e d e ve nts s h o ul d b e c o nsi dere d as se parate e ve nts or as a pr ol o n ge d o ne. If a sec o n d e x acer bati o n is re p orte d less t ha n 7 da ys after t he e n d date of a pre vi o us e pis o de, t he n t his will be ass u me d t o be o ne c o nti n u o us e x acer bati o n wit h t he start date ta k e n fr o m t he first e pis o de a n d t he e n d d ate fr o m t h e sec o n d or last e pis o de. If t w o e ve nts ar e mer ge d base d o n t his “ 7 da y r ule”, t he hi g hest re p orte d se verit y will be use d t o descri be t he o verall se verit y of t he pr ol o n ge d e ve nt. T he treat me nt of ast h ma e x acer bati o ns i ncl u di n g t h e i nitiati o n of S C S or i ncr eas e i n t he mai nte na nce d ose of O C S s h o ul d be d o ne acc or di n g t o i n vesti gat or’s or treati n g p h ysicia n’s me dical j u d ge me nt a n d s h o ul d be i n li ne wit h nati o nal a n d i nter nati o nal r ec o m me n dati o ns. If S C S are re q uire d, a patie nt ma y r et ur n t o t he st u d y after s uccessf ull y c o m pleti n g a ta p er."
50,page_50,"N o v arti s C o nfi d e nti al P a g e 5 1 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 6. 4. 7 A p pr o pri at e n e s s of effi c a c y a s s e s s m e nt s T he effi cac y assess me nts selecte d are sta n d ar d f or t hi s i n dicati o n/ patie nt p o p ulati o n. T he pri mar y e n d p oi nt, Ast h ma Q ualit y of Life ( A Q L Q) , ref ers t o t he p ercei v e d i m pact t hat ast h ma has o n t he p atie nt’s q ualit y of lif e ( Qo L) . T his e n d p oi nt is wi del y use d i n ast h ma tri als a n d i n m ore t ha n si x p u blis he d vali dati o n st u dies c o n d ucte d w orl d wi de a n d has s h o w n ver y str o n g m eas ur e me nt pr o p erties. It is i ncreasi n gl y r ec o g nize d t hat t he e v al uati o n of t her a pe utic i nter ve nti o ns s h o ul d i ncl u de assess me nt of o ut c o mes t hat m atter t o p atie nts. T he Q O L meas ures ca n pr o vi de u ni q ue i nf or mati o n a n d ca n t h us pr o vi de a m ore c o m plet e c haracterizati o n of t he st u d y p o p ul ati o n’s ast h ma a n d of t he be nefits or dra w bac ks of partic ular i nter v e nti o ns. 6. 5 S af et y T he f oll o wi n g s afet y assess me nts will be perf or m e d: • Me dical hist or y a n d p h ysical e x a mi nati o n • Vital si g ns • He mat ol o g y, Bl o o d c h e mistr y, Uri nal ysis • E C G • A d verse e ve nts i ncl u di n g seri o us a d vers e e v e nts • Pre g n a nc y (fe male p atie nts); a d diti o nal pre g n a nc y testi n g mi g ht be p erf or m e d if re q u este d b y l ocal re q uir e me nts • Seri o us ast h ma o utc o mes (ast h ma-r elate d h os pitalizati o ns, i nt u bati o ns or deat hs) • C C V e ve nts a n d ne w o ns et of atrial fi brillati o n A n i n de pe n d e nt a dj u dicati o n c o m mittee will be esta blis he d t o assess seri o us ast h ma o utc o mes (ast h ma-r elate d h os pitalizati o ns, i nt u bati o ns a n d deat hs), s eri o us car di o vasc ular a n d cere br o vasc ul ar ( C C V) e ve nts, ne w o ns et of atrial fi brillati o n a n d fl utter as well as all deat hs. Refer t o Secti o n 8. 5 f or m ore i nf or mati o n. 6. 5. 1 P h y si c al e x a mi n ati o n A c o m plete p h ysical e x a mi nati o n will i ncl u de t he e x a mi nati o n of ge ner al a p pear a nce, s ki n, nec k (i ncl u di n g t h yr oi d), e yes, ears, n ose, t hr o at, l u n gs, heart, a b d o me n, b ac k, l y m p h n o d es, e xtre mities , vasc ular a n d ne ur ol o gical. If i n dicate d bas e d o n me dical hist or y a n d/ or s y m pt o ms, rectal, e xter nal ge nitalia, breast, a n d pel vic e x a ms will be perf or me d as detaile d i n Sc he d ule of Assess me nts Ta ble 6 - 1. I nf or mati o n f or all p h ysi cal e x a mi nati o ns m ust be i ncl u de d i n t he s o urce d oc u me ntati o n at t he st u d y site. Si g nifica nt fi n di n gs t hat are pr ese nt pri or t o i nf or me d c o nse nt bei n g si g ne d m ust be i ncl u de d i n t he Rele va nt Me dical Hist or y/ C urr e nt Me dical C o n diti o ns scree n o n t he patie nt’s e C R F. Si g nifica nt fi n di n gs ma de after i nf or me d c o nse nt ( Visit 1) is gi ve n w hic h meet t he defi niti o n of a n A d vers e E ve nt m ust be rec or de d o n t he A d verse E ve nt e C R F."
51,page_51,"N o v arti s C o nfi d e nti al P a g e 5 2 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 6. 5. 2 Vit al si g n s S yst olic a n d diast olic bl o o d press ure a n d r a dial p ulse rate ( o ver a 3 0 sec i nter val), perf or m e d i n t he sitti n g p ositi o n, will be r ec or d e d at sc he d ule d visits as detail e d i n Sc h e d ule of Assess me nts Ta ble 6 - 1. Vitals ca n be perf or m e d j ust bef ore or j ust after E C G. 6. 5. 3 H ei g ht a n d w ei g ht Hei g ht i n ce nti meters ( c m) will be meas ure d . B o d y w ei g ht (t o t he nearest 0. 1 kil o gra m [ k g] i n i n d o or cl ot hi n g, b ut wit h o ut s h oes) will be meas ure d acc or di n g t o Sc he d ule of Assess me nts Ta ble 6 - 1. B MI will be calc ulate d bas e d o n hei g ht a n d wei g ht. 6. 5. 4 L a b or at or y e v al u ati o n s A ce ntral la b orat or y will be use d f or a nal ysis of all s peci me ns c ollecte d. Details o n t he c ollecti o ns, s hi p me nt of sa m ples a n d re p orti n g of res ults b y t h e ce ntral la b orat or y ar e pr o vi de d t o i n vesti gat ors i n t he la b orat or y ma n u al. All patie nts wit h la b orat or y tests c o ntai ni n g cli nicall y si g nifica nt a b n or malities s h o ul d be f oll o we d re g ularl y u ntil t he val ues r et ur n t o wit hi n t he n or mal ra n ges or u ntil a vali d reas o n ot her t ha n dr u g -relate d a d verse e x perie nces is i de ntifie d, e ve n after t he me dicati o n has disc o nti n ue d. Safet y La b or at or y assess me nts ( he mat ol o g y, cli nical c he mistr y, uri nal ysis ) will be perf or me d acc or di n g t o Sc he d ul e of Assess me nts Ta ble 6 - 1. 6. 5. 4. 1 H e m at ol o g y He m o gl o bi n, he mat ocrit, re d bl o o d cell c o u nt, w hite bl o o d cell c o u nt wit h differe ntial, a n d platelet c o u nt will be meas ure d. 6. 5. 4. 2 Cli ni c al c h e mi str y Al b u mi n, al kali ne p h os p hatase, A S T ( S G O T), A L T ( S G P T), bilir u bi n, creati ni ne, γ- G T, gl uc ose, p otassi u m, ma g nesi u m, B U N a n d uric aci d will be meas ure d. If t h e t otal bilir u bi n c o nce ntratio n is i ncreas e d a b o ve 1. 5 ti mes t he u p per li mit of n or mal ra n ge, t otal bilir u bi n s h o ul d be differ e ntiate d i nt o t he direct a n d i n dir ect reacti n g bilir u bi n. 6. 5. 4. 3 Uri n al y si s Di pstic k meas ure me nts f or s pecific gra vit y, p H, pr otei n, gl u c ose a n d bl o o d will be perf or m e d acc or di n g t o t he Sc h e d ule of Assess me nts Ta bl e 6 - 1. If t he uri ne di pstic k is a b n or mal, t he sa m ple will be se nt t o ce ntr al la b or at or y f or a d diti o nal testi n g, i ncl u di n g assess me nt of W B C a n d R B C s e di me nts. 6. 5. 5 El e ctr o c ar di o gr a m ( E C G) E C Gs m ust be rec or d e d after 1 0 mi n utes rest i n t he s u pi ne p ositi o n t o e ns ure a sta ble bas eli ne. Ce ntralize d E C G e q ui p me nt:"
52,page_52,"N o v arti s C o nfi d e nti al P a g e 5 3 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 E C Gs will be meas ure d pre -d ose. All electr o car di o gra ms s h o ul d i ncl u de 1 2 sta n dar d lea ds. A n E C G traci n g will be t a ke n f or t h ose patie nts w h o pre mat urel y disc o nti n ue fr o m t he st u d y. Eac h E C G will be se nt el ectr o nicall y fr o m t he E C G mac hi ne t o t he ce ntral la b orat or y. A pri nt o ut of t he E C G r ec or d will be ge ner ate d a n d ke pt at t he i n vesti gat or site as s o urce d oc u me ntat i o n a n d as b ac k-u p f or s u b missi o n t o t he ce ntral la b orat or y i n case of pr o ble ms wit h t he electr o nic tr a ns missi o n. Eac h pri nt o ut will be ke pt at t he i n vesti gat or site a n d will be date d a n d si g n e d. T he s u bject's n u m ber, t h e date, act ual ti me of t he traci n g, a n d St u d y C o d e m ust a p pear o n eac h p a ge of t he traci n g. F ull details of all pr oce d ures relati n g t o t he E C G c ollecti o n a n d re p orti n g will be c o ntai ne d i n a n i n vesti gat or ma n u al t o be pr o vi de d b y t he ce ntral la b orat or y t o eac h i n vesti gat or site. A cli nicall y si g nifica nt a b n or malit y s h o ul d be r e p ort e d as a n A E. If necessar y a car di ol o gist ma y be c o ns ulte d. Cli nicall y si g nifica nt E C G fi n di n gs at baseli ne m ust be disc usse d wit h t he s p o ns or bef or e a d mi nistrati o n wit h i n vesti gati o nal treat me nt. If a patie nt e x perie nces a cli nicall y si g nifica nt c ha n ge i n car diac r h yt h m or ot her cli nicall y si g nifica nt car di o vasc ul ar a b n or malit y, t he i n vesti gat or s h o ul d c o nsi d er wit h dr a wi n g t h e patie nt fr o m t he st u d y. Cli nicall y si g nifica nt a b n or malities s h o ul d be r ec or de d o n t he rel e va nt secti o n of t he me dical hist or y/ C urre nt me dical c o n diti o ns/ A E C R F/e -C R F pa ge as a p pr o priate. Ne w cases ( n ot pr ese nt d uri n g scree ni n g/r u n -i n peri o ds) of atrial fi brillati o n re p orte d fr o m t he E C G meas ure me nts ( or r e p orte d as a n A E d uri n g t he c o urse of t he st u d y) will be a dj u dicate d. A d diti o nal i nf or mati o n re gar di n g t he Atrial Fi brillati o n/ Atrial Fl utter ma y be re q ueste d t o be se nt t o t he A dj u dicati o n C o m mittee. All cases of atrial fi brillati o n, re gar dl ess of seri o us ness, will be re vie we d b y t h e A dj u dicat i o n C o m mittee. 6. 5. 6 Pr e g n a n c y a n d a s s e s s m e nt s of f ertilit y A uri ne or s er u m pre g n a nc y test will be perf or me d i n pr e -me n o p a usal w o me n w h o ar e n ot s ur gicall y st erile (t ests pr o vi de d b y t he Ce ntr al La b orat or y) per Sc he d ule of Assess me nts Ta ble 6 - 1. If t he uri ne pr e g n a nc y test is p ositi ve, a plas ma testi n g is t o be d o ne t o c o nfir m t he pre g na nc y. A p ositi ve pr e g n a nc y test d uri n g t he st u d y re q uir es t he patie nt t o be disc o nti n ue d fr o m t he st u dy tr eat me nt. Refer t o S ecti o n 5. 6. 2 a n d Secti o n 7. 5 f or m ore details. A d diti o nal pre g na nc y t esti n g mi g ht be perf or me d if r e q ueste d b y l ocal re q uir e me nts . 6. 5. 7 A p pr o pri at e n e s s of s af et y m e a s ur e m e nt s T he safet y assess me nts s electe d are sta n d ar d f or t his i n dicati o n/ patie nt p o p ulati o n."
53,page_53,"N o v arti s C o nfi d e nti al P a g e 5 4 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 7 S af et y m o nit ori n g 7. 1 A d v er s e e v e nt s A n a d verse e ve nt ( A E) is a n y u nt o war d me di cal occ urr e nce (e. g., a n y u nfa v or a ble a n d u ni nte n de d si g n [i ncl u di n g a b n or mal la b orat or y fi n di n gs], s y m pt o m or dis ease) i n a s u bject or cli nical i n vesti gati o n s u bject after pr ovi di n g writte n i nf or me d c o nse nt f or partici pati o n i n t he st u d y u ntil t he e n d of st u d y visit. T heref ore, a n A E ma y or ma y n ot be t e m p orall y or ca usall y ass ociate d wit h t he use of a me dici nal (i n v esti gati o nal) pr o d uct. I n a d diti o n, all re p orts of i nte nti o nal mis use a n d a b use of t he pr o d uct are als o c o nsi dere d a n a d verse e ve nt irr es pecti v e if a cli nical e ve nt has o cc urr e d. T he occ urre nce of a d v erse e ve nts m ust be s o u g ht b y n o n -directi ve q uesti o ni n g of t he patie nt at eac h visit d uri n g t he st u d y. A d verse e ve nts als o ma y b e detect e d w he n t he y are v ol u nteer e d b y t he patie nt d uri n g or bet wee n visits or t hr o u g h p h ysical e x a mi nati o n fi n di n gs, la b orat or y test fi n di n gs, or ot her ass ess me nts. A b n or mal la b orat or y val ues or test res ults c o nstit ute a d verse e ve nts o nl y if t he y f ulfill at least o ne of t he f oll o wi n g criteria: • t he y i n d uce cli nical si g ns or s y m pt o ms,"
54,page_54,"N o v arti s C o nfi d e nti al P a g e 5 5 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 • t he y are c o nsi dere d cli nicall y si g nifica nt, • t he y r e q uire t h era p y. Cli nicall y si g nifica nt a b n or mal la b or at or y v al ues or test res ults m ust be i de ntifie d t hr o u g h a re vie w of val u es o utsi de of n or mal ra n ges/cli nicall y n otable ra n ges, si g nifi ca nt c ha n ges fr o m baseli ne or t he pre vi o us visit, or val ues w hic h are c o nsi dere d t o be n o n -t y pical i n patie nt wit h u n derl yi n g diseas e. I n vesti gat ors ha ve t he r es p o nsi bilit y f or ma n a gi n g t he s afet y of i n di vi d ual patie nt a n d i de ntif yi n g a d verse e ve nts. Al ert r a n ges f or la b or at or y a n d ot h er test a b n or malities are i ncl u de d i n A p p e n di x 1. A d verse e v e nts m ust be rec or d e d i n t he A d vers e E ve nts C R F u n der t he si g ns, s y m pt o ms or dia g n osis ass oci ate d wit h t he m, acc o m pa ni e d b y t he f oll o wi n g i nf or mati o n: • t he se verit y gra d e • mil d: us uall y tr a nsie nt i n nat ure a n d ge ner all y n ot i nterferi n g wit h n or m al acti vities • m o derate: s uffi cie ntl y dis c o mf orti n g t o i nterfer e wit h n or mal acti vities • se vere: pr e ve nts n or mal acti vities All a d verse e v e nts m ust be treate d a p p r o priat el y. Treat me nt ma y i ncl u de o ne or m ore of t h e f oll o wi n g: • n o acti o n ta ke n ( e. g. f urt her o bser v ati o n o nl y) • [i n vesti gati o nal] treat me nt d osa ge a dj uste d/te m p oraril y i nterr u pte d • [i n vesti gati o nal] treat me nt per ma ne ntl y disc o nti n ue d d ue t o t his a d verse e ve nt • c o nc o mita nt me dicati o n gi ve n • n o n- dr u g t her a p y gi ve n • patie nt h os pitalize d/ patie nt’s h os pitalizati o n pr ol o n ge d (see Secti o n 7. 2 ) f or defi niti o n of S A E) • its o utc o me ( n ot rec o vere d/ n ot res ol ve d; rec o v ere d/res ol ve d; rec o v eri n g/res ol vi n g, rec o vere d/r es ol ve d wit h se q uelae; f atal; or u n k n o w n) O nce a n a d verse e v e nt is detecte d, it m ust be f oll o we d u ntil its res ol uti o n or u ntil it is j u d ge d t o be per ma ne nt, a n d ass ess me nt m ust be ma de at eac h visit ( or m ore fr e q u e ntl y, if necessar y) of a n y c ha n ges i n se v erit y, t he s us p ecte d relati o ns hi p t o t he st u d y dr u g, t h e i nter ve nti o ns re q uire d t o treat it, a n d t he o utc o me. I nf or mati o n a b o ut c o m m o n si de effects alrea d y k n o w n a b o ut t he i n vesti gati o nal dr u g ca n b e f o u n d i n t he I n vesti gat or Br oc h ure (I B). T his i nf or mati o n will be i ncl u de d i n t he patie nt i nf or me d c o nse nt a n d s h o ul d be disc usse d wit h t he patie nt d uri n g t he st u d y as nee de d. A n y ne w i nf or mati o n re gar di n g t he safet y pr ofile of t he me dici nal pr o d uct t hat is i de nt ifie d bet wee n I B u p d ates will be c o m m u nicate d as a p pr o priate, f or e x a m ple, via a n I n vesti gat or N otificati o n or a n A g gre gat e Safet y Fi n di n g. Ne w i nf or mati o n mi g ht r e q uire a n u p date t o t he i nf or me d c o nse nt a n d h as t he n t o be disc usse d wit h t he patie nt. T he i n vesti gat or m ust als o i nstr uct eac h patie nt t o re p ort a n y ne w a d verse e ve nt ( be y o n d t he pr ot oc ol o bser vati o n peri o d) t hat t he patie nt, or t he patie nt’s pers o nal p h ysicia n, belie v es mi g ht reas o na bl y be rel ate d t o st u d y treat me nt. T his i nf or mati o n m ust be rec or d e d i n t he"
55,page_55,"N o v arti s C o nfi d e nti al P a g e 5 6 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 i n vesti gat or’s s o ur ce d oc u me nts; h o we ver, if t he A E meets t he criteria of a n S A E, it m ust be re p orte d t o N o v artis. 7. 2 S eri o u s a d v er s e e v e nt s 7. 2. 1 D efi niti o n of S A E A S A E is defi n e d as a n y a d vers e e v e nt [ a p pear a nce of ( or w ors e ni n g of a n y pre -e xisti n g)] u n desira ble si g n(s), s y m pt o m(s) or me dical c o n diti o ns(s) w hic h meets a n y o n e of t he f oll o wi n g criteria: • is fatal or life-t hr eate ni n g • res ults i n persiste nt or si g nifica nt disa bilit y/i n ca pacit y • c o nstit utes a c o n ge nital a n o mal y/ birt h def ect • req uires i n patie nt h os pitalizati o n or pr ol o n gati o n of e xisti n g h os pitalizati o n, u nless h os pitalizati o n is f or: • r o uti ne treat me nt or m o nit ori n g of t he st u die d i n di cati o n, n ot ass ociate d wit h a n y deteri orati o n i n c o n diti o n (s pecif y w h at t his i ncl u des) • electi ve or pre -pla n n e d tr eat me nt f or a pre -e xisti n g c o n diti o n t hat is u nrelat e d t o t he i n dicati o n u n der st u d y a n d has n ot w orse ne d si nce si g ni n g t he i nf or me d c o nse nt • treat me nt o n a n e m er ge n c y o ut p atie nt basis f or a n e ve nt n ot f ulfilli n g a n y of t he defi niti o ns of a S A E gi v e n a b o ve a n d n ot r es ulti n g i n h os pital a d missi o n • s ocial reas o ns a n d res pite care i n t he a bse n ce of a n y det eri orati o n i n t he pati e nt’s ge n eral c o n diti o n • is me dicall y si g nifica nt, e. g. d efi ne d as a n e v e nt t hat je o par dizes t he patie nt or ma y re q uire me di cal or s ur gical i nter ve nti o n. All mali g na nt ne o plas ms will be assesse d as seri o us u n der “ me dicall y si g nifica nt ” if ot her seri o us ness criteria ar e n ot met. Lif e -t hreate ni n g i n t he c o nte xt of a S A E r ef ers t o a reacti o n i n w hic h t he p atie nt was at ris k of deat h at t he ti me of t he r eacti o n; it d oes n ot r ef er t o a reacti o n t hat h y p ot h eticall y mi g ht h a ve ca use d deat h if it wer e m ore se vere (s ee A n n e x I V, I C H - E 2 D G ui deli ne). Me dical a n d s cie ntific j u d g me nt s h o ul d be e x er cise d i n deci di n g w h et h er ot her sit uati o ns s h o ul d be c o nsi dere d seri o us reacti o ns, s uc h as i m p orta nt me dical e ve nts t hat mi g ht n ot be i m me diatel y life t hreat e ni n g or res ult i n deat h or h os pitalizati o n b ut mi g ht je o par dize t he patie nt or mi g ht re q uire i nter ve nti o n t o pre ve nt o ne of t he ot her o utc o mes liste d a b o ve. E x a m ples of s uc h e ve nts are i nte nsi ve tr eat me nt i n a n e mer ge nc y r o o m or at h o me f or aller gic br o nc h os pas m, bl o o d d ys crasias or c o n v ulsi o ns t hat d o n ot res ult i n h os pitalizati o n or de vel o p me nt of de p e n de nc y or a b use (see A n ne x I V, I C H- E 2 D G ui deli ne). A n y s us pect e d tra ns missi o n via a me dici nal pr o d uct of a n i nfecti o us a ge nt is als o c o nsi dere d a seri o us a d vers e reacti o n."
56,page_56,"N o v arti s C o nfi d e nti al P a g e 5 7 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 7. 2. 2 S A E r e p orti n g T o e ns ure patie nt safet y, e ver y S A E, re gar dless of ca usalit y, o cc urri n g after t he patie nt has pr o vi de d i nf or me d c o ns e nt a n d u ntil 3 0 da ys after t he last st u d y visit m ust be re p orte d t o N o vartis saf et y wit hi n 2 4 h o urs of lear ni n g of its occ urr e nce. A n y S A Es e x perie nce d after t he 3 0 da y p eri o d aft er t he last st u d y visit s h o ul d o nl y be r e p orte d t o N o vartis safet y if t h e i n vesti gat or s us pects a ca usal relati o ns hi p t o st u d y treat me nt. All f oll o w - u p i nf or mati o n f or t he S A E i n cl u di n g i nf or mati o n o n c o m plicati o ns, pr o gressi o n of t he i nitial S A E a n d rec urre nt e pis o des m ust be r e p orte d as f oll o w-u p t o t he ori gi n al e pis o de wit hi n 2 4 h o urs of t h e i n vesti gat or recei vi n g t he f oll o w -u p i nf or mati o n. A S A E occ urri n g at a differe nt ti me i nter val or ot her wise c o nsi dere d c o m pletel y u nrelat e d t o a pre vi o usl y re p orte d o ne m ust be re p orte d s e p aratel y as a ne w e ve nt. I nf or mati o n a b o ut all S A Es is c ollecte d a n d rec or de d o n t he Seri o us A d verse E ve nt Re p ort F or m; all a p plica ble secti o ns of t he f or m m ust be c o m plete d i n or der t o pr o vi de a cli nicall y t h or o u g h re p ort. T he i n v esti gat or m ust assess t he relati o ns hi p of eac h S A E t o e ac h s p ecific c o m p o ne nt of st u dy tre at me nt, c o m plete t he S A E Re p ort F or m i n E n glis h, a n d s u b mit t he c o m plete d f or m wit hi n 2 4 h o urs t o N o vartis. Det aile d i nstr ucti o ns re gar di n g t he s u b missi o n pr ocess a n d re q uir e me nts f or si g n at ure ar e t o be f o u n d i n t he i n vesti gat or f ol der pr o vi de d t o eac h site. F oll o w- u p i nf or mati o n is s u b mitte d as i nstr ucte d i n t he i n vesti gat or f ol der. Eac h re - occ urr e nce, c o m plicati o n, or pr o gr essi o n of t he ori gi nal e ve nt m ust be re p orte d as a f oll o w - u p t o t hat e ve nt re gar dl ess of w he n it occ urs. T h e f oll o w-u p i nf or mati o n s h o ul d descri be w h et her t he e ve nt h as r es ol ve d or c o nti n ues, if a n d h o w it was treate d, w h et her t he bli n d was br o ke n or n ot, a n d w het her t he p atie nt c o nti n ue d or wit h dre w fr o m st u d y p artici pati o n. If t he S A E is n ot pre vi o usl y d oc u me nte d i n t h e I n vesti gat or’s Br oc h ur e or Pac k a ge I nsert ( ne w o cc urre nce) a n d is t h o u g ht t o be relat e d t o t he st u d y treat me nt a Dr u g Safet y a n d E pi de mi ol o g y D e part me nt ass ociate ma y ur ge ntl y r e q uire f urt h er i nf or mati o n fr o m t he i n vesti gat or f or healt h a ut h orit y re p orti n g. N o vartis ma y n ee d t o iss ue a n I n v esti gat or N otificati o n (I N) t o i nf or m all i n vesti gat ors i n v ol ve d i n a n y st u d y wit h t he sa me st u d y treat me nt t hat t his S A E has bee n re p orte d. S us pecte d U ne x pecte d Seri o us A d verse Reacti o ns ( S U S A Rs) will be c ollecte d a n d re p orte d t o t he c o m pete nt a ut h orities a n d rele va nt et hics c o m mittees i n acc or da n ce wit h E U G ui da nce 2 0 1 1/ C 1 7 2/ 0 1 or as per nati o nal re g ulat or y re q uire me nts i n partici pati n g c o u ntries. 7. 3 Li v er s af et y m o nit ori n g T o e ns ure patie nt safet y a n d e n ha n ce r elia bilit y i n deter mi ni n g t he h e pat ot o xic p ote ntial of a n i n vesti gati o nal dr u g, a st a n dar dize d pr o cess f or i de ntificati o n, m o nit ori n g a n d e val uati o n of li ver e ve nts has t o be f oll o we d. T he f oll o wi n g t w o cate g ories of a b n or malities/a d verse e ve nts ha ve t o be c o nsi dere d d uri n g t he c o urse of t h e st u d y (irres pecti ve of w h et her cl assifie d/re p orte d as ( S) A E): • Li ver la b orat or y tri g gers, w hic h will re q uire r e peate d assess me nts of t he a b n or mal la b orat or y para meter"
57,page_57,"N o v arti s C o nfi d e nti al P a g e 5 8 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 • Li ver e v e nts, w hic h will re q uir e cl os e o bser vati o n, f oll o w -u p m o nit ori n g a n d c o m pleti o n of t he sta n dar d b ase li ver C R F pa ges Please ref er t o A p pe n di x 1 f or c o m plete defi niti o ns of li ver la b orat or y tri g gers a n d li ver e ve nts. E ver y li ver la b orat or y tri g ger or li ver e ve nt as d efi ne d i n A p pe n di x 1 s h o ul d be f oll o we d u p b y t he i n vesti gat or or d esi g nat e d pers o nal at t he trial site as s u m marize d bel o w. Detaile d i nf or mati o n is o utli ne d i n Ta ble 1 3- 1 Li ver E ve nt a n d La b or at or y Tri g ger Defi niti o ns . F or t he li ver l a b orat or y tri g ge r: • Re peati n g t h e li ver f u n cti o n test ( L F T) wit hi n t he ne xt wee k t o c o nfir m ele vati o n. T he re p eat of L F T s m ust be perf or me d usi n g t he ce ntral la b orat or y , if p ossi ble. If t his is n ot p ossi ble, t he n t he re peats ca n be perf or me d at a l ocal la b orat or y t o m o nit or t he safet y of t h e patie nt. If a li ver e v e nt is s u bse q ue ntl y r e p orte d, a n y l o cal L F Ts pr e vi o usl y c o n d ucte d t hat are ass ociate d wit h t his e ve nt m ust be re p orte d o n t he Li ver C R F pa ges. • If t he ele vati o n is c o nfir me d, cl ose o bs er vati o n of t he p atie nt will be i niti ate d, i ncl u di n g c o nsi derati o n of tr eat me nt i nterr u pti o n if dee me d a p pr o priate. F or t he li ver e ve nts: • Re peati n g t h e L F T t o c o nfir m ele vati o n as a p p r o priate • Disc o nti n uati o n of t he i n vesti gati o nal dr u g if a p pr o priate • H os pitalizati o n of t he patie nt if a p pr o priate • A ca usalit y assess me nt of t he li ver e v e nt via e x cl usi o n of alter nati ve ca uses (e. g., disease, c o-me dicati o ns) • A n i n vesti gati o n of t he li ver e ve nt w hi c h nee ds t o be f oll o we d u ntil res ol uti o n. T hese i n vesti gati o ns ca n i ncl u de ser ol o g y tests, i ma gi n g a n d pat h ol o g y assess me nts, he pat ol o gist’s c o ns ulta nc y, base d o n i n vesti gat or’s discreti o n. All f oll o w -u p i nf or mati o n, a n d t he pr oce d ures perf or me d m ust be rec or d e d o n a p pr o priate eC R F p a ges, i ncl u di n g t he li ver e ve nt o ver vie w e C R F pa ges. 7. 4 R e p orti n g of st u d y tr e at m e nt err or s i n cl u di n g mi s u s e/ a b u s e Me dicati o n err ors ar e u ni nte nti o nal err ors i n t h e pr escri bi n g, dis pe nsi n g, a d mi nistrati o n or m o nit ori n g of a me dici ne w hile u n der t he c o ntr ol of a healt hcare pr of essi o nal, patie nt or c o ns u mer ( E M A d efi niti o n). Me dicati o n err ors are us uall y u ni nte nti o nal, alt h o u g h a patie nt ca n i nte nti o nall y ‘c o m mit’ a me dicati o n err or d u e t o a lac k of me dical k n o wl e d ge or s o u n d j u d g me nt (e. g. i nte nti o nall y re m o vi n g dr u g fr o m ca ps ule a n d diss ol vi n g i n j uice) or t here is a n acci de ntal dr u g o missi o n b y a n H C P). Me dicati o n err ors are n ot c o nsi d ere d t o be mis use or a b use. Mis use refers t o sit uati o ns w here t he me dici nal pr o d uct is i nte nti o nall y a n d i na p pr o priatel y use d n ot i n acc or d a nce wit h t he pr ot oc ol. A b use c orr es p o n ds t o t he persiste nt or s p ora di c, i nte nti o nal e x cessi ve use of a me dici nal pr o d uct, w hic h is acc o m pa nie d b y har mf ul p h ysical or ps yc h ol o gical effects."
58,page_58,"N o v arti s C o nfi d e nti al P a g e 5 9 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Me dicati o n err ors wit h ra n d o mize d st u d y treat me nt (st u d y treat me nt err ors ) will be c ollecte d o n t he D A R ( dose a d mi nistrati o n rec or d) e C R F. Refer t o Secti o n 5. 5. 5 f or i nf or mati o n re gar di n g i nterr u pti o ns of st u d y tr eat ment. Mis use or a b us e of ra n d o mize d st u d y treat me nt will be c ollecte d o n t he A E e C R F a n d re p orte d i n t he safet y dat a base irr es pecti ve of it bei n g ass oci ate d wit h a n A E/ S A E. T a bl e 7 -1 G ui d a n c e f or c a pt uri n g t h e st u d y tr e at m e nt err or s i n cl u di n g mi s u s e/ a b u s e Tr e at m e nt err or t y p e D o c u m e nt i n D o s e A d mi ni str ati o n ( D A R) e C R F ( Y e s/ N o) D o c u m e nt i n A E e C R F C o m pl et e S A E f or m S t u d y tr e at m e nt err or Y e s O nl y if a s s o ci at e d wit h a n A E O nl y if a s s o ci at e d wit h a n S A E Mi s u s e/ A b u s e Y e s Y e s, e v e n if n ot a s s o ci at e d wit h A E Y e s, e v e n if n ot a s s o ci at e d wit h S A E 7. 5 Pr e g n a n c y r e p orti n g T o e ns ure patie nt safet y, eac h pre g na nc y occ urri n g after si g ni n g t he i nf or me d c o nse nt m ust be re p orte d t o N o vartis wit hi n 2 4 h o urs of lear ni n g of its occ urre n ce. T he pre g na nc y s h o ul d b e f oll o we d u p t o deter mi ne o utc o me, i ncl u di n g s p o nta ne o us or v ol u ntar y t er mi nati o n, details of t he birt h, a n d t he pr ese nce or a bse nce of a n y birt h defects, c o n ge nital a b n or malities, or mater nal a n d/ or n e w b or n c o m plicati o ns. Pre g n a nc y m ust be rec or de d o n t he P har mac o vi gila nce Pre g n a nc y F or m a n d re p orte d b y t h e i n vesti gat or t o t h e l ocal N o vartis Dr u g Safet y a n d E pi de mi ol o g y De p art me nt. Pre g na nc y f oll o w-u p s h o ul d be rec or de d o n t he sa m e f or m a n d s h o ul d i n cl u de a n assess me nt of t he p ossi ble relati o ns hi p t o t he st u d y tr eat me n t. A n y S A E e x perie nce d d uri n g t he pre g n a nc y a n d u nrelate d t o t he pre g na n c y m ust be re p ort e d o n a S A E f or m. 8 D at a r e vi e w a n d d at a b a s e m a n a g e m e nt 8. 1 Sit e m o nit ori n g Bef ore st u d y i nitiati o n, at a site i nitiati o n visit or at a n i n vesti gat or’s meeti n g, a N o v arti s re pres e ntati ve will r e vie w t he pr ot oc ol a n d d ata ca pt ur e re q uire me nts (i. e. e S o urce D D E or e C R Fs) wit h t he i n vesti gat ors a n d t heir staff. D uri n g t he st u d y, N o v artis e m pl o ys se v er al met h o ds of e ns uri n g pr ot oc ol a n d G C P c o m plia nce a n d t he q u alit y/i nte grit y of t he sites’ d ata. T he fiel d m o nit or will visit t he site t o c hec k t he c o m plete ness of patie nt rec or ds, t he acc urac y of data ca pt ur e / data e ntr y, t he a d h ere n ce t o t he pr ot oc ol a n d t o G o o d Cli nical Practice, t he pr o gress of e nr oll me nt, a n d t o e ns ure t hat st u d y treat me nt is bei n g st ore d, dis pe nse d, a n d acc o u nte d f or acc or di n g t o s pecificati o ns. Ke y st u d y pers o n nel m ust be a v aila ble t o assist t he fiel d m o nit or d uri n g t hese visits. C o nti n u o us re m ote m o nit ori n g of eac h site’s data ma y b e perf or me d b y a ce ntr a lize d N o vartis C R A or ga nizati o n. A d diti o nall y, a ce ntral a n al yti cs or ga nizati o n ma y a n al yz e data & i de ntif y ris ks & tre n ds f or site o perati o nal para met ers, a n d pr o vi de re p orts t o N o v artis Cli nical Tea ms t o assist wit h trial o versi g ht."
59,page_59,"N o v arti s C o nfi d e nti al P a g e 6 0 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 T he i n vesti gat or m ust mai ntai n s o urce d o c u me nts f or eac h patie nt i n t he st u d y, c o nsisti n g of case a n d visit n otes ( h os pital or cli nic me dical rec or ds) c o ntai ni n g de m o gra p hic a n d me dical i nf or mati o n, la b orat or y data, electr ocar di o gra ms, a n d t he res ults of a n y ot her tests or assess me nts. All i nf or m ati o n o n C R Fs m ust be tracea ble t o t hese s o urce d oc u me nts i n t he patie nt's file. T he i n vesti gat or m ust als o kee p t he ori gi nal i nf or me d c o ns e nt f or m si g ne d b y t he patie nt (a si g ne d c o p y is gi ve n t o t he patie nt). T he i n vesti gat or m ust gi ve t he m o nit or access t o all rele va nt s o ur ce d o c u me nts t o c o nfir m t heir c o nsiste nc y wit h t he C R F e ntries. N o vartis m o nit ori n g sta n dar ds re q uire f ull verificati o n f or t he pres e nce of i nf or me d c o nse nt, a d here nce t o t he i ncl usi o n/e x cl usi o n criteria, d oc u me nta ti o n of S A Es, a n d of data t hat will be use d f or all pri mar y varia bles. A d diti o nal c hec ks of t h e c o nsiste n c y of t he s o urce d ata wit h t he C R Fs ar e perf or m e d acc or di n g t o t he st u d y-s pecific m o nit ori n g pla n. N o i nf or mati o n i n s o urce d oc u m e nts a b o ut t he i de ntit y of t h e patie nts will be discl ose d. 8. 2 D at a c oll e cti o n Desi g n ate d i n vesti gat or site staff will n ot be gi v e n access t o t he s yste m u ntil t he y ha ve b ee n trai ne d. All data will be ha n dle d i n ali g n me nt wit h c urre nt le gislati o n o n data pr otecti o n. St u d y d oc u m e nts i ncl u di n g patie nts' files will be st ore d sec ur e at cl i nical site. O nl y a pri nci pal i n vesti gat or a n d na me d st u d y pers o n al will ha ve access t o patie nts' files. Data tra nsferre d t o N o vartis s yste ms are c o de d a n d pr otecte d fr o m u na ut h orize d brea k -i n. I de ntifie d site users will recei ve a n i n di vi d ual l o gi n a n d p a ss w or d or bi o metric fi n ger pri nt i de ntificati o n. Pass w or ds use d t o access N o vartis (a n d its ve n d ors) s yst e ms nee d t o be of a p pr o priate stre n gt h a n d n ee d t o be c ha n ge d r e g ularl y. N o v artis pers o n al c o m p uters re q uir e t w o f act or a ut h orizati o ns. A d diti o nall y access t o all data ser ver r o o ms use d t o st ore har d w are a n d s oft ware f or t his trial is restricte d o nl y t o t h ose st aff wit h a p pr o priate access ri g hts. Access t o s yste ms w hic h are n o l o n ger i n use will be r e m o ve d; als o access of users n o l o n ger i n v ol ve d i n t he c o n d uct of t he st u d y will be re m o ve d. O n t he c o ntrar y, ne w staff will be caref ull y trai ne d bef or e bei n g all o we d t o access c o nfi d e ntial or pers o nal files ( o n-site trai ni n g, i n vesti gat or meeti n g a n d ve n d or s pecific trai ni n gs). Staff m ust e ns ure t hat u na ut h orize d pers o ns ar e u na ble t o vi e w or pr ocess pers o n al or se nsiti ve i nf or mati o n i n a pa per f or m or dis pla ye d electr o ni call y. Pers o nal data are st or e d ce ntr all y o nl y i n ps e u d o n y m o us f or m. Electr o nic tr a nsfer of data is al wa ys e n cr y pte d a n d ta kes place via sec ur e o n -li ne c h a n nels pr o vi di n g t he hi g hest le v el of sec urit y. S pir o meters a n d a n y ot her de vices ca pt uri n g cli nical or pers o nal data m ust n ot c o ntai n u na ut h orize d, u nlice nse d or p ers o nall y lice nse d s oft war e. All s oft ware m ust be a ut h ori ze d a n d pr oc ure d t hr o u g h N o vartis or its ve n d ors. Electr o nic de vices are sec ure d b y u p -t o-d ate a nti -vir us, a nti -s p y ware a n d pers o n al fire wall. O nl y k n o w n mac hi nes are all o we d t o re m otel y access ce ntrall y hel d p ers o nal or se nsiti ve data. I n a d diti o n N o vartis as w ell as cli ni cal s ite re g ul ate use of i nf or mati o n a n d c o m m u nicati o n tec h n ol o gies b y t heir staff i n or der t o a v oi d u na ut horize d brea k -i n t o t he net w or k. 8. 3 D at a b a s e m a n a g e m e nt a n d q u alit y c o ntr ol N o vartis staff [ or C R O w or ki n g o n b e half of N o vartis] re vie w t he data e ntere d i nt o t he C R Fs b y i n vesti gati o nal staff f or c o m plete ness a n d acc urac y a n d i nstr uct t he site pers o n nel t o ma k e a n y r e q uire d c orrecti o ns or a d diti o ns. Q ueries are se nt t o t he i n vesti gati o nal site usi n g a n"
60,page_60,"N o v arti s C o nfi d e nti al P a g e 6 1 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 electr o nic d ata q u er y. D esi g nate d i n v esti gat or site staff is re q uire d t o r es p o n d t o t he q uer y a n d c o nfir m or c orrect t he dat a. C o nc o mita nt me dicati o ns e ntere d i nt o t he data base will be c o de d usi n g t he W H O Dr u g Refere n ce List, w hic h e m pl o ys t he A nat o mical T hera p e utic C he mical cl assificati o n s yste m. C o nc o mita nt pr oce d ur es, n o n -dr u g t hera pi es a n d a d verse e ve nts will b e c o d e d usi n g t h e Me dical dicti o nar y f or re g ulat or y acti vities ( Me d D R A) ter mi n ol o g y. La b orat or y sa m ples , E C G rea di n gs, a n d S pir o metr y rea di n gs will be pr ocesse d ce ntrall y a n d t he res ults will be se nt el ectr o nicall y t o N o vartis ( or a desi g nate d C R O). Diar y data will be e nt ere d i nt o a n electr o nic diar y b y t h e patie nt a n d patie nts will fill i n t heir P R O data i n a site base d ta blet. T he s yste m will be s u p plie d b y a ve n d or(s), w h o will als o ma na ge t he d ata base. T he data bas e will be se nt electr o nicall y t o N o vartis pers o n nel ( or desi g nat e d C R O). Ra n d o mizati o n c o des a n d data a b o ut all st u d y dr u g(s) dis pe nse d t o t he patie nt a n d all d osa ge c ha n ges will be trac k e d usi n g a n I nt eracti ve Res p o nse Tec h n ol o g y (I R T). T he s yste m will be s u p plie d b y a ve n d or, w h o will als o ma na ge t he data base. T h e dat a base will be se nt electr o nicall y t o N o v artis ( or a desi g nat e d C R O). Eac h o cc urre nce of a c o de br ea k vi a I R T will be r e p orte d t o t he cli nical tea m a n d m o nit or. T he c o d e brea k f u n cti o nalit y will re mai n a vaila ble u ntil st u d y s h ut d o w n or u p o n re q uest of N o vartis. T he occ urre nce of rele v a nt pr ot oc ol de viati o ns will be deter mi ne d. After t hese acti o ns ha v e bee n c o m plete d a n d t he data base has b ee n decl ar e d t o be c o m plete a n d acc urat e, it will be l oc ke d a n d t he treat me nt c o des will be u n bli n de d a n d ma de a vaila ble f or data a nal ysis. A n y c ha n ges t o t he data b ase after t h at ti me ca n o nl y be ma de after writte n a gree me nt b y N o vartis De vel o p me nt ma na ge me nt. 8. 4 D at a M o nit ori n g C o m mitt e e N ot re q uire d. 8. 5 A dj u di c ati o n C o m mitt e e A n i n de pe n d e nt a dj u dicati o n c o m mittee will be esta blis he d t o assess seri o us ast h ma o utc o mes (ast h ma-r elate d h os pitalizati o ns, i nt u bati o ns a n d deat hs), s eri o us car di o vasc ular a n d cere br o vasc ul ar ( C C V) e ve nts, ne w o ns et of atri al fi brillati o n a n d fl utter as well as all deat hs. All seri o us C C V e ve nts occ urri n g fr o m t he ti me of ra n d o mizati o n u ntil t he 3 0 da ys aft er t he per ma ne nt disc o nti n uati o n of st u d y dr u g, w her e a p plica ble, will be a dj u dicate d. T he c o m mittee will c o nsist of e x p erts o utsi de N o vartis w h o ar e n ot i n v ol ve d i n t he st u d y c o n d uct, w h o will peri o dicall y re vie w bli n de d, perti ne nt patie nt d ata a n d t he s u p p orti n g d oc u me ntati o n t o settle t he s pecifie d a dj u dicati o n o bjecti ves. F urt her d etails will be pr o vi de d i n t he A dj u dica ti o n C o m mittee C harter."
61,page_61,"N o v arti s C o nfi d e nti al P a g e 6 2 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 9 D at a a n al y si s T he a nal ysis will be c o n d ucte d o n all s u bject data at t he ti me t he trial e n ds. A detaile d Statistical A nal ysis Pla n ( S A P) will be fi nalize d bef or e t he st u d y data b ase l oc k. A n y dat a a nal ysis carrie d o ut i n d e pe n de ntl y b y t he i n v esti gat or s h o ul d be s u b mitte d t o N o vartis bef ore p u blicati o n or prese ntati o n. 9. 1 A n al y si s s et s T he f oll o wi n g a nal ysis sets are d efi ne d f or data a nal ysis. T he ra n d o mize d ( R A N) set will c o nsist of all patie nts w h o were assi g n e d a ra n d o mizati o n n u m ber, re gar dless of w het her or n ot t he y act uall y recei ve d st u d y me di cati o n. Patie nts i n R A N will be a nal yze d acc or di n g t o t he treat me nt t he y wer e ra n d o mize d t o. T he F ull A nal ysis Set ( F A S) will c o nsist of all patie nts i n t he R A N set w h o recei ve d at least o n e d ose of st u d y m e dicati o n. F oll o wi n g t he i nte nt -t o-treat pri nci ple, patie nts will be a nal yze d acc or di n g t o t he tr eat me nt t he y w ere assi g n e d t o at ra n d o mizati o n. T he Per -Pr ot oc ol set ( P P S) will i ncl u de all patie nts i n t he F A S w h o di d n ot ha ve a n y m aj or pr o t oc ol de viati o ns. Maj or pr ot oc ol de viati o ns will be defi ne d i n t he statistical a nal ysis pla n pri or t o data bas e l oc k a n d t he u n -bli n di n g of t he st u d y. Patie nts will be a n al yze d acc or di n g t o t he treat me nt t he y r ecei v e d. T he Saf et y S et will c o nsist of all p at ie nts w h o recei ve d at least o n e d ose of st u d y me dicati o n. Patie nts will be a nal yze d acc or di n g t o t he tr eat me nt t he y r ecei v e d. T he F A S will be us e d i n t he a nal ysis of all efficac y v aria bles. T h e R A N s et will be use d f or a s u m mar y of patie nt dis p ositi o n, de m o gra p hics a n d baseli ne c haracteristics. T he P P S will be use d f or s u p p orti ve a nal ysis of t he pri mar y a n al ysis o nl y. T he Safet y Set will be use d i n t he a nal ysis of all safet y v ari a bles. N ote t hat t he F A S a n d Safet y Sets ar e t he sa me e x ce pt t hat t he Safet y Set all o ws t he i ncl usi o n of n o n -ra n d o mize d pati e nts w h o recei ve d st u d y dr u g i n err or. Als o, t he F A S assi g n ra n d o mize d treat me nt a n d t he Safet y Set assi g n e d recei v e d treat me nt. 9. 2 P ati e nt d e m o gr a p hi c s a n d ot h er b a s eli n e c h ar a ct eri sti c s De m o gra p hic a n d baseli n e c har acteristics meas ure d bef ore ra n d o mizati o n i ncl u di n g a ge, ge n d er, r ace, et h nicit y, hei g ht, wei g ht, b o d y m ass i n de x ( B MI), rel e va nt me dical hist or y, scree ni n g s pir o metr y para meters: ( F E V 1, F V C, F E V 1/ F V C a n d F E F 2 5 -7 5), F E V 1 re versi bilit y, % of pre dicte d F E V 1, d urati o n of ast h ma, hist or y of ast h ma e x acer bati o ns, s m o ki n g hist or y, pri or c o nc urre nt m e dicati o ns ( ast h ma-relate d a n d n o n-ast h ma-relate d), vital si g ns (s yst olic a n d diast olic bl o o d press ure, p ulse rate), Q T c usi n g Fri dericia’s c orr ecti o n a n d baseli ne A Q L Q - S, A C Q - 7, will be s u m marize d b y treat me nt gr o u p. C o nti n u o us varia bles will be s u m marize d usi n g d escri pti ve statistics ( mea n, me dia n, sta n dar d de viati o n, mi ni m u m, a n d ma xi m u m) a n d cate g orical varia bl es will be s u m marize d i n ter ms of t he n u mber a n d perce nta ge of patie nts i n eac h cate g or y f or t he treat me nt gr o u ps. Baseli ne is d efi ne d as t he last meas ure m e nt be f ore first d ose of st u d y dr u g. N o statistical a nal ys es will be pr o vi de d f or baseli ne c o m par a bilit y a m o n g t he tr eat me nt gr o u ps."
62,page_62,
63,page_63,"N o v arti s C o nfi d e nti al P a g e 6 4 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 H2: Q V M 1 4 9 1 5 0/ 5 0/ 8 0 μ g is i nferi or t o free c o m bi nati o n of sal meter ol/ fl uticas o ne 5 0/ 5 0 0 μ g + ti otr o pi u m 5 μ g i n c ha n ge fr o m b aseli ne f or A Q L Q t otal sc or e at Wee k 2 4 Ha 2: Q V M 1 4 9 1 5 0/ 5 0/ 8 0 is n o n-i nferi or t o free c o m bi nati o n of sal meter ol/ fl uticas o ne 5 0/ 5 0 0 μ g + ti otr o pi u m 5 μ g i n c ha n ge fr o m b aseli ne f or A Q L Q at t otal sc or e Wee k 2 4 T he pri mar y v aria ble will be a nal yz e d usi n g a mi x e d m o del f or re peate d meas ure ( M M R M) o n t he F A S. T h e m o del will c o ntai n treat me nt, r e gi o n, visit, bac k gr o u n d I C S/ L A B A ( me di u m or hi g h d ose), bas eli ne -b y -visit i nter acti o n a n d tr eat me nt -b y -visit i nteracti o n as fi x e d effects wit h baseli ne A Q L Q t otal sc ore as t he c o variate, a n d ce nter neste d wit hi n r e gi o n as a ra n d o m effect. T he wit hi n -patie nt c orrelati o n will be m o dele d usi n g t he u nstr uct ure d c o v aria nce matri x i n t he mi x e d m o del. T he Ke n war d -R o ger a p pr o xi mati o n will be use d t o esti mate de n o mi nat or de grees of free d o m ( Ke n war d a n d R o ger, 1 9 9 7). If t he m o del d oes n ot c o n ver ge, t he n t he c o m p o u n d s y m metr y c o v aria n ce matri x will be use d i n t he mi x e d m o del. Restricte d ma xi m u m li keli h o o d met h o d will be use d. T he least s q uares mea ns of t he treat me nt differe nces, sta n dar d err ors, 9 7. 5 % ( o ne -si de d) CI, a n d o ne-si de d p- val ues f or n o n-i nferi orit y test (a dj uste d a n d u na dj uste d) a n d n o mi nal t w o-si de d p-val ues at wee k 2 4 of eac h d ose Q V M 1 4 9 vs. t he c o m bi nati o n of sal meter ol/ fl uticas o ne 5 0/ 5 0 0 μ g + ti otr o pi u m 5 μ g, will be prese nte d. N o n -i nferi orit y of Q V M1 4 9 will be clai me d if t he m ulti plicit y a dj uste d o ne -si de d p-val ue is < 0. 0 2 5. 9. 4. 3 H a n dli n g of mi s si n g v al u e s/ e arl y di s c o nti n u ati o n s T he M M R M m o del, w hic h is use d f or t h e a n al ysis of pri mar y v aria ble is b ase d o n missi n g at ra n d o m ass u m pti o n f or t he missin g val u es a n d assesses t he treat me nt effects wit h o ut e x plicit i m p utati o n. T he esti ma n d f or t his st u d y is diff ere n ce b et wee n t he eff ect of i nitiall y ra n d o mize d treat me nts ha d all patie nts re mai ne d o n t heir ra n d o mize d treat me nt t hr o u g h o ut t he st u d y. A Q L Q T he t otal A Q L Q sc or e is t he mea n res p o ns e t o all 3 2 q uesti o ns; n o i m p utati o n will be use d f or missi n g q uesti o ns or missi n g t otal sc ore . 9. 4. 4 M ulti pli cit y A dj u st m e nt T o c o ntr ol t h e f a mil y -wise t y pe -I err or r ate at t he o ne-si de d 2. 5 % si g nifica nce le vel, a m ulti ple testi n g pr oce d ur e base d o n t he tri m me d Si mes test i n Bra n nat h et. al. (2 0 0 9) is use d. T he f a mil y f or t he o ver all t y pe -I err or rat e c o ntr ol c o ntai ns t otal 2 h y p ot heses f or t he pri mar y e n d p oi nt, A Q L Q .. D e n ote t he t w o h y p ot hes es f or t he pri mar y e n d p oi nt as H 1 a n d H 2 f or c o m pari n g Q V M 1 4 9 1 5 0/ 5 0/ 1 6 0 µ g o. d. Vers us free c o m bi nati o n of sal meter ol/ fl uticas o n e 5 0/ 5 0 0 μ g + ti otr o pi u m 5 μ g a n d Q V M 1 4 9 1 5 0/ 5 0/ 8 0 µ g o. d. vers us free c o m bi nati o n of sal meter ol/fl uticas o ne 5 0/ 5 0 0 μ g + ti otr o pi u m 5 μ g, i n ter ms of c ha n ge fr o m baseli ne i n A Q L Q t otal sc or e . Bel o w is a brief des cri pti o n of t he testi n g pr oce d ure base d o n t he ge neralize d Si mes test i n Bra n n at h et al (2 0 0 9 )."
64,page_64,"N o v arti s C o nfi d e nti al P a g e 6 5 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Let p 1 a n d p 2 be t he c orr es p o n di n g p -v al ues ( 1- si de d, p-val ue r elate d t o NI h y p ot hes es ) of t he t w o h y p ot hes es of H 1 a n dH 2. Ste p 1: Retai n b ot h H 1 a n d H 2 if A N Y p i ≥ = 0. 9 7 5(i.e. L o ose tri ple is perf or mi n g better t ha n Q V M) f or i = 1, 2st o p h er e; ot her wise g o t o ste p 2; Ste p 2: Reject H 1 a n d H 2 if p i< 0. 0 2 5 f or B O T H i = 1, 2, st o p here; ot her wise g o t o ste p 3; Ste p 3: If neit her ste p 1 or 2 a p plies, p erf or m B o nferr o ni t est t o H 1 a n d H 2.T h us reject H 1 if p1< 0. 0 1 2 5 a n d reject H 2 if p2< 0. 0 1 2 5 a n d st o p. F or eac h of t h e t w o h y p ot heses, t he c orres p o n di n g testi n g statistics (esti mate d least s q uar e mea n differe nce) f oll o ws n or mal distri b uti o n. He nce f or H 1 a n d H 2, t heir c orres p o n di n g testi n g statistics is ass u me d t o f oll o w j oi ntl y bi v ariate n or mal distri b uti o n. T heref ore t his testi n g pr oce d ure c o ntr ols t he o verall t y pe – I err or rate at t he 1-si de d 0. 0 2 5 le vel i n t he str o n g se nse re gar dless if t he bi variate n or m al distri b uti o ns ha ve p ositi ve or ne gati ve c orr elati o ns as s h o w n i n Bra n n at h et al ( 2 0 0 9). Ot her t ha n t he t w o a nal yses me nti o ne d a b o v e f or t he pri mar y e n d p oi nt, all ot her a n al ys es will be perf or me d at t he n o mi nal 2-si de d 0. 0 5 le vel ( 2- si de d) wit h o ut m ulti plicit y a dj ust me nt. 9. 4. 5 S u p p orti v e a n al y s e s F oll o wi n g s u p p le me ntar y a n al ys es will be perf or me d f or pri mar y. T he M M R M m o del use d f or t he a n al ysis of pri mar y varia bles will be perf or me d o n t he P P S. P ri mar y vari a bles will be a nal yz e d usi n g t he sa me M M R M m o del as t hat of pri mar y a n al ysis usi n g t he data fr o m all ti me - p oi nts (i.e. o n a n d a v aila ble off tr eat me nt data ) o n F A S. 9. 5 A n al y si s of s e c o n d ar y e n d p oi nt s All a nal ys es will be perf or me d o n F A S. 9. 5. 1 Effi c a c y v ari a bl e s 9. 5. 1. 1 A Q L Q S c or e, d o m ai n s, a n d r e s p o n d er s at e a c h vi sit C ha n ge fr o m baseli ne i n eac h of t he A Q L Q d o mai ns (s y m pt o ms, e m oti o ns, e x p os ure t o e n vir o n me ntal sti m uli a n d acti vit y li mitati o n) as well as t he c ha n ge fr o m baseli ne i n t otal sc ore at p ost-baseli ne visits will be a nal yze d usi n g mi x e d m o del of r e peate d meas ure me nts ( M M R M) si milar t o pri mar y varia ble. A p pr o pri ate bas eli ne A Q L Q d o mai n sc ores will be use d as c o variate i nstea d of baseli ne A Q L Q t otal sc ore i n t he m o del. T h e bet wee n -treat me nt c o m paris o n will be carrie d o ut usi n g t he a dj uste d mea n (least -s q uare mea n) differe nce c orres p o n di n g t o t he res pecti ve visit. A dj uste d mea n ( L S m ea n) will be dis pla ye d f or eac h treat me nt gr o u p al o n g wit h t he esti mate d treat me nt differe n ces a n d t h e 9 5 % c o nfi de nce i nter vals a n d t he t w o si de d p-val ues b y visit. T he pr o p orti o n of patie nts w h o ac hie ve a n i m pr o ve me nt of at least 0. 5 i n t he c ha n ge fr o m baseli ne i n A Q L Q t otal sc ore (i.e. i ncreas e of A Q L Q t otal sc or e of at least 0. 5 fr o m baseli ne) at p ost -baseli ne visits will be a nal yze d usi n g t he sa me l o gistic re gressi o n m o del via G E E"
65,page_65,"N o v arti s C o nfi d e nti al P a g e 6 6 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 s pecifie d f or t he AC Q- 7 a nal ysis e x ce pt t hat bas eli ne A Q L Q will b e use d as t he c o v ariate i n t he m o del, i nstea d of t he baseli ne A C Q- 7. 9. 5. 1. 2 S pir o m etr y A ll s pir o metr y effi cac y varia bles will be a nal yz e d f or t he F A S, u nless ot her wise s pecifie d. S pir o metr y meas ure m e nts ta ke n wit hi n 7 da ys of s yste mic c ortic oster oi d use d as ac ute treat me nt f or e x acer bati o n, or wit hi n 3 m o nt hs of si n gle de p ot c ortic oster oi d i njecti o n, or wit hi n 6 h o urs of resc ue me dicati o n, will be set t o missi n g a n d n ot be i m p ute d, u nless s pecifie d ot her wise. S pir o met r y d at a at e a c h visit C ha n ge fr o m bas eli ne i n tr o u g h F E V 1 at wee k 2 4 will be a nal yze d usi n g a mi x e d m o del f or re peat e d meas ure (M M R M) si milar t o t he m o del use d f or pri mar y v aria ble o n t h e F A S. Tr o u g h F E V 1 is calc ulate d as a ver a ge of 1 5 mi n a n d 4 5 mi n pre-d ose meas ure me nts . T h e m o del will i ncl u de bas eli ne F E V 1 i nstea d of baseli ne A Q L Q sc or e as c o variate. T h e least s q uares mea ns of t he tr eat me nt differ e nces, sta n dar d err ors, 9 5 % (t w o-si de d) CI, a n d p- val ues ( n o mi nal) at wee k 2 4 of eac h d os e Q V M 1 4 9 vs t he c o m bi nati o n of sal meter ol/fl uticas o ne 5 0/ 5 0 0 µ g + ti otr o pi u m 5 µ g will be pres e nte d. Tr o u g h F E V 1 will als o b e a n al yze d usi n g t he s a m e M M R M m o del as s pecifie d a b o v e, w her e t he bet wee n-treat me nt c o m paris o n will be carrie d o ut usi n g t he a dj uste d mea n (least-s q uar e mea n) diff ere n ce c orres p o n di n g t o t he res p ecti v e visit. A dj uste d mea n ( L S mea n) will be dis pla ye d f or eac h tr eat me nt gr o u p al o n g wit h t he esti mate d tr eat me nt differe n ces a n d t h e 9 5 % c o nfi de n ce i nter v als a n d t he t w o si de d p- val u es b y visit. Si milar a nal ys es will be perf or me d f or F V C a n d F E F 2 5 -7 5. C ha n ge fr o m baseli ne i n t h e s pir o metr y v al ues will be als o a nal yze d usi n g t he s a me MM R M m o del. 9. 5. 1. 3 A C Q - 7 S c or e a n d r e s p o n d er s at e a c h vi sit C ha n ge fr o m baseli ne i n A C Q -7 sc or e at p ost -bas eli ne visits will be a n al yz e d usi n g t he mi x e d m o del of r e peate d meas ure me nts ( M M R M) si milar t o pri mar y v aria bl e. Bas eli ne A C Q -7 sc ore will be use d as c o v ariate i nstea d of baseli ne A Q L Q t otal sc or e i n t he m o del. T he least s q uares mea ns of t he treat me nt diff ere n ces, sta n dar d err ors, 9 5 % (t w o-si de d) CI, a n d p- val ues at eac h visit of eac h d os e Q V M 1 4 9 vs. t he c o m bi nati o n of sal meter ol/ fl uticas o n e 5 0/ 5 0 0 μ g + ti otr o pi u m 5 μ g, will be pres e nte d. T he pr o p orti o n of p atie nts w h o ac hie v e a n i m pr o ve me nt of at least 0. 5 i n A C Q -7 (i.e. decrease of A C Q -7 s c ore of at least 0. 5 fr o m baseli ne) at p ost -baseli ne visits will be a nal yze d usi n g t he l o gistic re gressi o n m o del via t he ge neralize d esti mati n g e q uati o ns ( G E E). T h e m o del will i ncl u de ter ms f or tr eat me nt, re gi o n, visit, bac k gr o u n d I C S/ L A B A ( me di u m or hi g h d ose), baseli ne -b y -visit i nteracti o n a n d treat me nt -b y -visit i nteracti o n as fi x e d effects, wit h baseli ne A C Q -7 as c o v ariates. T he wit hi n -patie nt c orrelati o n will b e m o dele d usi n g t h e u nstr uct ure d c o varia n ce matri x i n t he G E E m o del. T he esti mate d a dj uste d o d ds rati os of t he treat me nt c o m paris o ns will be dis pla ye d al o n g wit h t he ass ociate d 9 5 % (t w o- si de d) c o nfi de nce i nter vals a n d p- val ues."
66,page_66,"N o v arti s C o nfi d e nti al P a g e 6 7 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 9. 5. 2 S af et y v ari a bl e s A d v er s e e v e nt s All st u d y e mer ge nt a d verse e v e nts i ncl u di n g ast h ma e x acer b ati o ns will be liste d. A d v ers e e ve nts starti n g o n or after t he ti me of t he first i n halati o n of st u d y dr u g b ut n ot later t ha n 7 da ys ( 3 0 da ys i n t he case of a S A E) after t he last a d mi nistrati o n of st u d y dr u g, will be classifie d as a treat me nt e mer ge nt a d vers e e v e nt. A n y a d verse e v e nts t hat starte d d uri n g t he st u d y bef ore t he ti me of t he first i n halati o n of st u d y dr u g will be classifie d as a prior a d verse e ve nt. T he f oll o wi n g tr eat me nt e mer ge nt a d v erse e v e nt s u m maries will be pr o d uce d, o v erall b y s yste m or ga n cl ass a n d preferre d ter m, o verall b y s yste m or ga n class, preferre d ter m a n d ma xi m u m se verit y, s us pecte d dr u g -relate d a d v erse e ve nts b y s yste m or ga n class a n d pref err e d ter m, seri o us a d v erse e v e nts b y s yste m or ga n cl ass a n d preferre d ter m, a n d a d verse e v e nts lea di n g t o p er ma ne nt dis c o nti n uati o n of st u d y-dr u g b y s yste m or ga n class a n d preferre d t er m. T he n u m ber a n d perce nt a ge of patie nts wit h t he m ost fre q ue nt A Es will be s u m marize d b y treat me nt. El e ctr o c ar di o gr a m ( E C G) a n d vit al si g n s Data fr o m t he electr o car di o gra m will be s u m marize d b y treat me nt a n d visit. Vital si g ns ( bl o o d pr ess ure a n d ra dial p ulse rate) data will be s u m mariz e d b y treat me nt a n d visit. C ha n ges fr o m baseli ne will als o be s u m marize d b y treat me nt. Wei g ht will be s u m marize d b y visit a n d treat me nt gr o u p. All data will be i ncl u de d i n t he a nal ysis re gar dl ess of resc ue me dicati o n usa ge. T h e n u m ber ( %) of patie nts wit h p ulse rate of < 4 0 a n d > 9 0 b p m; s yst olic bl o o d press ure of < 9 0 a n d > 1 4 0 m m H g; diast olic bl o o d press ur e of < 5 0 a n d > 9 0 m m H g will be s u m marize d b y treat me nt gr o u p. N ota ble val ues f or vital si g ns a n d c ha n ge fr o m b aseli ne will be s u m marize d. A n ota ble val ue is defi ne d as f oll o ws: S yst olic bl o o d press ure “ L o w” criteri o n: < 7 5 m m H g, or ≤ 9 0 m m H g a n d decrease fr o m baseli ne ≥ 2 0 m m H g “ Hi g h ” criteri o n: > 2 0 0 m m H g, or ≥ 1 8 0 m m H g a n d i ncrease fr o m baseli ne ≥ 2 0 m m H g Diast olic bl o o d press ure “ L o w” criteri o n: < 4 0 m m H g, or ≤ 5 0 m m H g a n d decrease fr o m baseli ne ≥ 1 5 m m H g “ Hi g h ” criteri o n: > 1 1 5 m m H g, or ≥ 1 0 5 m m H g a n d i ncrease fr o m baseli ne ≥ 1 5 m m H g P ulse rate ” L o w” criteri o n: < 4 0 b p m, or ≤ 5 0 b p m a n d decr ease fr o m baseli ne ≥ 1 5 b p m “ Hi g h ” criteri o n: > 1 3 0 b p m, or ≥ 1 2 0 b p m a n d i ncreas e fr o m b aseli ne ≥ 1 5 b p m N ota ble Q Tc val ues a n d c ha n ges fr o m baseli n e will be s u m marize d. A n ota ble val ue is defi ne d as a Q Tc i nter val of gr eater t ha n 4 5 0 ms ( male), 4 6 0 ms (fe mal e) a n d 5 0 0 ms ( b ot h) at"
67,page_67,
68,page_68,N o v arti s C o nfi d e nti al P a g e 6 9 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6
69,page_69,N o v arti s C o nfi d e nti al P a g e 7 0 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6
70,page_70,"N o v arti s C o nfi d e nti al P a g e 7 1 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 9. 7 I nt eri m a n al y se s N o i nteri m a nal ysis is pla n ne d i n t his st u d y. 9. 8 S a m pl e si z e c al c ul ati o n T he sa m ple size calc ulati o n ta kes i nt o acc o u nt t he f oll o wi n g c o nsi derati o n: • T o ac hie ve at least 9 0 % p o wer ( wit h m ulti plicit y a dj ust me nt) f or pri mar y e n d p oi nt, t o de m o nstrate t he n o n-i nf eri orit y of eit her of Q V M 1 4 9 d ose vs. t he free tri ple c o m bi nati o n of sal meter ol/fl uticas o ne + ti otr o pi u m i n patie nts wit h u nc o ntr olle d ast h ma f or A Q L Q at t he wee k 2 4. Wit h t he ass u m pti o n of 0. 2 5 f or t he NI mar gi n, zer o as t he p oi nt esti mati o n of t he tre at me nt differ e nce, o n e- si de d al p h a le v el of 0. 0 2 5, a n d 0. 8 of t he sta n dar d de viati o n bas e d o n st u dies Q M F 1 4 9 E 2 2 0 3 a n d Kerstje ns ( 2 0 1 2); If 1 0 % dr o p o ut r ate is ass u me d, t he n t he calc ulati o n s h o ws t hat t he sa m ple size of 1 2 5 1 patie nts (i.e 4 1 7 /ar m) will pr o vi de 9 9 % p o wer wit h m ulti plicit y a dj ust me nt as gi ve n i n Fi g ur e 9- 1 . T he sa m ple size a n d p o w er cal c ulati o ns are p erf or me d i n R 3. 1. 2 wit h pac ka ge g M C P. 1 0 Et hi c al c o n si d er ati o n s 1 0. 1 R e g ul at or y a n d et hi c al c o m pli a n c e i nf or m e d c o n s e nt pr o c e d ur e s T his cli nical st u d y was desi g n e d a n d s hall be i m ple me nte d, e x ec ute d a n d r e p orte d i n acc or d a nce wit h t he I C H Har m o nize d Tri partite G ui deli nes f or G o o d Cli nical Practice, wit h a p plica ble l o cal r e g ulati o ns (i ncl u di n g E ur o p ea n Directi ve 2 0 0 1/ 2 0/ E C, U S C F R 2 1, a n d J a pa nese Mi nistr y of Healt h, La b or, a n d Welf are), a n d wit h t he et hical pri n ci ples lai d d o w n i n t he Declarati o n of H elsi n ki."
71,page_71,"N o v arti s C o nfi d e nti al P a g e 7 2 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 1 0. 2 I nf or m e d c o n s e nt pr o c e d ur e s Eli gi ble patie nts/s u bjects ma y o nl y b e i ncl u d e d i n t he st u d y after pr o vi di n g writte n ( wit nesse d, w her e re q uir e d b y la w or r e g ulati o n), I R B/I E C-a p pr o v e d i nf or me d c o nse nt, o nl y f ull y le gal c o m p ete nt patie nts ca n b e i ncl u de d Th e patie nt m ust i n dicat e asse nt b y pers o n all y si g ni n g a n d dati n g t he writte n i nf or me d c o nse nt d oc u me nt or a se parate asse nt f or m. I nf or me d c o nse nt m ust be o btai n e d bef or e c o n d u cti n g a n y st u d y -s p ecific pr oce d ures ( e. g. all of t he pr oce d ur es des cri be d i n t he pr ot oc ol). T h e pr ocess of o btai ni n g i nf or me d c o nse nt m ust be d oc u me nte d i n t he patie nt s o urce d oc u me nts. N o vartis will pr o vi de t o i n vesti gat ors i n a se par ate d oc u me nt a pr o p ose d i nf or me d c o nse nt f or m t hat c o m plies wit h t he I C H G C P g ui deli ne a n d re g ul at or y re q uire me nts a n d is c o nsi dere d a p pr o priat e f or t his st u d y. A n y c h a n ges t o t he pr o p ose d c o ns e nt f or m s u g geste d b y t he i n vesti gat or m ust be a gree d t o b y N o v artis bef ore s u b missi o n t o t he I R B/I E C, a n d a c o p y of t he a p pr o v e d versi o n m ust be pr o vi de d t o t he N o vartis m o nit or after I R B/I E C a p pr o v al. W o me n of c hil d b eari n g p ot e ntial m ust be i nf or me d t ha t t a ki n g t he st u d y tr eat me nt m a y i n v ol ve u n k n o w n ris ks t o t he fet us if pre g na n c y w ere t o occ ur d uri n g t he st u d y a n d a gree t hat i n or der t o partici pat e i n t he st u d y t he y m ust a d h ere t o t he c o ntrace pti o n re q uire me nt f or t h e d urati o n of t he st u d y. If t here is a n y q uesti o n t hat t he patie nt will n ot relia bl y c o m pl y, t he y m ust n ot be e ntere d i n t h e st u d y. 1 0. 3 R e s p o n si biliti e s of t h e i n v e sti g at or a n d I R B/I E C Bef ore i nitiati n g a trial, t he i n vesti gat or/i nstit uti o n m ust o btai n a p pr o val/fa v ora ble o pi ni o n fr o m t he I nstit uti o nal Re vie w B o ar d/I n de p e n de nt Et hics C o m mittee (I R B/I E C) f or t he trial pr ot oc ol, i nf or me d c o nse nt f or m, c o nse nt f or m u p dates, s u bject recr uit me nt pr oce d ures (e. g., a d vertise me nts) a n d a n y ot her writte n i nf or mati o n t o be pr o vi de d t o patie nts/s u bjects. Pri or t o st u d y start, t he i n v esti gat or is re q uire d t o si g n a pr ot oc ol si g n at ure p a ge c o nfir mi n g his/ her a gree m e nt t o c o n d uct t he st u d y i n acc or d a nce wit h t hese d oc u me nts a n d all of t he i nstr ucti o ns a n d pr oce d ures f o u n d i n t his pr ot oc ol a n d t o gi v e access t o a ll rele v a nt data a n d rec or ds t o N o vartis m o nit ors, a u dit ors, N o vartis Q ualit y Ass ura nce re pr ese ntati ves, desi g nat e d a ge nts of N o vartis, I R Bs/I E Cs, a n d re g ulat or y a ut h orities as re q uire d. If a n i ns pecti o n of t he cli nical site is re q ueste d b y a r e g ulat or y a ut h orit y, t he i n vesti gat or m ust i nf or m N o vartis i m me diatel y t hat t his re q uest has bee n m a de. 1 0. 4 P u bli c ati o n of st u d y pr ot o c ol a n d r e s ult s T he ke y desi g n ele me nts of t his pr ot oc ol will be p oste d i n a p u blicl y accessi ble data base s uc h as cli nicaltrials. g o v. I n a d diti o n, u p o n st u d y c o m pleti o n a n d fi nalizati o n of t he st u d y r e p ort t he res ults of t his trial will be eit her s u b mitte d f or p u blicati o n a n d/ or p oste d i n a p u blicl y accessi ble data bas e of cli nical trial res ults. 1 0. 5 Q u alit y C o ntr ol a n d Q u alit y A s s ur a n c e N o varti s mai ntai ns a r o b ust Q ualit y Ma n a ge me nt ( Q M) s yste m t hat i n cl u des all acti vities i n v ol ve d i n q ualit y ass ura nce a n d q ualit y c o ntr ol, i ncl u di n g t he assi g n me nt of r oles a n d res p o nsi bilities, t he re p orti n g of res ults, a n d t he d oc u me ntati o n of acti o ns a n d escalati o n of iss ues i de ntifie d d uri n g t he re vie w of q ualit y metrics, i nci de nts, a u dits a n d i ns pecti o ns."
72,page_72,"N o v arti s C o nfi d e nti al P a g e 7 3 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 A u dits of i n vesti gat or sit es, ve n d ors, a n d N o vartis s yste ms ar e perf or me d b y N o v artis P har ma A u diti n g a n d C o m plia nce Q ualit y Ass ur a nce, a gr o u p i n de p e n de nt fr o m t h ose i n v ol ve d i n c o n d ucti n g, m o nit ori n g or perf or mi n g q ualit y c o ntr ol of t he cli nical trial. T he cli nical a u dit pr ocess uses a k n o wle d ge/ris k base d a p pr oac h. A u dits are c o n d uct e d t o assess G C P c o m plia nce wit h gl o b al a n d l ocal re g ulat or y re q uire me nts, pr ot o c ols a n d i nter nal S O Ps, a n d are p erf or m e d acc or di n g t o writte n N o vartis pr ocesses. 1 1 Pr ot o c ol a d h er e n c e T his pr ot oc ol defi nes t he st u d y o bjecti ves, t he st u d y pr oce d ures a n d t he data t o be c ollecte d o n st u d y partici pa nts. A d diti o nal assess me nts re q uire d t o e ns ure s afet y of patie nts/s u bjects s h o ul d be a d mi nistere d as dee me d n ecess ar y o n a case b y cas e basis. U n d er n o cir c u msta nces i ncl u di n g i nci de ntal c oll ecti o n is a n i n vesti gat or all o we d t o c ollect a d diti o nal data or c o n d uct a n y a d diti o nal pr oce d ur es f or a n y p ur p ose i n v ol vi n g a n y i n v esti gati o n al dr u gs u n der t h e pr ot oc ol, ot her t ha n t he p ur p ose of t he st u d y. If des pite t his i nter dicti o n, data, i nf or mati o n, o bser vati o n w o ul d b e i n ci de ntall y c ollect e d, t he i n vesti gat or s h all i m me diatel y dis cl ose it t o N o var tis a n d n ot use it f or a n y p ur p os e ot her t ha n t he st u d y, e x ce pt f or t he a p pr o priate m o nit ori n g o n st u d y p artici pa nts. I n v esti gat ors ascertai n t he y will a p pl y d ue dili ge n ce t o a v oi d pr ot oc ol de viati o ns. If a n i n vesti gat or feels a pr ot o c ol de viati o n w o ul d i m pr o ve t he c o n d u ct of t he st u d y t his m ust b e c o nsi dere d a pr ot oc ol a m e n d me nt, a n d u nless s u c h a n a me n d me nt is a gree d u p o n b y N o vartis a n d a p pr o ve d b y t h e I R B/I E C a n d healt h a ut h orities, w here re q uire d, it ca n n ot be i m ple me nte d. 1 1. 1 Pr ot o c ol a m e n d m e nt s A n y c ha n ge or a d diti o n t o t he pr ot oc ol ca n o nl y b e ma de i n a writte n pr ot o c ol a me n d me nt t hat m ust be a p pr o ve d b y N o vartis, healt h a ut h orities w here re q uire d, a n d t h e I R B/I E C pri or t o i m ple me ntati o n. O nl y a me n d me nts t hat are i nt e n de d t o eli mi nate a n a p pare nt i m me diate hazar d t o patie nts/s u bjects ma y b e i m ple me nte d i m me diatel y pr o vi de d t he healt h a ut h orities are s u bse q u e ntl y n otifie d b y pr ot oc ol a m e n d me nt a n d t he re vie wi n g I R B/I E C is n otifie d. N ot wit hsta n di n g t he nee d f or a p pr o val of f or mal pr ot oc ol a me n d m e nts, t he i n vesti gat or is e x pecte d t o ta ke a n y i m me diate acti o n r e q uire d f or t he safet y of a n y pati e nt i ncl u de d i n t his st u d y, e ve n if t his acti o n re pres e nts a de viati o n fr o m t he pr ot oc ol. I n s uc h cases, t he re p orti n g re q uire me nts i de ntifie d i n Secti o n 7, Safet y M o ni t ori n g m ust be f oll o we d. 1 2 R ef er e n c e s Refere n ces are a vaila ble u p o n re q uest: Bar n es PJ, Casale B, Da hl R et al ( 2 0 1 4) T he Ast h ma C o ntr ol Q uesti o n naire as a cli nical trial e n d p oi nt: past e x perie nce a n d rec o m me n d ati o ns f or f ut ure use. J Aller g y Cli n I m m u n ol; 6 9: 1 1 1 9 – 1 1 4 0."
73,page_73,"N o v arti s C o nfi d e nti al P a g e 7 4 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Bate ma n E D, B o us h e y H A, B o us q u et J et al ( 2 0 0 4) Ca n G ui d eli ne- defi ne d Ast h ma c o ntr ol Be Ac hie ve d? T he Gai ni n g o pti mal Ast h ma C o ntr o l St u d y. A m J Res pir Crit Care Me d; 1 7 0: 8 3 6 -8 4 4. Bate ma n E D, K or n ma n n O, Sc h mi dt P et al ( 2 0 1 1) Ti otr o pi u m is n o n i nferi or t o sal meter ol i n mai ntai ni n g i m pr o ve d l u n g f u n cti o n i n B 1 6 -Ar g/ Ar g p atie nts wit h ast h ma. J Aller g y Cli n I m m u n ol 2 0 1 1; 1 2 8: 3 1 5- 2 2. Bea k es D E ( 1 9 9 7) T he use of a ntic h oli ner gics i n ast h ma. J Ast h ma 3 4 ( 5): 3 5 7- 3 6 8). Mas oli M, Fa bia n D, H olt S et al ( 2 0 0 4). T h e gl o b al b ur de n of ast h ma: e x ec uti ve s u m mar y of t he GI N A Disse mi nati o n C o m mittee re p ort, Gl o bal I nitiati ve f or Ast h ma ( GI N A) Pr o gr a m. A vaila ble fr o m GI N A w e bsite. Beasl e y R, La nier B, Var k o n yi I et al ( 2 0 1 2). Safet y of o n ce -d ail y Q M F 1 4 9 i n pa tie nts wit h persiste nt ast h ma. E ur Res pir J; 4 0 ( S u p pl 5 6). Beasl e y R, La nier B, M ar k Z et al ( 2 0 1 2 a). L o n g -ter m efficac y of Q M F 1 4 9 i n persiste nt ast h ma. E ur Res pir J; 4 0 ( S u p pl 5 6). Beasl e y R. , D o n o h ue, Ja mes F, Me hta R et al ( 2 0 1 5). Effect of o nce -dail y i n dacater ol maleate/ m o metas o ne f ur oate o n e x acer bati o n ris k i n a d olesce nt a n d a d ult ast h ma: a d o u ble -bli n d ra n d o mise d c o ntr olle d trial; B MJ O pe n 5:e 0 0 6 1 3 1. d oi: 1 0. 1 1 3 6/ b mj o pe n- 2 0 1 4- 0 0 6 1 3 1 Bef e ka d u E, O n ofrei C, C olice G L ( 2 0 1 4) . Ti otr o pi u m i n ast h ma, a s yste mic re vie w. J A A; 7: 1 1- 2 1. Bra n n at h et al. Tri m me d wei g ht e d Si mes’ test f or t w o o ne -si de d h y p ot heses wit h ar bitraril y c orrel ate d test statistics. Bi o metrical J o ur nal 2 0 0 9; 5 1( 6): 8 8 5- 8 9 8 Bretz F, Ma urer W, Bra n nat h W et al ( 2 0 0 9). A gr a p hical a p pr oa c h t o se q ue ntiall y r ejecti v e m ulti ple test pr oce d ures. Statistics i n Me dici ne; 2 8: 5 8 6 - 6 0 4. Bretz F, P osc h M, Gli m m E , et al ( 2 0 1 1). Gra p hical a p pr o ac hes f or m ulti ple c o m paris o n pr oce d ur es usi n g w ei g hte d B o nferr o ni, Si mes, or par a metric tests. Bi o m etrical J o ur nal; 5 3: 8 9 4- 9 1 3. C ha p ma n K R, Bee h K M, Beier J, et al. ( 2 0 1 4) A bli n de d e val uati o n of t he efficac y a n d safet y of gl yc o p yrr o ni u m, a o nce -dail y l o n g -acti n g m uscari nic a nta g o nist, vers us ti otr o pi u m, i n patie nts wit h C O P D: t he G L O W 5 st u d y. B M C P ul m Me d. 2 0 1 4; 1 4: 4. A N O N , E ur o pea n Me dici nes A ge nc y ( 2 0 1 3). N ote f or g ui da n ce o n cli nical i n vesti gati o n of me dici nal pr o d ucts f or tr eat me nt of ast h ma. C H M P/ E W P/ 2 9 2 2/ 0 1-re v. 1. 2 7 J u ne 2 0 1 3. Far d o n T, H a g gart K, Lee D K C et al ( 2 0 0 7) A pr o of of c o n ce pt st u d y t o e val uate ste p pi n g d o w n t he d ose of fl uticas o ne i n c o m bi nati o n wit h sal meter ol a n d ti otr o pi u m i n se ver e persiste nt ast h ma. Res pirat or y Me dici ne; 1 0 1: 1 2 1 8- 1 2 2 8. Gl o bal I nitiati ve f or Ast h ma ( GI N A) 2 0 1 7 Gl o bal Strate g y f or Ast h ma Ma na ge me nt a n d Pre ve nti o n ) htt p:// gi nast h ma. or g/ 2 0 1 7- gi na -re p ort-gl o b al -strate g y-f or-ast h ma-ma na ge me nt -a n d- pre v e nti o n/ G u yer A C, L o n g A A ( 2 0 1 3) L o n g -acti n g a ntic h oli ner gi cs i n t he treat me nt of ast h ma. Aller g y Cli n I m m u n ol; 1 3: 3 9 2- 3 9 8"
74,page_74,"N o v arti s C o nfi d e nti al P a g e 7 5 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 J u ni per E F, G u yatt G H, Ferrie PJ, Griffit h L E ( 1 9 9 3) Meas uri n g q ualit y of life i n ast h ma. A m Re v Res pir Dis.; 1 4 7( 4): 8 3 2- 8 J u ni per E F, G u yatt G H, Ferrie PJ et al ( 1 9 9 4) D eter mi ni n g a mi ni mal i m p orta nt c ha n ge i n a disease -s pecific q ualit y of life q uesti o n naire. J Cli n E pi de mi ol; 4 7: 8 1- 8 7. J u ni per E F, O’ B yr n e P M, G u yatt G H et al ( 1 9 9 9) De vel o p me nt a n d vali dati o n of t he q uesti o n naire t o meas ur e ast h ma c o ntr ol. E ur Res p J; 1 4: 9 0 2- 9 0 7. J u ni per E F, S ve nss o n K, M or k A C et al. Meas ur e me nt pr o perties a n d i nt er pret ati o n of t hree s h orte ne d versi o ns of t h e ast h ma c o ntr ol q uesti o n naire. Res pir Me d 2 0 0 5; 9 9: 5 5 3- 8. J u ni per E F, B o us q u et J, A betz L et al ( 2 0 0 6) I de ntif yi n g ‘ well-c o ntr olle d’ a n d ‘ n ot w ell - c o ntr olle d’ ast h ma usi n gt he Ast h ma C o ntr ol Q uesti o n naire. Res pir Me d; 1 0 0: 6 1 6- 2 1. Ke n war d M G, R o ger J H. S mall sa m pl e i nfere nce f or fi x e d effects fr o m restricte d ma xi m u m li keli h o o d. Bi o metrics 1 9 9 7; 5 3( 3): 9 8 3- 9 7. Kerstje ns H A M, Disse B, Sc hr o der -Ba b o, W et al ( 2 0 1 1) Ti otr o pi u m i m pr o ves l u n g f u ncti o n i n patie nts wit h se vere u nc o ntr olle d ast h ma: A ra n d o mize d c o ntr olle d trial. J Aller g y Cli n I m m u n ol; 1 2 8: 3 0 8- 3 1 4. Kerstje ns H A M, E n gle M, Da hl R, et al ( 2 0 1 2). Ti otr o pi u m i n Ast h ma P o orl y C o ntr olle d wit h Sta n dar d C o m bi nati o n T hera p y. N E n gl J Me d; 3 6 7: 1 1 9 8- 1 2 0 7 Kerstje ns H A M, Casale T, Blec ker E, et al ( 2 0 1 5) Ti otr o p i u m or sal meter ol as a d d-o n t hera p y t o i n hale d c ortic oster oi ds f or patie nts wit h m o derate s y m pt o matic ast h ma: t w o re plicate, d o u ble- bli n d, place b o -c o ntr olle d, parallel -gr o u p, acti ve -c o m p arat or, r a n d o mise d trials. La ncet Res pir Me d. 3( 5): 3 6 7- 7 6 Mas oli M et a l ( 2 0 0 4). T he Gl o bal B ur de n of Ast h ma Re p ort, Gl o bal I nitiati ve f or Ast h ma ( GI N A). htt p:// gi nast h ma. or g/ 2 0 1 7-gi n a -r e p ort- gl o bal-strate g y-f or-ast h ma-ma na ge me nt -a n d-pre ve nti o n/ Peters S P, K u nsel ma n J., Sicit o vic N et al ( 2 0 1 0) Ti otr o pi u m br o mi de ste p -u p t hera p y f or a d ults wit h u nc o ntr olle d ast h ma. N E n gl J Me d; 3 6 3( 1 8): 1 7 1 5- 1 7 2 6. Q ua njer P H., Ta m meli n g, GJ, C oites,J E et al. ( 1 9 9 3), L u n g v ol u mes a n d f orce d ve ntilat or y fl o ws. Re p ort W or ki n g Part y Sta n d ar dizati o n of L u n g F u n cti o n Tests, E ur o pea n C o m m u nit y f or Steel a n d C o al. Official State me nt of t he E ur o pea n Res pirat or y S o ciet y. E ur Res pir J; 6 s u p pl. 1 6: 5- 4 0. R o h me yer K, Kli n gl m ueller F, a n d B or n ka m p B ( 2 0 1 2). Pac k a ge ‘ g M C P’ gra p h bas e d m ulti ple c o m paris o n pr oce d ures: htt p://cra n.r- pr oj ect. or g/ we b/ pac ka ges/ g M C P/ g M C P. p df. Testi 2 0 1 4, W hite Pa per, L o n g Acti n g M uscari nic A ge nt ( L A M A). A ne w Fr o ntier f or C O P D a n d Ast h ma Treat me nt. A vaila ble o n w w w. cr o ms o urce.c o m Vai d ya S, K hi n dri S, R o berts o n J , et al ( 2 0 1 2) P har mac o ki netics ( P K) of si n gl e d oses of m o metas o ne f ur oat e ( M F) deli vere d via t he Br eez haler ® ( B H) a n d T wist haler ® de vices i n healt h y s u bjects. E ur Res pir J; 4 0 ( S u p pl 5 6): P 3 8 2."
75,page_75,"N o v arti s C o nfi d e nti al P a g e 7 6 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 1 3 A p p e n di x 1: Li v er e v e nt a n d L a b or at or y tri g g er D efi niti o n s a n d F oll o w -u p R e q u ir e m e nt s T a bl e 1 3 - 1 Li v er E v e nt a n d L a b or at or y Tri g g er D efi niti o n s D efi niti o n/ t hr e s h ol d LI V E R L A B O R A T O R Y T RI G G E R S • 3 x U L N < A L T / A S T ≤ 5 x U L N • 1. 5 x U L N < T B L ≤ 2 x U L N LI V E R E V E N T S • A L T or A S T > 5 × U L N • A L P > 2 × U L N (i n t h e a b s e n c e of k n o w n b o n e p at h ol o g y) • T B L > 2 × U L N (i n t h e a b s e n c e of k n o w n Gil b ert s y n dr o m e) • A L T or A S T > 3 × U L N a n d I N R > 1. 5 • P ot e nti al H y’ s L a w c a s e s ( d efi n e d a s A L T or A S T > 3 × U L N a n d T B L > 2 × U L N [ m ai nl y c o nj u g at e d fr a cti o n] wit h o ut n ot a bl e i n cr e a s e i n A L P t o > 2 × U L N) • A n y cli ni c al e v e nt of j a u n di c e ( or e q ui v al e nt t er m) • A L T or A S T > 3 × U L N a c c o m p a ni e d b y ( g e n er al) m al ai s e, f ati g u e, a b d o mi n al p ai n, n a u s e a, or v o miti n g, or r a s h wit h e o si n o p hili a • A n y a d v er s e e v e nt p ot e nti all y i n di c ati v e of a li v er t o xi cit y* * T h e s e e v e nt s c o v er t h e f oll o wi n g: h e p ati c f ail ur e, fi br o si s a n d cirr h o si s, a n d ot h er li v er d a m a g e-r el at e d c o n diti o n s; t h e n o n -i nf e cti o u s h e p atiti s; t h e b e ni g n, m ali g n a nt a n d u n s p e cifi e d li v er n e o pl a s m s T B L: t ot al bilir u bi n; U L N: u p p er li mit of n or m al T a bl e 1 3 - 2 F oll o w U p R e q uir e m e nt s f or Li v er E v e nt s a n d L a b or at or y Tri g g er s Crit eri a A cti o n s r e q uir e d F oll o w -u p m o nit ori n g P ot e nti al H y’ s L a w c a s e a • Di s c o nti n u e t h e st u d y tr e at m e nt i m m e di at el y • H o s pit ali z e, if cli ni c all y a p pr o pri at e • E st a bli s h c a u s alit y • C o m pl et e li v er C R F A L T, A S T, T B L, Al b, P T/I N R, A L P a n d γ G T u ntil r e s ol uti o nc (fr e q u e n c y at i n v e sti g at or di s cr eti o n) A L T or A S T > 8 × U L N • Di s c o nti n u e t h e st u d y tr e at m e nt i m m e di at el y • H o s pit ali z e if cli ni c all y a p pr o pri at e • E st a bli s h c a u s alit y • C o m pl et e li v er C R F A L T, A S T, T B L, Al b, P T/I N R, A L P a n d γ G T u ntil r e s ol uti o nc (fr e q u e n c y at i n v e sti g at or di s cr eti o n) > 3 × U L N a n d I N R > 1. 5 • Di s c o nti n u e t h e st u d y tr e at m e nt i m m e di at el y • H o s pit ali z e, if cli ni c all y a p pr o pri at e • E st a bli s h c a u s alit y • C o m pl et e li v er C R F A L T, A S T, T B L, Al b, P T/I N R, A L P a n d γ G T u ntil r e s ol uti o nc (fr e q u e n c y at i n v e sti g at or di s cr eti o n) > 5 t o ≤ 8 × U L N • R e p e at L F T wit hi n 4 8 h o ur s • If el e v ati o n p er si st s, c o nti n u e f oll o w-u p m o nit ori n g • If el e v ati o n p er si st s f or m or e t h a n 2 w e e k s, di s c o nti n u e t h e st u d y dr u g • E st a bli s h c a u s alit y • C o m pl et e li v er C R F A L T, A S T, T B L, Al b, P T/I N R, A L P a n d γ G T u ntil r e s ol uti o nc (fr e q u e n c y at i n v e sti g at or di s cr eti o n)"
76,page_76,"N o v arti s C o nfi d e nti al P a g e 7 7 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Crit eri a A cti o n s r e q uir e d F oll o w -u p m o nit ori n g > 3 × U L N a c c o m p a ni e d b y s y m pt o m sb • Di s c o nti n u e t h e st u d y tr e at m e nt i m m e di at el y • H o s pit ali z e if cli ni c all y a p pr o pri at e • E st a bli s h c a u s alit y • C o m pl et e li v er C R F A L T, A S T, T B L, Al b, P T/I N R, A L P a n d γ G T u ntil r e s ol uti o nc (fr e q u e n c y at i n v e sti g at or di s cr eti o n) > 3 t o ≤ 5 × U L N ( p ati e nt i s a s y m pt o m ati c) • R e p e at L F T wit hi n t h e n e xt w e e k • If el e v ati o n i s c o nfir m e d, i niti at e cl o s e o b s er v ati o n of t h e p ati e nt I n v e sti g at or di s cr eti o n M o nit or L F T wit hi n 1 t o 4 w e e k s A L P (i s ol at e d) > 2 × U L N (i n t h e a b s e n c e of k n o w n b o n e p at h ol o g y) • R e p e at L F T wit hi n 4 8 h o ur s • If el e v ati o n p er si st s, e st a bli s h c a u s alit y • C o m pl et e li v er C R F I n v e sti g at or di s cr eti o n M o nit or L F T wit hi n 1 t o 4 w e e k s or at n e xt vi sit T B L (i s ol at e d) > 2 × U L N (i n t h e a b s e n c e of k n o w n Gil b ert s y n dr o m e) • R e p e at L F T wit hi n 4 8 h o ur s • If el e v ati o n p er si st s, di s c o nti n u e t h e st u d y dr u g i m m e di at el y • H o s pit ali z e if cli ni c all y a p pr o pri a t e • E st a bli s h c a u s alit y • C o m pl et e li v er C R F A L T, A S T, T B L, Al b, P T/I N R, A L P a n d γ G T u ntil r e s ol uti o n c (fr e q u e n c y at i n v e sti g at or di s cr eti o n) T e st f or h e m ol y si s ( e. g., r eti c ul o c yt e s, h a pt o gl o bi n, u n c o nj u g at e d [i n dir e ct] bilir u bi n) > 1. 5 t o ≤ 2 × U L N ( p ati e nt i s a s y m pt o m ati c) • R e p e at L F T wit hi n t h e n e xt w e e k • If el e v ati o n i s c o nfir m e d, i niti at e cl o s e o b s er v ati o n of t h e p ati e nt I n v e sti g at or di s cr eti o n M o nit or L F T wit hi n 1 t o 4 w e e k s or at n e xt vi sit J a u n di c e • Di s c o nti n u e t h e st u d y tr e at m e nt i m m e di at el y • H o s pit ali z e t h e p ati e nt • E st a bli s h c a u s alit y • C o m pl et e li v er C R F A L T, A S T, T B L, Al b, P T/I N R, A L P a n d γ G T u ntil r e s ol uti o nc (fr e q u e n c y at i n v e sti g at or di s cr eti o n) A n y A E p ot e nti all y i n di c ati v e of a li v er t o xi cit y* • C o n si d er st u d y tr e at m e nt i nt err u pti o n or di s c o nti n u ati o n • H o s pit ali z ati o n if cli ni c all y a p pr o pri at e • E st a bli s h c a u s alit y • C o m pl et e li v er C R F I n v e sti g at or di s cr eti o n aEl e v at e d A L T/ A S T > 3 × U L N a n d T B L > 2 × U L N b ut wit h o ut n ot a bl e i n cr e a s e i n A L P t o > 2 × U L N b( G e n er al) m al ai s e, f ati g u e, a b d o mi n al p ai n, n a u s e a, or v o miti n g, or r a s h wit h e o si n o p hili a cR e s ol uti o n i s d efi n e d a s a n o ut c o m e of o n e of t h e f oll o wi n g: ( 1) r et ur n t o b a s eli n e v al u e s, ( 2) st a bl e v al u e s at t hr e e s u b s e q u e nt m o nit ori n g vi sit s at l e a st 2 w e e k s a p art, ( 3) r e m ai n at el e v at e d l e v el aft er a m a xi m u m of 6 m o nt h s, ( 4) li v er tr a n s pl a nt ati o n, a n d ( 5) d e at h."
77,page_77,"N o v arti s C o nfi d e nti al P a g e 7 8 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 1 4 A p p e n di x 2: S pir o m etr y G ui d a n c e E q ui p me nt S pir o meters m ust meet t he s pecificati o ns a n d perf or m a nce criteria r ec o m me n de d i n t h e A merica n T h or acic S oci et y ( A T S)/ E ur o pea n Res pirat or y S ociet y ( E R S) Sta n dar dizati o n of S pir o metr y 1. S pir o meters m ust ha ve t he ca pacit y t o pri nt F V C traci n gs. All s pir o metr y val ues s h o ul d be re p orte d at B T P S b y t he m et h o d esta blis he d b y t h e ma n ufact urer. C ali br ati o n T he s pir o meter s h o ul d b e cali brat e d e ver y m or ni n g bef ore a n y s pir o metri c meas ur e me nts f or t he st u d y are perf or me d. Cali brati o n re p orts s h o ul d be pri nte d a n d st ore d as s o urce data at t he site. Pre p ari n g t he test s u bject O n st u d y da ys w h e n s pir o metr y will be p erf or me d, patie nts s h o ul d refrai n fr o m t he f oll o wi n g: • C offee, tea, c h oc ol ate, c ola a n d ot her caff ei ne - c o ntai ni n g be v era ges a n d f o o ds a n d ice- c ol d be ver a ges f or 4 h o urs pri or t o s pir o metr y • Alc o h ol f or 4 h o urs pri or t o s pir o metr y • Stre n u o us acti vit y f or 1 2 h o urs pri or t o s pir o metr y • S m o ki n g wit hi n at least 1 h o ur of testi n g • E x p os ure t o e n vir o n me ntal s m o ke, d ust or areas wit h str o n g o d ors E ver y eff ort s h o ul d be ma de t o ass ure c o nsiste nt testi n g c o n diti o ns t hr o u g h o ut t he st u d y. A seate d p ositi o n wit h n ose cli ps is rec o m me n de d t o re d uce ris ks relate d t o dizzi ness or s y nc o p e. W he n p ossi bl e, s pir o metr y s h o ul d be c o n d ucte d b y t h e sa me t ec h nicia n usi n g t he sa me s pir o meter. T o mi ni mize t he effects of di ur nal vari ati o n o n l u n g f u ncti o n, s pir o metr y visits s h o ul d start at a p pr o xi matel y t he sa m e ti me of da y at eac h visit. Perf or mi n g S pir o metr y T he s u bject’s a ge, hei g ht a n d ge n der will be e nter e d i nt o t he s pir o m eter. It is i m p orta nt t hat t he hei g ht is meas ure d acc ur atel y at t he st u d y site. S pir o metr y, a n eff ort-de pe n d e nt test, re q uires caref ul i nstr ucti o n a n d c o o perati o n of t he s u bject. T he tec h nicia n s h o ul d e ns ure a g o o d s eal ar o u n d t he m o ut h piece, a n d c o nfir m t hat t he s u bject’s p ost ure is c orrect. T h e s u bject s h o ul d be i nstr ucte d t o perf or m a ma xi mal i ns pirati o n, f oll o we d b y ma xi m u m f orce d e x pirati o n u ntil n o m ore air ca n b e e x hale d or f or at least 6 sec o n ds. E x pir ati o n m ust be ra pi d wit h e x erti o n of ma xi mal eff ort. T he res ults of s pir o metr y s h o ul d meet t he A T S/ E R S criteria f or acce pta bilit y a n d re p eata bilit y. Acce pta bilit y criteria s h o ul d be a p plie d bef ore r e peat a bilit y is deter mi ne d. N u m ber of tri als A mi ni m u m of 3 acce pta ble f orce d vital ca pacit y ( F V C) ma n e u vers s h o ul d be perf or me d. If a s u bject is u na bl e t o p erf or m a si n gle acce pt a ble ma ne u ver aft er 8 atte m pts, testi n g m a y b e disc o nti n ue d. Acce pt a bilit y A n acce pta ble ma n e u ver ha s t he f oll o wi n g c har act eristics:"
78,page_78,"N o v arti s C o nfi d e nti al P a g e 7 9 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 • N o hesitati o n or false start; • A ra pi d start; • N o c o u g h, es peciall y d uri n g t he first sec o n d of t he ma ne u ver; • N o gl ottic cl os ur e or o bstr ucti o n b y t o n g ue or de nt ures • N o earl y ter mi nati o n of e x halati o n ( mi ni m u m e x halati o n ti me of 6 sec o n ds is rec o m me n de d, a n d n o v ol u me c ha n ge f or at least 1 sec o n d), or t h e s u bject ca n n ot c o nti n ue t o e x hale f urt her. O ver all acce pta bilit y will be deter mi ne d b y e x pert o ver-rea d b y s pir o metr y v e n d or Re pe at a bilit y T he 2 lar gest F E V 1 val ues fr o m 3 ac ce pta ble ma ne u vers s h o ul d n ot v ar y b y m or e t ha n 0. 1 5 0 L. Rec or di n g of d at a T he hi g hest F E V 1 a n d F V C fr o m a n y of t he acce pta bl e c ur ves ar e rec or de d. ( T he hi g h est F E V 1 a n d F V C ma y n ot necessaril y res ult fr o m t h e sa me acce pt a ble c ur v e). Pre dicte d n or m al T his st u d y will utilize t he s pir o metric pre dicati o n e q uati o n sta n dar ds f or t he E ur o pea n C o m m u nit y f or C oal a n d Steel 2, N ha nes3, E R S Gl o bal L u n g F u n cti o n I nitiati ve ( G LI)2 or J a pa nese Res pirat or y S ociet y3. Re versi bilit y All re versi bilit y e v al uati o ns s h o ul d f oll o w t he r ec o m me n dati o ns of t he A T S/ E R S Tas k f orce: Sta n dar dizati o n of L u n g F u ncti o n Testi n g A d mi nister 4 0 0 µ g of sal b uta m ol 3 6 0 µ g al b uter ol t hr o u g h a s pacer f oll o wi n g t he c o m pleti o n of t he baseli ne assess m e nt. A sec o n d s pir o metr y assess me nt is t he n perf or me d 1 5 t o 3 0 mi n utes after a d mi nistrati o n of t he sal b u mat ol/al b uter ol. Re versi bilit y is calc ulat e d as: 1 0 0 x F E V 1 ( p ost β 2-a g o nists) – F E V 1 ( bas eli ne) F E V 1 ( baseli ne) S u bjects will be c o nsi dere d re versi ble if a n i n creas e of at least 1 2 % (a n d 2 0 0 m L) is de m o nstrate d aft er a d mi nistrati o n of t he br o nc h o dilat or. R ef er e n c e s 1 Miller M R et al, Sta n dar dizati o n of L u n g F u n cti o n Testi n g. E ur Res p J 2 0 0 5; 2 6: 1 5 3- 1 6 1. 2 Q ua njer P H et al. E R S Gl o bal L u n g F u ncti o n I nitiati ve. M ulti et h nic refere n ce val ues f or s pir o metr y f or t he 3-9 5 year a ge r a n ge: t he gl o b al l u n g f u ncti o n 2 0 1 2 e q uati o ns. Re p ort of t he Gl o bal L u n g F u n cti o n I nitiati ve ( G LI). E R S Tas k F orce t o esta blis h i m pr o ve d L u n g F u n cti o n Refere n ce V al ues. 3K u b ota, K o b a yas hi, Q ua njer P H, et al. Ref er e nce val ues f or s pir o metr y, i ncl u di n g vital ca pacit y, i n J a pa n ese a d ults calc ulate d wi t h t he L M S met h o d a n d c o m p are d wit h pre vi o us"
79,page_79,N o v arti s C o nfi d e nti al P a g e 8 0 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 val ues. Cli nical P ul m o nar y F u n cti o ns C o m mittee of t he J a pa nese R es pirat or y S ociet y. Res pirat or y I n vesti gati o ns 2 0 1 4: 2 4 2- 2 5 0.
80,page_80,"N o v arti s C o nfi d e nti al P a g e 8 1 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 1 5 A p p e n di x 3: I n str u cti o n f or U s e of C o n c e pt 1 I nstr ucti o ns f or usi n g i n h aler a n d c a ps ules. D o n ot s w all o w c a ps ules. F oll o w t he i nstr ucti o ns bel o w f or usi n g y o ur i n haler. Y o u will ta ke t he st u d y dr u g c o ntai ne d wit hi n t he ca ps ules b y i n halati o n usi n g t h e i n haler. If y o u ha ve a n y q u esti o ns, please as k t h e d oct or or n urse at t he st u d y ce nter. Y o ur i n h aler a n d c a ps ules T he st u d y dr u g pac k a ge c o nsists of b ot h t he i n haler a n d o ne or m or e blister -pac k a ge d ca ps ules. • Ca ps ules are s u p plie d i n blisters. • I n h aler c o nsists of a ca p, m o ut h piece a n d a b ase. Y o ur i n haler is desi g ne d t o deli ver t he me dici ne c o ntai ne d wit hi n t he ca ps ules. D o n ot use t he st u d y me dicati o n ca ps ules wit h a n y ot her ca ps ul e i n haler, a n d d o n ot use t he i n haler t o ta ke a n y ot h er ca ps ule me dici ne. H o w t o use y o ur i n h aler P ull off c a p."
81,page_81,"N o v arti s C o nfi d e nti al P a g e 8 2 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 O pe n i n h aler: H ol d t he base of t he i n haler fir ml y a n d tilt bac k t he m o ut h piece. T his o pe ns t he i n haler. Pre p are c a ps ule: I m me diat el y b ef or e use, wit h dr y ha n ds, s e par at e o ne of t he blisters fr o m t he blister car d b y teari n g al o n g t he perf or ati o ns a n d lift t he c or ner of t he f oil. Re m o ve a c a ps ule: Peel a wa y t he f oil a n d re m o ve t he ca ps ule fr o m t he blister. I nsert c a ps ule: Place t he ca ps ule i nt o t he ca ps ule c h a m ber. Ne ver pl ace a c a ps ule directl y i nt o t he m o ut h piece. Cl ose t he i n h aler: Y o u s h o ul d hear a “ clic k” as t h e m o ut h piece cl oses o nt o t he i n haler base."
82,page_82,"N o v arti s C o nfi d e nti al P a g e 8 3 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Pierce t he c a ps ule: • H ol d t he i n haler u pri g ht wit h t he m o ut h piece p oi nti n g u p. • Pierce t he ca ps ule b y fir ml y pressi n g t o get her b ot h si de b utt o ns at t he sa me ti me. D o t his o nl y o nce. • Y o u s h o ul d hear a “clic k ” as t he ca ps ule is bei n g pierce d. Rele ase t he si de b utt o ns f ull y. Bre at he o ut: Bef ore placi n g t he m o ut h piece i n y o ur m o ut h, breat he o ut f ull y. D o n ot bl o w i nt o t he m o ut h piece. I n h ale t he me dici ne T o breat he t h e me dici ne dee pl y i nt o y o ur air w a ys: • H ol d t he i n haler as s h o w n i n t he pict ure. T he si de b utt o ns s h o ul d be faci n g left a n d ri g ht. D o n ot pr ess t he si de b utt o ns. • Place t he m o ut h piece i n y o ur m o ut h a n d cl ose y o ur li ps fir ml y ar o u n d it. • Breat he i n ra pi dl y b ut stea dil y a n d as dee pl y as y o u ca n. N ote: As y o u breat he i n t hr o u g h t he i n haler, t he ca ps ule s pi ns ar o u n d i n t he c ha m ber a n d y o u s h o ul d hear a w hirri n g n oise. Y o u will e x perie nce a s weet fla v or as t he me dici ne g oes i nt o y o ur l u n gs. A d diti o nal i nf or mati o n Occasi o nall y, ver y s mall pieces of t he ca ps ule ca n get past t he scree n a n d e nter y o ur m o ut h. If t his ha p pe ns, y o u ma y b e a bl e t o feel t hese pieces o n y o ur t o n g u e. It is n ot har mf ul if t hese"
83,page_83,"N o v arti s C o nfi d e nti al P a g e 8 4 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 pieces are s w all o we d. T he c ha n ces of t he ca ps ule brea k a ge will be i ncrease d if t he ca ps ule is acci de ntall y pierce d m ore t ha n o nce (ste p 7). T h eref ore it is r ec o m me n d e d t hat y o u f oll o w t he st ora ge directi o ns, re m o ve t he ca ps ule fr o m t he blister i m me diatel y bef ore use a n d pier ce eac h ca ps ule o nl y o nce. If y o u d o n ot hear a w hirri n g n oise: T he ca ps ule ma y b e st uc k i n t he ca ps ule c ha m ber. If t his ha p pe ns: • O pe n t he i n haler a n d car ef ull y l o ose n t h e ca ps ule b y ta p pi n g t he b ase of t he i n haler. D o n ot pr ess t he si de b utt o ns. • I n h ale t he me dici n e a gai n b y r e peati n g ste ps 9 t o 1 1. H ol d bre at h: After y o u ha v e i n hale d t h e me dici ne : • H ol d y o ur breat h f or at least 5- 1 0 sec o n ds or as l o n g as y o u c o mf orta bl y ca n w hile ta ki n g t he i n h aler o ut of y o ur m o ut h. • T he n breat he o ut. • O pe n t he i n haler t o s ee if a n y p o w der is left i n t he ca ps ule. If t here is p o w der left i n t he c a ps ule: • Cl ose t he i n haler. • Re peat ste ps 9, 1 0, 1 1 a n d 1 2. M ost pe o ple are a ble t o e m pt y t h e ca ps ule wit h o ne or t w o i n halati o ns. A d diti o n al i nf or m ati o n S o me pe o ple ma y o ccasi o nall y c o u g h briefl y s o o n after i n hali n g t he me dici ne. If y o u d o, d o n’t w orr y. As l o n g as t he ca ps ul e is e m pt y, y o u ha ve recei ve d y o ur m e dici n e. After y o u h a ve fi nis he d t a ki n g y o ur me dici ne: • Y o u ma y b e directe d b y y o ur p h ysici a n t o ri nse m o ut h wit h water a n d s pit it o ut; d o n ot s wall o w t he water. • O pe n t he m o ut h piece a gai n, a n d re m o ve t he e m pt y ca ps ule b y ti p pi n g it o ut of t he ca ps ule c ha m ber. P ut t he e m pt y ca ps ule i n y o ur h o use h ol d waste. • Cl ose t he i n haler a n d r e place t he ca p. D o n ot st ore t he c a ps ules i n t he i n h aler."
84,page_84,"N o v arti s C o nfi d e nti al P a g e 8 5 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 R E M E M B E R: • D o n ot s w all o w c a ps ules. • O nl y use t h e i n haler c o ntai ne d i n t his pac k. • Ca ps ules m ust al wa ys b e st ore d i n t he blister, a n d o nl y re m o v e d i m me diatel y bef ore use. • Ne ver place a ca ps ul e dir ectl y i nt o t he m o ut h piece of t he i n haler. • D o n ot press t he si de b utt o ns m ore t ha n o nce. • Ne ver bl o w i nt o t he m o ut h piece of t he i n hal er. • Al wa ys release t he p us h b utt o ns bef ore i n halati o n. • Ne ver was h t he i n haler wit h water. Kee p it dr y. See “ H o w t o cl ea n y o ur i n h aler”. • Ne ver ta k e t he i n haler a p art. • T he i n haler s h o ul d be us e d f or a m a xi m u m of 3 0 da ys, t he n re place d wit h a ne w i n haler • Al wa ys use t he ne w i n haler t hat c o mes wit h y o ur ne w me dicati o n pac k. • D o n ot st ore t he ca ps ules i n t he i n haler. • Al wa ys kee p t h e i n haler a n d ca ps ules i n a dr y place, a n d a v oi d ver y h ot or c ol d te m perat ur es. H o w t o cle a n y o ur i n h aler • Clea n y o ur i n haler o n ce a wee k. • Wi pe t he m o ut h piece i nsi de a n d o utsi de t o re m o v e a n y p o w der wit h a clea n, dr y li nt- free cl ot h. • D o n ot was h y o ur i n haler wit h water. K ee p it dr y. • D o n ot ta ke t he i n haler a part. 1 6 A p p e n di x 4: I n str u cti o n f or U s e of A c c u h al er®/ Di s k u s® I n str u cti o n s f or u s e F ol l o w t he i nstr ucti o ns b el o w f or usi n g y o ur A cc u haler ® i n h alati o n de vice. Y o u will bre at he i n (i n h ale) t he me dici ne f r o m t he Acc u h aler ® . D o n ot use t he A cc u haler ® u nless y o ur healt hcar e pr o vi der has t a u g ht y o u, a n d y o u u n dersta n d e ver yt hi n g. If y o u ha ve a n y q u esti o ns, as k t he d oct or, n urs e or p har macist pers o n n el at t h e st u d y site."
85,page_85,"N o v arti s C o nfi d e nti al P a g e 8 6 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Fi g ur e 1 P art s of t h e A c c u h al er ® Ta ke t he Acc u h aler ® o ut of t he me dicati o n pac k gi ve n t o y o u. T he A cc u h aler ® will be i n t he cl ose d p ositi o n. T he d ose i n dic at or o n t he t o p of t he Acc u haler ® tells y o u h o w ma n y d oses are left. T h e d ose i n dicat or n u m ber will decrease eac h ti me y o u use t he Acc u haler ® . After y o u h a ve us e d 5 5 d os es fr o m t he A cc u h aler ® , t h e n u m bers 5 t o 0 will a p pear i n re d t o war n y o u t hat t her e are o nl y a fe w d oses left (see Fi g ur e 2). Fi g ur e 2 D o s e I n di c at or f or t h e A c c u h al er ® Ta ki n g a d ose fr o m t he Acc u hal er ® r e q uires t he f oll o wi n g 3 ste ps: O pe n, Clic k, I n hal e. 1. O P E N H ol d t he A cc u hal er ® i n o ne ha n d a n d p ut t he t h u m b of y o ur ot her h a n d o n t he t h um b gri p. P us h y o ur t h u m b a w a y fr o m y o u as far as it will g o u ntil t he m o ut h piece a p pears a n d s na ps i nt o p ositi o n (see Fi g ure 3)."
86,page_86,"N o v arti s C o nfi d e nti al P a g e 8 7 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Fi g ur e 3 O p e ni n g t h e M o ut h pi e c e C o v er 2. C LI C K H ol d t he A cc u h aler ® i n a le vel, flat p ositi o n wit h t he m o ut h piece t o war ds y o u. Sli de t he le v er a wa y fr o m y o u as f ar as it will g o u ntil it clic ks (see Fi g ur e 4). T he A cc u haler ® is n o w rea d y t o use. Fi g ur e 4 Sli di n g t h e L e v er U ntil It Cli c k s E ver y ti me t he le v er is p us he d bac k, a d os e is rea d y t o b e i n hale d. T his is s h o w n b y a dec rease i n n u m b ers o n t he d ose c o u nter. T o a v oi d rele asi n g or w asti n g d oses o nce t he Acc u h aler ® is re a d y: • D o n ot cl ose t he Acc u hal er ® . • D o n ot tilt t he Acc u haler ® . • D o n ot pla y wit h t he le v er. • D o n ot m o ve t he le ver m ore t ha n o nce. 3. I N H A L E Bef ore i n hali n g y o ur d os e fr o m t he Acc u haler ® , breat he o ut ( e x hale) f ull y w hile h ol di n g t he Acc u hal er ® le v el a n d a wa y fr o m y o ur m o ut h (s ee Fi g ure 5). Re me m ber, ne ver bre at he o ut i nt o t he Acc u h aler ® m o ut h piece."
87,page_87,"N o v arti s C o nfi d e nti al P a g e 8 8 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Fi g ur e 5 E x h ali n g P ut t he m o ut h piece t o y o ur li ps (see Fi g ur e 6). Breat he i n q uic kl y a n d dee pl y t hr o u g h t h e Acc u hal er ® . D o n ot br eat he i n t hr o u g h y o ur n os e. Fi g ur e 6 I n h ali n g Re m o ve t he Acc u h aler ® fr o m y o ur m o ut h. H ol d y o ur br eat h f or a b o ut 1 0 sec o n ds, or f or as l o n g as is c o mf orta ble. Breat he o ut sl o wl y. T he A cc u haler ® deli vers y o ur d ose of me dici ne as a ver y fi ne p o w der. M ost patie nts ca n taste or feel t he p o w der. D o n ot use a n ot her d ose fr o m t he Acc u h aler ® if y o u d o n ot feel or taste t he m e dici ne. 4. C L O S E Cl ose t he Acc u h aler ® w he n y o u are fi nis he d t a ki n g a d ose s o t h at t he Acc u h aler ® will be re a d y f or y o u t o t a ke y o ur ne xt d ose. P ut y o ur t h u m b o n t he t h u m b gri p a n d sli de t he t h u m b gri p bac k t o war ds y o u as far as it will g o (see Fi g ure 7). T he Acc u haler ® will clic k s h ut. T he le ver will a ut o maticall y r et ur n t o its ori gi nal p ositi o n. T he A cc u haler ® is n o w r ea d y f or y o u t o ta ke y o ur n e xt sc he d ule d d ose, d ue i n a b o ut 1 2 h o urs. ( Re peat ste ps 1 t o 4 at t hat ti me)."
88,page_88,"N o v arti s C o nfi d e nti al P a g e 8 9 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 Fi g ur e 7 Cl o si n g t h e M o ut h pi e c e C o v er Re me m b er: • Ne ver breat h e i nt o t he A cc u haler ® . • Ne ver ta k e t he A cc u hal er ® a part. • Al wa ys rea d y a n d use t h e Acc u h aler ® i n a l e vel, flat p ositi o n. • D o n ot use t he Acc u haler ® wit h a s pacer de vice. • Ne ver was h t he m o ut h piece or a n y part of t he Acc u haler ® . Kee p it dr y. • Al wa ys kee p t h e Acc u haler ® i n a dr y place. • Ne ver ta k e a n e xtra d ose, e ve n if y o u di d n ot taste or feel t he m e dici ne."
89,page_89,N o v arti s C o nfi d e nti al P a g e 9 0 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 1 7 A p p e n di x 5: I n str u cti o n s f or U s e of t h e R e s pi m at®
90,page_90,N o v arti s C o nfi d e nti al P a g e 9 1 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6
91,page_91,N o v arti s C o nfi d e nti al P a g e 9 2 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6
92,page_92,N o v arti s C o nfi d e nti al P a g e 9 3 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6
93,page_93,N o v arti s C o nfi d e nti al P a g e 9 4 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 1 9 A p p e n di x 7: A Q L Q - S ( T he s a m pl e pr ovi de d h ere is f or ill ustr ative p ur p oses o nly)
94,page_94,N o v arti s C o nfi d e nti al P a g e 9 5 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6
95,page_95,N o v arti s C o nfi d e nti al P a g e 9 6 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6
96,page_96,N o v arti s C o nfi d e nti al P a g e 9 7 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6
97,page_97,N o v arti s C o nfi d e nti al P a g e 9 8 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6
98,page_98,N o v arti s C o nfi d e nti al P a g e 9 9 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 2 0 A p p e n di x 8: A C Q - 7 ( T he s a m pl e pr ovi de d h ere is f or ill ustr ative p ur p oses o nly)
99,page_99,N o v arti s C o nfi d e nti al P a g e 1 0 0 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6
100,page_100,N o v arti s C o nfi d e nti al P a g e 1 0 1 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6
101,page_101,N o v arti s C o nfi d e nti al P a g e 1 0 2 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6
102,page_102,N o v arti s C o nfi d e nti al P a g e 1 0 3 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6
103,page_103,N o v arti s C o nfi d e nti al P a g e 1 0 4 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6
104,page_104,N o v arti s C o nfi d e nti al P a g e 1 0 5 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6
105,page_105,"N o v arti s C o nfi d e nti al P a g e 1 0 6 A m e n d e d Pr ot o c ol V er si o n v 0 2/ Cl e a n Pr ot o c ol N o. C Q V M 1 4 9 B 2 3 0 6 2 2 A p p e n di x 1 0: L o w, m e di u m a n d hi g h D ail y D o s e s of I n h al e d Gl u c o c orti c o st er oi d s f or A d ult s1 Dr u g T ot al D ail y D o s e ( µ g/ d a y) L o w M e di u m Hi g h B e cl o m et h a s o n e di pr o pi o n at e – C F C2 2 0 0 -5 0 0 > 5 0 0 – 1 0 0 0 > 1 0 0 0 B e cl o m et h a s o n e di pr o pi o n at e – H F A 1 0 0 -2 0 0 > 2 0 0 – 4 0 0 > 4 0 0 B u d e s o ni d e - D PI 2 0 0 -4 0 0 > 4 0 0 – 8 0 0 > 8 0 0 Ci cl e s o ni d e – H F A 8 0 -1 6 0 > 1 6 0 – 3 2 0 > 3 2 0 Fl uti c a s o n e F ur o at e – D PI3 N A 1 0 0 2 0 0 Fl uti c a s o n e pr o pi o n at e – D PI 1 0 0 -2 5 0 > 2 5 0 – 5 0 0 > 5 0 0 Fl uti c a s o n e pr o pi o n at e – H F A 1 0 0 -2 5 0 > 2 5 0 – 5 0 0 > 5 0 0 M o m et a s o n e f ur o at e 1 1 0 -2 2 0 > 2 2 0 -4 4 0 ≥ 4 4 0 Tri a m ci n ol o n e a c et o ni d e 4 0 0 -1 0 0 0 > 1 0 0 0 – 2 0 0 0 > 2 0 0 0 1, 3 C at e g ori e s b a s e d o n GI N A 2 0 1 7 wit h e x c e pti o n of Fl uti c a s o n e F ur o at e w hi c h i s b a s e d o n t h e S u m m ar y of Pr o d u ct C h ar a ct eri sti c s of R el v ar ® Elli pt a ® 2B e cl o m et h a s o n e di pr o pi o n at e C F C i s i n cl u d e d f or c o m p ari s o n wit h ol d er lit er at ur e. C F C: c hl or ofl u or o c ar b o n pr o p ell a nt; D PI: dr y p o w d er i n h al er; H F A: h y dr ofl u or o al k a n e pr o p ell a nt."
